A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687751] 2015 / Page 1of 72
1 TITLE
PROTOCOL N01199
An open -label, multicenter, follow- up trial to evaluate the long -term safet y and efficacy  of 
brivaracetam used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day 
in subjects aged 16 years or older suffering fr om epi[INVESTIGATOR_002] .
Sponsor :
UCB Pharma Inc.
[ADDRESS_687752]
[LOCATION_003] - GA [ZIP_CODE]
Smyrna
UNITED STATES
Hereafter “UCB”
Brivaracetam - INDNumber : 70,205
Confidential Material
“The information contained in this document is strictly  confidential. It is disclosed to y ou as a 
(potential) Investigator or (potential) consultant. Acceptance of this document constitutes 
your agreement that the information contained herein will not be disclosed or in any way 
communicated to an y third part y without prior written approval of the Sponsor (or its 
representative(s) of the clinical study described therein except - to the extent necessary  -to 
your staff, to members of appropriate review committee(s) and/or to persons to whom the 
investigational product may  be admini stered or to their legal representative(s) to obtain their 
informed consent.”REDACTED rivaracetam
REDACTED rivaracetam -
REDACTED -IN
REDACTED INCOPY UNITED STATES
COPY UNITED STATES
Hereafter “UCB”COPY Hereafter “UCB”
This document representative(s) of the clinical study
document representative(s) of the clinical study
yo
document your staff, to members of appropriate review committee(s) and/or to persons to whom the 
document ur staff, to members of appropriate review committee(s) and/or to persons to whom the 
investigational product may
document investigational product maycannot ur agreement that the information contained herein will not be disclosed or in any
cannot ur agreement that the information contained herein will not be disclosed or in any
communicated to an
cannot communicated to an
representative(s) of the clinical studycannot representative(s) of the clinical studybe Investigatorbe Investigator
ur agreement that the information contained herein will not be disclosed or in any be ur agreement that the information contained herein will not be disclosed or in anyused Confidential Material
used Confidential Material
“The information contained in this document is strictlyused “The information contained in this document is strictly
Investigatorused Investigatorto Confidential Material to Confidential Materialsupport any marketing authorization Hereafter “UCB”
authorization Hereafter “UCB”
IN
authorization IND
authorization DNumber
authorization Numberapplication and any extensions mg
extensions mgor and efficacy
or and efficacy  of 
or  of 
mgor mg/dayor /dayvariations  of variations  of thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687753] 2015 / Page 2of 72
Protocol Signatures:
Authorized signature [CONTACT_529495]:
Principal Investigator
“By [CONTACT_12006], I acknowledge that I have read the protocol RPCE05 C2110and 
agree that it contains all necessary details for carry ing out the clinical study  describ ed therein. 
Furthermore, I agree to conduct this clinical study in compliance with said Protocol, the ICH 
Good Clinical Practice guideline, as well as with any and all applicable federal, state and/or local laws and regulations and with my contractual obligations towards the Sponsor of the clinical study  or its representatives(s).”
Signature: __________________________________ Date: _________
Printed Name: __________________________________Address: ____________________________________________________________________
Phone: __________________________________ Site Number: _________
REDACTED Phone: __________________________________
REDACTED Phone: __________________________________ COPY ________________
COPY ________________
__________________________________
COPY __________________________________
__________________________________COPY __________________________________
Phone: __________________________________ COPY Phone: __________________________________
This document cannot be used to support any marketing authorization __________________________________
authorization __________________________________
Phone: __________________________________
authorization Phone: __________________________________application Date:
application Date:
________________
application ________________
__________________________________application __________________________________and  contractual obligations towards the Sponsor of the 
and  contractual obligations towards the Sponsor of the any able federal, state and/or 
any able federal, state and/or 
 contractual obligations towards the Sponsor of the any  contractual obligations towards the Sponsor of the extensions [ADDRESS_687754] this clinical study in compliance with said Protocol, the I
able federal, state and/or extensions able federal, state and/or or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687755] 2015 / Page 3of [ADDRESS_687756]
[LOCATION_003] -GA [ZIP_CODE]
Smyrna
UNITED STATES
Study Physician
Name: ,MD Phone:
Fax:
Clinical Project Manager
Name: [CONTACT_7626]:Fax:
Safety Physician
Name: , MB BCh 
BAO, MRCGPPhone:
Fax:
Clinical Trial Statistician
Name: [CONTACT_7626]:
Fax:REDACTED Fax:
REDACTED Fax:
MB BCh 
REDACTED MB BCh COPY Phone:COPY Phone:
Fax:COPY Fax:
This document cannot be used to support any marketing authorization Fax:
authorization Fax:
Phone:authorization Phone:application application and and any any extensions or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687757] 2015 / Page 4of 72
SAE Reporting (24h/24), Safety Related Issues (GCSP)
Email: Global: [EMAIL_2443]
Fax: Europe and Rest of the World:
[LOCATION_003]: [PHONE_2778] +1-
[PHONE_10960]
Canada: +[PHONE_2777]
Investigator(s)
The complete and updated list of Investigators is maintained in the Trial Master File (TMF) at 
the sponsor.
REDACTED COPY nvestigators is maintained in the Trial Mast
COPY nvestigators is maintained in the Trial Mast
This document cannot be used to support any marketing authorization application nvestigators is maintained in the Trial Mast
application nvestigators is maintained in the Trial Mastand any extensions -6949
extensions -6949
extensions -582
extensions -582-8842
extensions -8842or +1
or +1variations +1variations +1-variations -thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687758] 2015 / Page 5of [ADDRESS_687759].....................................................24
6.3 Efficacy  with BRV in fixed-dose Phase II/III studies in POS .........................25
6.4 Safety with BRV ..............................................................................................25
6.5 Study  Rationale ................................................................................................26
6.5.1 Dose Selection....................................................................................26
6.5.2 Subjects Population............................................................................26
[IP_ADDRESS] Minimal Age ...............................................................26
6.5.3 Duration of Treatment........................................................................26
7 STUDY OBJECTIVES ................................................................................................27
7.1 Primary Objective ............................................................................................27
7.2 Secondary  Objectives.......................................................................................27
7.3 Exploratory  Objectives.....................................................................................27
8 STUDY DESIGN ..........................................................................................................28
8.1 Type/Design .....................................................................................................28
8.2 Subjects/Sites Numbers....................................................................................[ADDRESS_687760] Replacement Policy...............................................................32
10 TREATMENT OF SUBJECTS (INVESTIGATIONAL PRODUCT AND 
CONCOMITANT MEDICATI ONS) .........................................................................[ADDRESS_687761] I
used used Study
used Study
used End of Studyused End of Studyused to 8.2 Subjects/Sites Numbers................................
to 8.2 Subjects/Sites Numbers................................
Subject Ito Subject Ito support ................................
support ................................
support pe/Design
support pe/Design ................................
support ................................
support 8.2 Subjects/Sites Numbers................................support 8.2 Subjects/Sites Numbers................................support Subject Isupport Subject I dentifiersupport dentifierany  Objectives
any  Objectives
any marketing ................................
marketing ................................
................................
marketing ................................
 Objectivesmarketing  Objectives ................................marketing ................................marketing  Objectives marketing  Objectivesauthorization ................................
authorization ................................
................................
authorization ................................
................................
authorization ................................
Minimal Age
authorization Minimal Age
authorization Duration of Treatmentauthorization Duration of Treatment ................................authorization ................................authorization application ................................
application ................................
................................
application ................................
III studies in POS
application III studies in POS
application ................................
application ................................
................................ application ................................and ................................
and ................................
................................and ................................any ..........................21
any ..........................21extensions ........................9
extensions ........................9
...........................12
extensions ...........................12
................................extensions ................................
..........................21extensions ..........................21or ...............................5or ...............................5 variations .......................3
variations .......................3
variations ...............................5 variations ...............................5thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687762] 2015 / Page 6of [ADDRESS_687763] Compliance....................................................34
10.1.7 Investigational Products Accountability ............................................34
10.2 Concomitant Treatments and Rescue Medications ..........................................35
10.2.1 Permitted Concomitant Treatments (Medications and Therapi[INVESTIGATOR_014]) ....35
10.2.2 Prohibited Concomitant Treatments (Medications and 
Therapi[INVESTIGATOR_014])...........................................................................................[ADDRESS_687764] (DRC) ..................................................................38
11.1.14 Laboratory Assessments .....................................................................38
11.1.15 Adverse Events (AEs)........................................................................39
11.1.16 Assessment of Suicidality ..................................................................39
11.1.17 Medical Procedures ............................................................................40
11.1.18 Non-Antiepi[INVESTIGATOR_529332]........41
11.1.19 Patient Reported Outcomes................................................................41
11.1.20 Quality  of Life in Epi[INVESTIGATOR_122146] (QOLIE-31 -P).................41
11.1.21 Hospi[INVESTIGATOR_74017] (HADS) ..............................42
11.1.22 EQ-5D Questionnaire.........................................................................42
11.1.23 Hospi[INVESTIGATOR_7985] ......................................................................................42
11.1.24 Healthcare Provider Consultation not Foreseen b y Protocol .............43
11.1.25 Socio -professional Data .....................................................................43
11.1.26 End of Study .......................................................................................43
11.2 Description Visit by  [CONTACT_4838] .................................................................................44
11.2.1 E ntry Visit ..........................................................................................44
11.2.2 Full Evaluation Visit ..........................................................................45
11.2.3 Minimal Evaluation Visit...................................................................46
11.2.4 Yearl y Evaluation Visit (replaces the first FEV of each year)...........46REDACTED ................................
REDACTED ................................
Antiepi[INVESTIGATOR_529333] ................................
REDACTED ................................
Weight and Height
REDACTED Weight and Height
REDACTED sical ExaminationREDACTED sical ExaminationREDACTED REDACTED 11.1.11 Neurological Examination ................................REDACTED 11.1.11 Neurological Examination ................................COPY Childbearing Potential and Birth Control
COPY Childbearing Potential and Birth Control
COPY General Medical and Procedure History
COPY General Medical and Procedure History
COPY ................................ COPY ................................
This document cannot be used used 11.1.19 Patient Reported Outcomes................................
used 11.1.19 Patient Reported Outcomes................................
used 11.1.19 Patient Reported Outcomes................................
used 11.1.19 Patient Reported Outcomes................................
used 11.1.20used 11.1.20used used to 11.1.18to 11.1.18to support Adverse Events (AEs)
support Adverse Events (AEs)
support Asse
support Asse
support ssment of Suicidality
support ssment of Suicidality
support 11.1.17support 11.1.[ADDRESS_687765] (DRC)
any  Record Card (DRC)
any Laboratoryany Laboratory  Assessmentsany  Assessments Laboratory  Assessments Laboratoryany Laboratory  Assessments Laboratoryany Adverse Events (AEs) any Adverse Events (AEs)marketing sical Examination
marketing sical Examination
marketing marketing 11.1.[ADDRESS_687766] (DRC)marketing  Record Card (DRC)marketing  Assessmentsmarketing  Assessmentsauthorization General Medical and Procedure History
authorization General Medical and Procedure History
authorization ................................
authorization ................................
Antiepi[INVESTIGATOR_529334] ................................
authorization ................................
................................authorization ................................
sical Examination authorization sical Examinationapplication ................................
application ................................
................................
application ................................
................................
application ................................
Childbearing Potential and Birth Control
application Childbearing Potential and Birth Control
application General Medical and Procedure History application General Medical and Procedure History application and ................................
and ................................
................................ and ................................any ..............................35any ..............................35
................................ any ................................extensions ..........35
extensions ..........35
10.2.1 Permitted Concomitant Treatments (Medications and Therapi[INVESTIGATOR_014]) ....35
extensions 10.2.1 Permitted Concomitant Treatments (Medications and Therapi[INVESTIGATOR_014]) ....35
extensions ...........................35extensions ...........................35or ............34
or ............34
..........35or ..........35variations ....................34
variations ....................34
variations ............34 variations ............34thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687767] 2015 / Page 7of 72
11.2.5 Early Discontinuation Visit ................................................................47
11.2.6 Down -Titration Phone Call................................................................48
11.2.7 Final Visit (FV following a Stud y Drug Free Period after an 
EDV or FV initiated upon Sponsor request at the end of the 
program) .............................................................................................48
11.2.8 Additional Visit..................................................................................49
11.3 Handling of Biological Samples ......................................................................49
11.4 Other Suppli es..................................................................................................49
12 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS...................................49
12.1 Adverse Events.................................................................................................49
12.1.1 Definition of Adverse Event (AE) .....................................................[ADDRESS_687768]..................................................54
12.2 Serious Adverse Events....................................................................................54
12.2.1 Definition of Serious Adverse Event (SAE) ......................................54
12.2.2 Procedures for Reporting Serious Adverse Events (SAE).................55
12.2.3 Anticipated Serious Adverse Events..................................................56
13 STATISTICS.................................................................................................................56
13.1 Statistical and Analy tical Plans ........................................................................56
13.1.1 Study  Population(s)............................................................................[ADDRESS_687769] Confiden tiality .....................................................................................63
14.4 Informing the General Practitioner (or Pediatrician) .......................................64
15 STUDY MANAGEMENT AND ADMINISTRATION ............................................64
15.1 Monitoring........................................................................................................64REDACTED ................................
REDACTED ................................
12.2.1 Definition of Serious Adverse Event (SAE) ................................
REDACTED 12.2.1 Definition of Serious Adverse Event (SAE) ................................
REDACTED Procedures for Reporting Serious Adverse Events (SAE)
REDACTED Procedures for Reporting Serious Adverse Events (SAE)
REDACTED Anticipated Serious Adverse Events
REDACTED Anticipated Serious Adverse Events
REDACTED ................................ REDACTED ................................COPY ................................
COPY ................................ ................................
COPY ................................
12.1.[ADDRESS_687770]................................
COPY ................................ COPY ................................
This document 14 ETHICS AND REGULATOR
document 14 ETHICS AND REGULATOR
document cannot 13.4
cannot 13.4
cannot 13.5
cannot 13.5
cannot 14 ETHICS AND REGULATORcannot 14 ETHICS AND REGULATORbe used 13.3.2
used 13.3.2
used 13.3.3used 13.3.3used 13.3.4used 13.3.4to 13.3.1
to 13.3.1
to 13.3.2to 13.3.2support Statistical Evaluation
support Statistical Evaluation
support Determination of the Sample Size
support Determination of the Sample Size
support Statistical a
support Statistical a nd Analy
support nd Analy
support Handling of Dropouts of Missing Datasupport Handling of Dropouts of Missing Datasupport any Efficacy
any Efficacy  and Safet
any  and Safet
any Statistical Evaluation any Statistical Evaluation any Determination of the Sample Sizeany Determination of the Sample Sizemarketing ................................
marketing ................................ ................................
marketing ................................
tical Plans
marketing tical Plans
marketing  Population(s)
marketing  Population(s)
marketing  and Safetmarketing  and Safetauthorization 12.1.[ADDRESS_687771]................................
authorization ................................
authorization ................................
12.2.1 Definition of Serious Adverse Event (SAE) ................................
authorization 12.2.1 Definition of Serious Adverse Event (SAE) ................................
authorization Procedures for Reporting Serious Adverse Events (SAE)
authorization Procedures for Reporting Serious Adverse Events (SAE)
authorization Anticipated Serious Adverse Eventsauthorization Anticipated Serious Adverse Eventsauthorization application ................................
application ................................
................................
application ................................
12.1.[ADDRESS_687772]................................ application and 12.1.2 Procedures for Reporting and Recording Adverse Events.................50
and 12.1.2 Procedures for Reporting and Recording Adverse Events.................50
and ................................ and ................................any ................................any ................................
12.1.2 Procedures for Reporting and Recording Adverse Events.................50 any 12.1.2 Procedures for Reporting and Recording Adverse Events.................50extensions ................................
extensions ................................ ......49
extensions ......49
................................
extensions ................................
S................................
extensions S................................
................................extensions ................................or ..................49
or ..................49
......49or ......49variations .............................48
variations .............................48
variations ..................49 variations ..................49thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687773] 2015 / Page 8of [ADDRESS_687774] Access to Source Data/Documents .......................................................64
15.3 Audit and Inspection ........................................................................................65
15.4 Case Report Forms (CRF)................................................................................65
15.5 Adherence to Protocol......................................................................................66
15.6 Investigator Site File ........................................................................................67
15.7 Data Handling ..................................................................................................67
15.8 Termination of Study .......................................................................................67
15.8.1 Termination of Study  by [CONTACT_2728] ......................................................68
15.9 Clinical Study  Report .......................................................................................68
15.10 Insurance and Lia bility.....................................................................................68
15.11 Archiving and Data Retention..........................................................................68
15.12 Allocation of Responsibilities ..........................................................................69
15.13 Curriculum Vitae (CV).....................................................................................[ADDRESS_687775] of Table s
Table 5:1 Study  Flowchart...........................................................................................18
Table 5:[ADDRESS_687776] of Table
authorization ................................ authorization ................................application ................................
application ................................
................................
application ................................
application ................................
application ................................
................................ application ................................and ................................
and ................................
................................and ................................any ................................
any ................................
................................ any ................................extensions .......................67
extensions .......................67
......................68
extensions ......................68
.......................68
extensions .......................68
................................extensions ................................ .....................68extensions .....................68or ................................
or ................................ ..67
or ..67
.......................67 or .......................67variations ........................67
variations ........................67
variations ..67variations ..67thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687777] 2015 / Page 9of [ADDRESS_687778] OF ABBREVIATIONS
AE(s) Adverse Event(s)
AED(s) Antiepi[INVESTIGATOR_23935] D rug(s)
ALT 
(ALAT/SGPT)Alanine A minotransferase
ASAT/SGOT A spartate A minotransferase
ALP Alkaline Phosphatase
AV Additional Visit
b.i.d. Twice Dail y
BRV Brivaracetam
BZD Benzodiazepi[INVESTIGATOR_529335] D ata Management System
CPMP Committee for Proprietary  Medicinal Product
Cr Cl Creatinine C learance
CRF Case Report F orm
CRO Clinical R esearch Organization
C-SSRS Columbia Suicide Severity  Rating Scale
CTM Clinical Trial M anager
CV Curriculum Vitae
CYP Cytochrome
DBP Diastolic blood pressure
DHHS Department of Health and Human Services
dl Deciliter
DRC Daily Record C ard
DTP Down -titration P hone Call
ECG Electrocardiogram
EDV Early Discontinuation V isit
EQ-5D EuroQoL [ADDRESS_687779]
application  Medicinal Productand any extensions or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687780] 2015 / Page 10of [ADDRESS_687781]
IVRS Interactive voice response system
IWRS Interactive web response system
kg Kilogram
L Liter
LTG Lamotrigine
m Meter
MCH Mean Corpuscular Haemoglobin
MCHC Mean Corpuscular Haemoglobin Concentration
MCV Mean Corpuscular V olume
MedDRA Medical D ictionary  for Regulatory  Activities
MEV Minimal Evaluation V isit
µg Microgram
mg Milligram
min Minute
ml Milliliter
µL Microliter
µM Micromol
PBO Placebo
PGS Primary Generalized Epi[INVESTIGATOR_529336] s
POS Partial Onset Seizure
PRO Patient Reported Outcomes
QOLIE -31-P Patient Weighted Quality of L ife in Epi[INVESTIGATOR_30989] y Questionnaire
RBC Red Blood Cell
SAE Serious A dverse Event
SAP Statistical A nalysis Plan
SASStatistical A nalysis S ystem
SBP Systolic blood pressure
SDV Source Data Verification
SOC System O rgan Class
SOP Standard O perating P rocedure
SP Study Physician
SV2A Synaptic Vesicle Protein 2A
TMF Trial M aster File
WBC White B lood Cell
WHO World Health OrganizationREDACTED COPY egulatory
COPY egulatory
isitCOPY isit
This document SDV
document SDV
SOC
document SOCcannot SBP
cannot SBP
SDVcannot SDVbe used to support harmacokinetic
support harmacokinetic
support Partial Onset Seizure
support Partial Onset Seizure
Patient Reported Outcomesupport Patient Reported Outcome
Patient Weighted Quality of Lsupport Patient Weighted Quality of Lany Primary
any Primary  Generalized Epi[INVESTIGATOR_529337]. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687782] 2015 / Page 11of 72
YEV Yearly Evaluation Visit
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687783] 2015 / Page 12of [ADDRESS_687784]:
Brivaracetam (BRV)
Objectives:
Primary Objective
To evaluate the long-term safet y and tolerability of BRV at individualized doses with a 
maximum of 200mg/day in subjects suffering from epi[INVESTIGATOR_002].
Secondary ObjectiveTo evaluate the maintenance of efficacy  over time of BRV (for POS/PGS subjects).
Exploratory  Objectives
To explore the effects of BRV on the subject’s H ealth -related Quality  of Life, anxiety ,
and depression for the first 2 years .
To explore medical resource use and indirect cost parameters for the first 2 years.
To obtain a description of the subject’s self-reported health status for the first 2 years.
To explore any  change in the subject’s socio- professional status for the first 2 years.
This study  will provide subjects suffering from epi[INVESTIGATOR_002], who may  benefit from BRV as 
adjunctive treatment, the opportunity to receive open label adjunctive BRV treatment.  
Conversion to monotherapy  is not permitted an ymore; however, subjects alread y on 
monotherapy are allowed to continue BRV monotherap y.  The access will be limited to the 
subjects having completed a previous BRV study  as listed in Section 5.2.
Estimated Number of Subjects, Sites and Rationale:
It is estimated that approximately  500 - 1,000 subjects will enter the study  based on the 
assumption that 90% of subjects having completed a previous study  with BRV as adjunctive 
treatment in epi[INVESTIGATOR_529338] .
It is estimated that between [ADDRESS_687785] Population and Diagnosis:
Before an y study procedures are initiated for an y subject in this study , anIndependent Ethics
Committee (I EC)/Institutional Review Board (IRB) approved written informed consent form 
will be properly executed and documented.
Subject Inclusion Criteria:
An IEC/I RB approved written informed consent signed and dated by [CONTACT_28246] b y 
parent(s) or legall y acceptable representative. The consent form or a specific assent form, 
where required, will be signed and dated b y minors.REDACTED self
REDACTED self-
REDACTED -self-self
REDACTED self-selfreported health status
REDACTED reported health status
change in the subject’s 
REDACTED change in the subject’s socio
REDACTED socio
 will provide subjects suffering from epi[INVESTIGATOR_529339], the opportunity REDACTED adjunctive treatment, the opportunity  to receive open label REDACTED  to receive open label adjunctive treatment, the opportunity  to receive open label adjunctive treatment, the opportunity REDACTED adjunctive treatment, the opportunity  to receive open label adjunctive treatment, the opportunityCOPY ealth
COPY ealth
medical resource use and indirect cost parametersCOPY medical resource use and indirect cost parameters
reported health statusCOPY reported health status
This document Before an
document Before an
Committee (I
document Committee (I
will be properl
document will be properlcannot It is estimated that between [ADDRESS_687786] Population and Diagnosis:
cannot Population and Diagnosis:
Before ancannot Before anbe It is estimated that between 100 - 200 sites will participate in this global protocol.be It is estimated that between 100 - 200 sites will participate in this global protocol.used atment in epi[INVESTIGATOR_529340] y will roll over into the present 
used y will roll over into the present to assumption that 90% of subjects having completed a previous to assumption that 90% of subjects having completed a previous 
y will roll over into the present to y will roll over into the present support Subjects
support Subjects
It is estimated that approximatelysupport It is estimated that approximately
assumption that 90% of subjects having completed a previous support assumption that 90% of subjects having completed a previous any subjects having completed a previous BRV study
any subjects having completed a previous BRV studymarketing  will provide subjects suffering from epi[INVESTIGATOR_529341]
y are allowed to continue BRV monotherapmarketing y are allowed to continue BRV monotherap
subjects having completed a previous BRV studymarketing subjects having completed a previous BRV studyauthorization medical resource use and indirect cost parameters
authorization medical resource use and indirect cost parameters
reported health status
authorization reported health status
socio
authorization socio -
authorization -professional 
authorization professional 
 will provide subjects suffering from epi[INVESTIGATOR_529342] (for POS/PGS subjects)and (for POS/PGS subjects)any extensions es with a 
extensions es with a or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687787] 2015 / Page 13of 72
Male/female subjects from 16 years or older. Subjects under 18 years may  only  be 
included where legall y permitted and ethicall y accepted.
Subjects with epi[INVESTIGATOR_122149] .
Subjects from whom the Investigator believes a reasonable benefit from the long- term 
administration of BRV may be expected.
Female subjects without childbearing potential (premenarcheal; 2 years postmenopausal 
bilateral oophorectomy or ovariectomy, bilateral salpi[INVESTIGATOR_1656] , complete hy sterectom y, 
congenital sterility) are eligible. Female subjects with childbearing potential are eligible 
if they  use a medically  accepted contraceptive method for the duration of the study (Intra 
Uterine Device, diaphragm with spermicide, male or female condom with spermicide; 
oral hormonal contraceptive, non-oral hormonal contraceptive medication, bilateral tubal ligation, bilateral tubal implant, monogamous relationship with vasectomized partner). Oral or depot contraceptive treatment with at least 30 µg [or 50 µg if associated with other antiepi[INVESTIGATOR_006] (AEDs) known as inducers] ethin ylestradiol per intake must be 
used in conjunction with a barrier method. The subject must understand the consequences and potential risks of inadequately protected sexual activity, be educated about and understand the proper use of contraceptive methods, and undertake to inform the Investigator of an y potential change in status. According to the judgment of the 
Investigator, sexual inactivity  might be accepted on a case- by-case basis. 
Subject/legall y acceptable representative considered as reliable and capable of adhering to 
the protocol (e.g. able to understand and complete diaries and questionnaires), visit schedule or medication intake according to the judgment of the Investigator.
Subject Exclusion Criteria:
Severe medical, neurological and ps ychiat ric disorders or laboratory values which may  
have an impact on the safety of the subject.
Poor compliance with the visit schedule or medication intake in the previous BRV study .
Participation in any clinical study of another investigation drug or device du ring the 
study .
Pregnant or lactating woman.
Drug Administration: 
Subjects coming from BRVstudies have the opportunity to access BRV treatment at a 
flexible dose of up to a maximum of 200 mg/day in b.i.d. administration . It is recommended 
that the daily  dose be divided equall y and be taken with or without food. The first intake will 
be in the evening of the day  of the dispensation of the study medication. The individual 
starting dose of each subject will be the one defined/reached at the end of the previous study .
At each visit, an interactive voice response s ystem (IVRS) / interactive web response system 
(IWRS) will be responsible for issuing subjects kits of st udy medication, as appropriate, 
according to the visit schedule and according to the suppl ies needed b y the subject in terms of 
the number of tablets of each size (80 count or 200 count), and of each dosage (10 mg and 25 REDACTED understand the proper use of contraceptive methods,
REDACTED understand the proper use of contraceptive methods,
y potential change in status
REDACTED y potential change in status . According to the judgment of the 
REDACTED . According to the judgment of the 
 might be accepted on a case
REDACTED  might be accepted on a case
y acceptable representative considered as reliable and 
REDACTED y acceptable representative considered as reliable and 
the protocol (e.g. able to understand and complete diaries and questionnaires), visit REDACTED the protocol (e.g. able to understand and complete diaries and questionnaires), visit 
schedule or medication intake according to the judgment of the REDACTED schedule or medication intake according to the judgment of the COPY used in conjunction with a barrier method. The subject must understand the consequences 
COPY used in conjunction with a barrier method. The subject must understand the consequences 
y protected sexual activity, be educated about and 
COPY y protected sexual activity, be educated about and 
understand the proper use of contraceptive methods,COPY understand the proper use of contraceptive methods,
This document that the dai
document that the dai
be in the evening of the day
document be in the evening of the day
starting dose of each subject will be the one defined/reached at the end of the 
document starting dose of each subject will be the one defined/reached at the end of the cannot Drug Administration: 
cannot Drug Administration: 
Subjects 
cannot Subjects coming from 
cannot coming from 
cannot flexible dose of up to a maximum of cannot flexible dose of up to a maximum of 
that the daicannot that the daibe Drug Administration: be Drug Administration: used Pregnant or lactating woman.
used Pregnant or lactating woman.to Participation in any
to Participation in anysupport have an impact on the safety
support have an impact on the safety
Poor compliance with the visit schedule or medication intake in the previous 
support Poor compliance with the visit schedule or medication intake in the previous 
Participation in anysupport Participation in any  clinical support  clinical Participation in any  clinical Participation in anysupport Participation in any  clinical Participation in anyany Severe medical, neurological and psany Severe medical, neurological and ps
have an impact on the safety any have an impact on the safety  of the subject.any  of the subject. have an impact on the safety  of the subject. have an impact on the safety any have an impact on the safety  of the subject. have an impact on the safetymarketing the protocol (e.g. able to understand and complete diaries and questionnaires), visit 
marketing the protocol (e.g. able to understand and complete diaries and questionnaires), visit 
schedule or medication intake according to the judgment of the 
marketing schedule or medication intake according to the judgment of the 
Severe medical, neurological and psmarketing Severe medical, neurological and psauthorization y protected sexual activity, be educated about and 
authorization y protected sexual activity, be educated about and 
understand the proper use of contraceptive methods,
authorization understand the proper use of contraceptive methods, and undertake to inform the 
authorization and undertake to inform the 
. According to the judgment of the 
authorization . According to the judgment of the 
 might be accepted on a case
authorization  might be accepted on a case
y acceptable representative considered as reliable and authorization y acceptable representative considered as reliable and 
the protocol (e.g. able to understand and complete diaries and questionnaires), visit authorization the protocol (e.g. able to understand and complete diaries and questionnaires), visit application ligation, bilateral tubal implant, monogamous relationship with vasectomized partner). 
application ligation, bilateral tubal implant, monogamous relationship with vasectomized partner). 
Oral or depot contraceptive treatment with at least 30 µg [or [ADDRESS_687788] 30 µg [or 50 µg if associated with 
known as inducers] ethin
application known as inducers] ethin yl
application ylestradiol per intake must be 
application estradiol per intake must be 
used in conjunction with a barrier method. The subject must understand the consequences 
application used in conjunction with a barrier method. The subject must understand the consequences 
y protected sexual activity, be educated about and application y protected sexual activity, be educated about and 
and undertake to inform the application and undertake to inform the and oral hormonal contraceptive medi
and oral hormonal contraceptive medi cation, bilateral tubal 
and cation, bilateral tubal 
ligation, bilateral tubal implant, monogamous relationship with vasectomized partner). and ligation, bilateral tubal implant, monogamous relationship with vasectomized partner). 
Oral or depot contraceptive treatment with at least 30 µg [or [ADDRESS_687789] 30 µg [or 50 µg if associated with any Uterine Device, diaphragm with spermicide, male or female condom with spermicide; 
any Uterine Device, diaphragm with spermicide, male or female condom with spermicide; 
cation, bilateral tubal any cation, bilateral tubal extensions ars postmenopausal 
extensions ars postmenopausal 
sterectom
extensions sterectom
tial are eligible 
extensions tial are eligible 
 accepted contraceptive method for the duration of extensions  accepted contraceptive method for the duration of the extensions the studyextensions study
Uterine Device, diaphragm with spermicide, male or female condom with spermicide; extensions Uterine Device, diaphragm with spermicide, male or female condom with spermicide; or ars postmenopausal or ars postmenopausal variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687790] 2015 / Page 14of 72
mg tablets) according to the dose prescribed and the possibility to down-titrate/up-titrate b y a 
maximum of 50 mg/day steps o n a weekl y basis. In case of study drug discontinuation, a last 
down -titration step at 20mg/day for 1 week will be included prior to the study -drug free 
period.  Containers of 80 tablets will be progressively removed.
Oral tablets of 10 mg and 25 mg BRV will be used in this study .Initiall y, BRV 2.5 mg and 
10 mg tablets were packaged in blister cards containing 20 tablets each. Visit cartons of 80 
(4blister cards) and 200 (10 blister cards) tablets were provided and each visit carton had a 
unique, pre-printed identification number.In November 2006, a transition from blister cards to HDPE (High Density  Poly ethylene) 
bottles was implemented. Brivaracetam 2.5 mg oral tablets were packaged in bottles of 200 
tablets and BRV 10 mg oral tablets were packaged in bottles of 80 and 200 tablets. Each 
bottle has a unique, pre-printed identification number. Containers of 80 tablets will be 
progressivel y removed.
HDPE bottles containing 80 and 200 oral tablets of BRV 25 mg will be available when 
subjects begin enrolling from BRV Phase III studies (N01252, N01253, and N01254).   
Containers of [ADDRESS_687791] will be informed on how to take the drug and that there is an excess of drug in the visit carton or bottle.
Methodology:
This is a Phase III, therapeutic long -term follow-up, multicenter, non-comparative, open-label 
and single arm study .
This study will run throughout the duration of the clinical development period of BRV and 
will thus include the therapeutic explorator y study completed during the early  stage of 
development as well as therapeutic confirmatory studies which will be completed in the later 
stages of development.  For this reason, the study design of this stud y and in particular the 
frequency  of study visits is adapted for the 2types of phases as described below.
For those subjects coming from the therapeutic exploratory  study , visits will be scheduled as 
follows:
First y ear:
 During the first 6 months there will be 1 visit/month; 1 Full Evaluation Visit 
(FEV) alternating with 1 Minimal Evaluation Visit (MEV).
 During the next 6 months there will be 1 visit every 3 months; 2 FEV (at V7and V8).
Second and subsequent years:
 1 visit every  3 months; [ADDRESS_687792] will be informed on how to take the drug and that there is an excess of drug in COPY BRV
COPY BRV
udies (N01252, N01253, COPY udies (N01252, N01253, 
y removed.COPY y removed.
This document First y
document First ycannot For those subjects coming 
cannot For those subjects coming 
cannot follows:
cannot follows:
First ycannot First ybe For those subjects coming be For those subjects coming used stages of development.  For this reason, the 
used stages of development.  For this reason, the 
studyused studyto development as well as therapeutic confirmatoryto development as well as therapeutic confirmatory
stages of development.  For this reason, the to stages of development.  For this reason, the support will run throughout the duration of the clinical development period of 
support will run throughout the duration of the clinical development period of 
therapeutic explorator
support therapeutic explorator
development as well as therapeutic confirmatory support development as well as therapeutic confirmatoryany marketing hase III, therapeutic longmarketing hase III, therapeutic long -tmarketing -term followmarketing erm followauthorization udies (N01252, N01253, 
authorization udies (N01252, N01253, 
y removed.
authorization y removed.
Each subject will be informed on how to take the drug and that there is an excess of drug in 
authorization Each subject will be informed on how to take the drug and that there is an excess of drug in application Containers of 80
application Containers of 80
25 mg will be available when application 25 mg will be available when 
udies (N01252, N01253, application udies (N01252, N01253, and Brivaracetam 2.5 mg oral tablets were packaged in bottles of 200 
and Brivaracetam 2.5 mg oral tablets were packaged in bottles of 200 
ed in bottles of 80 and 200 tablets. and ed in bottles of 80 and 200 tablets. 
Containers of 80 and Containers of 80any  Poly
any  Poly
Brivaracetam 2.5 mg oral tablets were packaged in bottles of 200 any Brivaracetam 2.5 mg oral tablets were packaged in bottles of 200 extensions of 80 
extensions of 80 
blister cards) and 200 (10 blister cards) tablets were provided and each visit carton had a 
extensions blister cards) and 200 (10 blister cards) tablets were provided and each visit carton had a 
 Polyextensions  Poly ethextensions ethor 2.5 mg and 
or 2.5 mg and 
of 80 or of 80 variations 2.5 mg and variations 2.5 mg and thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687793] 2015 / Page 15of 72
 The Yearly Evaluation Visit (YEV) will be performed in replacement of the first 
FEV of each year.
For those subjects coming from therapeutic confirmatory studies:
First y ear:
 First 3 months: 1 visit/month: FEV alternating with MEV.
 Next 9 months: 1 visit/3 months: FEV alternating with MEV.
Second and subsequent years:
 1 visit/3 months: FEV alternating with MEV.
 The YEV will be performed in replacement of the first FEV of each year.
Variables and Assessments:
The efficacy variables will be assessed by  [CONTACT_529434].  The subject will be asked to record the date and the number (where possible) of 
epi[INVESTIGATOR_529343]/she has experienced.  The type of seizure (according to individual description of seizures) will be defined b y the Investigator b y adding the ILAE codes.  The 
Investigator will also confirm on the DRC the number of seizures of each type experienced by [CONTACT_423].
The periods considered in the definition of efficacy variables are the following:
3-month periods over the Evaluation Period (V1 until the last evaluation visit).
Primary  safet y variables :
Occurrence of a TEAE
Withdrawal due to an AE
Occurrence of an SAE
Other safety  variables:
Laboratory  tests (hematology , blood chemistry , urinaly sis)
Vital signs (s ystolic blood pressure [SBP]), diastolic blood pressure [DBP], pulse rate) 
and body weight
Electrocardiogram (ECG)
Physical and neurological examinationsREDACTED The periods considered in the definition of efficacy variables are the following:
REDACTED The periods considered in the definition of efficacy variables are the following:
-month periods over the Evaluation P
REDACTED -month periods over the Evaluation P eriod (V1 until the last evaluation visit).
REDACTED eriod (V1 until the last evaluation visit).COPY y the Investigator b
COPY y the Investigator b
Investigator will also confirm on the DRC the number of seizures of each ty
COPY Investigator will also confirm on the DRC the number of seizures of each ty
This document cannot Laboratory
cannot Laboratory
cannot Vital signs (scannot Vital signs (sbe Laboratorybe Laboratoryused  variables
used  variables
used to Occurrence of an SAE
to Occurrence of an SAE support Withdrawal due to an AE
support Withdrawal due to an AE
Occurrence of an SAE support Occurrence of an SAEany Withdrawal due to an AEany Withdrawal due to an AEmarketing authorization Investigator will also confirm on the DRC the number of seizures of each ty
authorization Investigator will also confirm on the DRC the number of seizures of each ty
The periods considered in the definition of efficacy variables are the following:
authorization The periods considered in the definition of efficacy variables are the following:
eriod (V1 until the last evaluation visit).authorization eriod (V1 until the last evaluation visit).application  using the seizure count informati
application  using the seizure count informati
DRC.  The subject will be asked to record the date and the number (where possible) of 
application DRC.  The subject will be asked to record the date and the number (where possible) of 
ype of seizure (according to individual 
application ype of seizure (according to individual 
y the Investigator b
application y the Investigator b y 
application y adding the ILAE codes.  The 
application adding the ILAE codes.  The 
Investigator will also confirm on the DRC the number of seizures of each ty application Investigator will also confirm on the DRC the number of seizures of each tyand  using the seizure count informati and  using the seizure count informatiany The YEV will be performed in replacement of the first FEV of each 
any The YEV will be performed in replacement of the first FEV of each extensions The YEV will be performed in replacement of the first FEV of each extensions The YEV will be performed in replacement of the first FEV of each yeextensions yeor variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687794] 2015 / Page 16of 72
Change in Hospi[INVESTIGATOR_5620] (HADS) scores from the Baseline 
of the previous stud y to each assessment for the first [ADDRESS_687795] 2 years
Secondary  efficacy  variables
POS (ty pe I) frequency  per 28 day s during the Evaluation Period
Percent reduction in POS (ty pe I)frequency  per 28 day s from Baseline of t he previous 
study  to the Evaluation Period
Responder rate for POS (ty pe I) frequency  over the Evaluation Period. A responder is
defined as a subject with a ≥50% reduction in seizure frequency  from the Baseline 
Period of the previous study
Other efficacy  variables
For subjects with focal- onset epi[INVESTIGATOR_002] :
Percentage of subjects continuously  seizure -free for all seizure types (I+II+III) for at 
least [ADDRESS_687796] 12 months during the Evaluation Period
For subjects with generalized epi[INVESTIGATOR_002]:
Generalized (type II) seizure day s per 28 day s during the Evaluation Period
Percent reduction in generalized (ty pe II) seizure day s per 28 day s from Baseline of the 
previous study to the Evaluation Period
Responder rate for generalized (ty pe II) seizure days over the Evaluation Period. A 
responder is defined as a subject with a ≥50% reduction in seizure day s from the 
Baseline Period of the previous study
Percentage of subjects continuously  seizure -free for all seizure ty pes (I+II+III) for at 
least [ADDRESS_687797] 12 months during the Evaluation Period
The following will be evaluated separatel y for subjects with focal -onset epi[INVESTIGATOR_529344] y:
Change in Patient Weighted Quality  of Life in Epi[INVESTIGATOR_122146] (QOLIE-31- P)
scores from Baseline of the previ ous study  to each assessment for the first [ADDRESS_687798] 12 months during the Evaluation Period
For subjects with generalized epi[INVESTIGATOR_529345] :
REDACTED :COPY free for all seizure tyCOPY free for all seizure ty
This document with generalized epi[INVESTIGATOR_529346] [ADDRESS_687799] with a 
Baseline Period of the previous study to Baseline Period of the previous studysupport previous study to the Evaluation Period
support previous study to the Evaluation Period
Responder rate for generalized (ty
support Responder rate for generalized (ty
responder is defined as a subject with a support responder is defined as a subject with a 
Baseline Period of the previous studysupport Baseline Period of the previous studyany Percent reduction in generalized (ty
any Percent reduction in generalized (ty
previous study to the Evaluation Periodany previous study to the Evaluation Periodmarketing pe II) seizure day
marketing pe II) seizure day s per 28 day
marketing s per 28 day
Percent reduction in generalized (ty marketing Percent reduction in generalized (tyauthorization free for all seizure ty
authorization free for all seizure ty
least [ADDRESS_687800] 12 months during the Evaluation Periodapplication and  from the Baseline 
and  from the Baseline any  over the Evaluation Period. A responder is
any  over the Evaluation Period. A responder is
 from the Baseline any  from the Baseline extensions he previous 
extensions he previous 
 over the Evaluation Period. A responder isextensions  over the Evaluation Period. A responder isor variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final /[ADDRESS_687801] 2015 / Page 17of 72
EuroQol 5 Dimensions (EQ-5D) questionnaire response for each assessment for the first 
2years for the Evaluation Period and for the las t assessment during the first 2 y ears of 
theEvaluation Period
Pharmacoeconomic variables
The following will be evaluated separatel y for subjects with focal -onset epi[INVESTIGATOR_529347] y:
Direct costs (healthcare provider consultations not foreseen b y the protocol, concurrent 
medical procedures, concomitant medications, hospi[INVESTIGATOR_602], and emergency  room 
[ER] visits) during the first 2 y ears of the Evaluation Period
Indirect costs (work day s or school days lost by  [CONTACT_122252] s subject received 
help from a caregiver) during the first 2 years of the Evaluation Period
Socio -professional data for each assessment for the first [ADDRESS_687802] received extensions y the protocol, concurrent 
extensions y the protocol, concurrent 
medical procedures, concomitant medications, hospi[INVESTIGATOR_602], and emergency
extensions medical procedures, concomitant medications, hospi[INVESTIGATOR_602], and emergencyor  and subjectsor  and subjects variations  and subjects variations  and subjectsthereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687803] 2015 / Page 18of 72
5.1 Study Schedule of Assessments
Table 5:1 Study  Flowchart
Entry 
Visit
(EV)Full 
Evaluation 
Visit 
(FEV)Minimal 
Evaluation 
Visit 
(MEV)Yearly 
Evaluation 
Visit 
(YEV)Additional 
Visit
(AV)Early 
Discontinuation 
Visit
(EDV)(a) Down -Titration 
Phone Call
(DTP)(a) Final Visit
(FV)Reference to 
Section
ASSESSMENTS
Written Informed Consent X 11.1.[ADDRESS_687804] 
DispensingX 11.1.2
Verification Inclusion/ Exclusion CriteriaX 9.1and 9.2
Demographic Data X 11.1.3
Childbearing Potential X 11.1.4
Medical and Procedures History X(b) 11.1.5
Epi[INVESTIGATOR_122153] X(b) 11.1.6
AED History X(b) 11.1.7
Vital Signs X(c) X X X X X X 11.1.8
Weight and Height(d) XX X X X 11.1.9
Physical Examination X(c) X X X X 11.1.10
Neurological Examination X(c) X X X X 11.1.11
ECG(e) X(c) X X X 11.1.[ADDRESS_687805] Retrieval XX X X X X 11.1.13
Recording of Seizures X(c) X X X X X 11.1.13
QOLIE -31-P(f)(k)X X X 11.1.20
HADS(f)(k)X X X 11.1.21REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED COPY COPY COPY COPY COPY COPY COPY 
This document cannot cannot cannot cannot cannot cannot cannot be X
be X(c) 
be (c) 
be used XX
used XX
used XXused XXused used used used (c) used (c) used to XX to XX to support support support support support support X
support X
support support any X
any X
any any marketing marketing marketing marketing marketing marketing marketing marketing marketing marketing marketing Xmarketing Xmarketing authorization authorization authorization authorization authorization authorization authorization authorization authorization authorization application Discontinuation 
application Discontinuation 
Visit
application Visit
application application application application application application application and Early and Early 
Discontinuation and Discontinuation and any extensions or variations CONFIDENTIAL
variations CONFIDENTIAL
15 Octvariations 15 Octthereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687806] 2015 / Page 19of 72
Table 5:1 Study  Flowchart (continued)
Entry 
Visit
(EV)Full 
Evaluation 
Visit
(FEV)Minimal 
Evaluation 
Visit 
(MEV)Yearly 
Evaluation 
Visit
(YEV)Additional 
Visit
(AV)Early 
Discontinuation 
Visit(a) 
(EDV)Down -Titration 
Phone Call
(DTP)(a) Final Visit
(FV)Reference to 
Section
EQ-5D(g) (k)X X X 11.1.[ADDRESS_687807] / 
days with caregiver’s help (k) X X X X X X11.1.13
Hospi[INVESTIGATOR_7985](k)X X X X X X 11.1.23
Heathcare Provider Consultations
not foreseen by [CONTACT_760](k) X X X X X X 11.1.24
Socio -professional D ata(h) (k)X X 11.1.25
Laboratory Assessments(i) X(c) X X X X 11.1.14
Recording of Adverse Events X X X X X X X X 11.1.15
C-SSRS(l)X X X X X X 11.1.16
Medical Procedures XX X X X X X 11.1.17
Concomitant AED XX X X X X X 11.1.18
Concomitant Non-AED XX X X X X X 11.1.18
Drug Dispensing XX X X X10.1.2 and 
10.1.6
Drug Return/Accountability X X X X X10.1.6 and 
10.1.7
End of Study Status(j) X 11.1.26REDACTED X
REDACTED X
REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED COPY COPY COPY COPY COPY COPY COPY 
This document cannot be used to to support support support support support support support any Xany Xany any marketing X
marketing X
X
marketing X
marketing marketing marketing marketing marketing marketing marketing marketing marketing marketing Xmarketing Xmarketing marketing authorization X
authorization X
X
authorization X
authorization authorization authorization authorization authorization authorization Xauthorization Xauthorization Xauthorization Xauthorization application (EDV)
application (EDV)
X
application X
application application application application application application application and Discontinuation 
and Discontinuation 
Visitand Visit(a) 
and (a) 
(EDV)and (EDV)any Discontinuation any Discontinuation any any extensions extensions or variations CONFIDENTIAL
variations CONFIDENTIAL
15 Octvariations 15 Octthereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protocol:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687808] 2015 / Page 20of 72
Table 5:1 Study  Flowchart (continued)
AED=antiepi[INVESTIGATOR_32551]; AV=Additional Visit; CRF=Case Report Form; C-SSRS=Columbia Suicide Severity Rating Scale; DTP=Down -titration Phone 
Call; ECG=electrocardiogram; EDV=Early Discontinuation Visit; EV=Entry Visit; FEV=Full Evaluation Visit; FV=Final Visit; HADS= Hospi[INVESTIGATOR_56106]; MEV=Minimal Evaluation Visit; QOLIE -31-P =Patient Weighted Quality of life in Epi[INVESTIGATOR_56005]; YEV=Yearly 
Evaluation Visit
(a) Dow n-Titration phone call at the end of the down -titration period is mandatory in case the subjects discontinue from more than 20mg/day BRV .
(b) The following data will be transferred from the database of the baseline visit of the previous study and should not be recorded into the CRF:  General 
Medical and Proce dure History, AED History and Epi[INVESTIGATOR_122153].
(c) The following data will be transferred from the database of the last visit of the previous study and should not be recorded in the CRF:  Vital Signs, 
Physical Examination, Neurological Examination, ECG, Recording of seizures , Laboratory Assessment including Safety (blood chemistry, hematology 
and urinalysis) 
(d) Height will be recorded at Visit 1 (Entry Visit).  Height will also be measured at each YEV and the Final Visit for those subjects that are still potentially 
grow ing.
(e) At Final Visit, ECG is mandatory except if Final Visit follows an Early D iscontinuation Visit where ECG results were normal .
(f)QOLIE -31-P and HADS are to be completed at the beginning of the visit by [CONTACT_35668] (except those coming from N01193) who are not mentally 
impaired.
(g) EQ-5D questionnaire is to be completed by [CONTACT_35668] (except those coming from N01193) who are not mentally impaired.
(h) Socio -professional data will be collected for all subjects except those coming from N01193.
(i) Laboratory assessment includes blood chemistry, hematology and urine analysis; where applicable (w omen of childbearing potential), a urine pregnancy 
test will be done . Laboratory assessment is mandatory at Final visit except if Fi nal Visit follow s an Early Discontinuation V isit where laboratory results 
were normal.
(j) End of study status will be completed at the FV for subjects having performed an EDV (discontinued subjects) and for subjects leaving the study at the 
end of the pr ogram (completed subjects).
(k) Procedures only performed during the first [ADDRESS_687809] participation in the study (eg, until last scheduled visit [Y3-Y EV]) or EDV/FV in case the 
subject discontinues participation within the first 2 years).
(l)The C-SSRS assessment will be implemented by [CONTACT_122259]/IEC approval and upon completion of required training.  As of the time of Protocol Amendment 6, all 
subjects had completed their Entry Visit.  Thus, the C-SSRS was not assessed for any subjects at the irEntry V isit.
(m)For subjects that may transition to another BRV study or a managed access program or similar type of program, the EDV will need to be completed, however 
down -titration and FV may not be applicable .REDACTED Recording of seizures
REDACTED Recording of seizures , 
REDACTED , Laboratory Assessment including Safety (blood chemistry, hematology 
REDACTED Laboratory Assessment including Safety (blood chemistry, hematology 
Height will be recorded at Visit 1 (Entry Visit).  Height will also be measured at 
REDACTED Height will be recorded at Visit 1 (Entry Visit).  Height will also be measured at 
s an 
REDACTED s an E
REDACTED Early 
REDACTED arly 
P and HADS are to be completed at the beginning of the visit by [CONTACT_35668] (except tho REDACTED P and HADS are to be completed at the beginning of the visit by [CONTACT_35668] (except thoCOPY The following data will be transferred from the database of the baseline visit of the previous 
COPY The following data will be transferred from the database of the baseline visit of the previous 
The following data will be transferred from the database of the last visit of the previous COPY The following data will be transferred from the database of the last visit of the previous 
Laboratory Assessment including Safety (blood chemistry, hematology COPY Laboratory Assessment including Safety (blood chemistry, hematology 
This document cannot For subjects that may transition to another BRV study or a managed access program or similar type of program, the EDV will ne
cannot For subjects that may transition to another BRV study or a managed access program or similar type of program, the EDV will ne
cannot titration and FV may not be applicable
cannot titration and FV may not be applicablebe subjects had completed their Entry Visit.  Thus, the Cbe subjects had completed their Entry Visit.  Thus, the C
For subjects that may transition to another BRV study or a managed access program or similar type of program, the EDV will ne be For subjects that may transition to another BRV study or a managed access program or similar type of program, the EDV will neused Procedures only performed during the first [ADDRESS_687810] 2
SSRS assessment will be implemented by [CONTACT_122259]/IEC approval and upon completion of required training.used SSRS assessment will be implemented by [CONTACT_122259]/IEC approval and upon completion of required training.
subjects had completed their Entry Visit.  Thus, the C used subjects had completed their Entry Visit.  Thus, the Cto Procedures only performed during the first 2to Procedures only performed during the first [ADDRESS_687811] 2support Laboratory assessment is mandatory at Final visit except if Fi
support Laboratory assessment is mandatory at Final visit except if Fi
status will be completed at the FV for subjects having performed an EDV (discontinued subjects) and for subjects leaving the 
support status will be completed at the FV for subjects having performed an EDV (discontinued subjects) and for subjects leaving the 
years of support years of any professional data will be collected for all subjects except those 
any professional data will be collected for all subjects except those 
Laboratory assessment includes blood chemistry, hematology and urine analysis; where applicable (w
any Laboratory assessment includes blood chemistry, hematology and urine analysis; where applicable (w
Laboratory assessment is mandatory at Final visit except if Fi any Laboratory assessment is mandatory at Final visit except if Fimarketing arly 
marketing arly 
P and HADS are to be completed at the beginning of the visit by [CONTACT_35668] (except tho
marketing P and HADS are to be completed at the beginning of the visit by [CONTACT_35668] (except tho
5D questionnaire is to be completed by [CONTACT_35668] (except those coming from N01193) who are not mentally impaired.
marketing 5D questionnaire is to be completed by [CONTACT_35668] (except those coming from N01193) who are not mentally impaired.
professional data will be collected for all subjects except those marketing professional data will be collected for all subjects except those 
Laboratory assessment includes blood chemistry, hematology and urine analysis; where applicable (wmarketing Laboratory assessment includes blood chemistry, hematology and urine analysis; where applicable (wauthorization The following data will be transferred from the database of the last visit of the previous 
authorization The following data will be transferred from the database of the last visit of the previous 
Laboratory Assessment including Safety (blood chemistry, hematology 
authorization Laboratory Assessment including Safety (blood chemistry, hematology 
Height will be recorded at Visit 1 (Entry Visit).  Height will also be measured at 
authorization Height will be recorded at Visit 1 (Entry Visit).  Height will also be measured at 
arly authorization arly Dauthorization Discontinuation Visit where ECG results were normalauthorization iscontinuation Visit where ECG results were normalapplication =Patient Weighted Quality of life in Epi[INVESTIGATOR_56005]; YEV=Yearly 
application =Patient Weighted Quality of life in Epi[INVESTIGATOR_56005]; YEV=Yearly 
period is mandatory in case the subjects discontinue from more than 
application period is mandatory in case the subjects discontinue from more than 
The following data will be transferred from the database of the baseline visit of the previous 
application The following data will be transferred from the database of the baseline visit of the previous study
application study
studyapplication studyand Call; ECG=electrocardiogram; EDV=Early Discontinuation Visit; EV=Entry Visit; FEV=Full Evaluation Vis
and Call; ECG=electrocardiogram; EDV=Early Discontinuation Visit; EV=Entry Visit; FEV=Full Evaluation Vis
=Patient Weighted Quality of life in Epi[INVESTIGATOR_56005]; YEV=Yearly and =Patient Weighted Quality of life in Epi[INVESTIGATOR_56005]; YEV=Yearly any SSRS=Columbia Suicide Severity Rating Scale; any SSRS=Columbia Suicide Severity Rating Scale; 
it; FV=Final Visit; HADS=any it; FV=Final Visit; HADS=extensions or variations CONFIDENTIAL
variations CONFIDENTIAL
15 Octvariations 15 Octthereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687812] 2015 / Page 21of 72
5.2 Schematic Diagram
For subjects coming from the therapeutic exploratory study  (N01193) , visits will be 
scheduled as follows:
First y ear:
 During the first 6 months there will be 1 visit/month; 1 Full Evaluation Visit 
(FEV) alternating with 1 Minimal Evaluation Visit (MEV).
 During the next 6 months there will be 1 visit every 3 months; 2 FEV (at V7
and V8) .
Second and subsequent years:
 1 visit every  3 months; 1 FEV alternating with 1 MEV.
 The Yearl y Evaluation Visit (YEV) will be performed in replacement of the first 
FEV of each year.
For th ose subjects coming from therapeutic confirmatory  studies (N01252, N01253, and 
N01254):
First y ear:
 First 3 months: 1 visit/month: FEV alternating with MEV.
 Next 9 months: 1 visit/3 months: FEV alternating with MEV.
Second and subsequent years:
 1 visit/3months: FEV alternating with MEV.
 The YEV will be performed in replacement of the first FEV of each year.REDACTED FEV alternating with MEV.
REDACTED FEV alternating with MEV.
1 visit/3 months:
REDACTED 1 visit/3 months:
REDACTED FEV alternating with MEV.REDACTED FEV alternating with MEV.COPY confirmatory
COPY confirmatory
This document cannot be used to support any marketing FEV alternating with MEV.
marketing FEV alternating with MEV.
The YEV will be performed in replacement of the first FEV of each 
marketing The YEV will be performed in replacement of the first FEV of each authorization FEV alternating with MEV.
authorization FEV alternating with MEV.
FEV alternating with MEV.
authorization FEV alternating with MEV.
FEV alternating with MEV.authorization FEV alternating with MEV.application be performed in replacement of the first 
application be performed in replacement of the first 
studies
application studiesand be performed in replacement of the first and be performed in replacement of the first any extensions During the first 6 months there will be 1 visit/month; [ADDRESS_687813] 6 months there will be 1 visit/month; 1 Full Evaluation Visit 
months there will be 1 visit every 3 months; 2 FEV (at V7
extensions months there will be 1 visit every 3 months; 2 FEV (at V7or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687814] 2015 / Page 22of 72
Table 5:2 Visit Schematic Diagrams
Subjects coming from Exploratory Study
(N01193)Subjects comi ng from Confirmatory  
Studies (N01252, N01253, N01254)
1st Year Follow -up 1stYear Follow -up
Month Visit Type of Visit Month Visit Type of Visit
M0 V1 Entry  Visit M0 V1 Entry  Visit
M1 V2 MEV M1 V2 MEV
M2 V3 FEV M2 V3 FEV
M3 V4 MEV M3 V4 MEV
M4 V5 FEV M4
M5 V6 MEV M5
M6 V7 FEV M6 V5 FEV
M7 M7
M8 M8
M9 V8 FEV M9 V6 MEV
M10 M10
M11 M11
2ndand subsequent years follow- up 2ndand subsequent years follow- up
M12 V9 YEV M12 V7 YEV
M15 V10 MEV1 M15 V8 MEV1
M18 V11 FEV M18 V9 FEV
M21 V12 MEV2 M21 V10 MEV2
In case the subject will not continue with the study drug, the Investigator will first plan an 
Early Discontinuation Visit followed by [CONTACT_529435]- titration of the study drug.  
During the down-titrat ion period, the dose may be decreased in steps of a maximum of
50mg/day  on a weekl y basis. A last down- titration step at 20mg/day for 1week will be 
included prior to the study  drug free period.
At the end of the down -titration period, a phone call will be given to subjects having down -
titrated from doses higher than 20 mg/day . The down-titration period will be followed b y a 
period free of study drug of a minimum of 2 weeks and a maximum of 4 weeks and 
subsequently , the Final Visit will occur.
When the time point is reached at which the stud y will be terminated b y the sponsor (as 
defined in Section 8.4), subjects will discontinue the study drug, following the Investigator’s 
instructions for down- titration if necessary .REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED REDACTED and subsequent years follow-
REDACTED and subsequent years follow- up
REDACTED up
REDACTED YEVREDACTED YEVREDACTED MEV1REDACTED MEV1REDACTED COPY M7
COPY M7
M8
COPY M8
COPY COPY COPY 
This document subsequently
document subsequently
When the
document When thecannot At the end of the down
cannot At the end of the down
titrated from doses higher than 
cannot titrated from doses higher than 
cannot period free of cannot period free of 
subsequentlycannot subsequentlybe At the end of the down be At the end of the downused  on a weekl
used  on a weekl
used included prior to the 
used included prior to the to titrat
to titrat
 on a weekl to  on a weekl y basis. to y basis. support In case the subject will not continue with 
support In case the subject will not continue with 
y Discontinuation Visit followed by [CONTACT_529436] y Discontinuation Visit followed by [CONTACT_529437], the dose maysupport ion period, the dose may
y basis. support y basis. any ME
any ME
any any In case the subject will not continue with any In case the subject will not continue with marketing marketing marketing marketing FEV
marketing FEV
marketing marketing MEmarketing MEmarketing V2marketing V2marketing marketing authorization M8
authorization M8
M9
authorization M9
authorization M10
authorization M10
authorization authorization authorization authorization authorization authorization authorization authorization authorization authorization application application application application application application application application application application application application application and and and any any any any any any any extensions Type of Visit
extensions Type of Visit
extensions Entry
extensions Entry  Visit
extensions  Visit Entry  Visit Entry
extensions Entry  Visit Entry
extensions extensions extensions or or variations variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687815] 2015 / Page 23of [ADDRESS_687816] common and challenging neurological disorders.  It has been 
estimated that over 50 million people are affected worldwide (Engel and Pedley , 1998; 
Hauser et al, 1993; L oiseau et al, 1990; Sander and Shorvon, 1996) .  The prevalence of 
epi[INVESTIGATOR_122154] 1%. The annual incidence in developed countries is approximately  [ADDRESS_687817] epi[INVESTIGATOR_30989] y 
lifelong.  The disease duration is often determined by [CONTACT_122262].  Sudden 
unexpected death, a complication of great concern, occur s in 1 to 5 per 1000 patient y ears, 
particularl y if the seizure disorder remains uncontrolled.  The treatment for epi[INVESTIGATOR_122155], and there is ongoing medical need for new antiepi[INVESTIGATOR_006] (AEDs).  For considerable proportions of patients, seizure freedom can still not be reached with currently available AEDs (Nasreddine et al, 2010; Kwan and Brodie, 2001).
Diagnosis of epi[INVESTIGATOR_122156].  Seizures may be caused b y an 
underly ing brain disorder or lesion or due to genetic conditions.  Characterization of the 
epi[INVESTIGATOR_122157].  The major 
dichotomy  for the diagnosis of epi[INVESTIGATOR_122158] (ie, 
related to a focal brain dy sfunction), which are the most frequent and account for 
approximately  60 to 70% of all cases, and generalized epi[INVESTIGATOR_002] s yndromes, which represent 
approximately  25 to 30% of all epi[INVESTIGATOR_30989] y syndromes.  I n about 10% of cases, other specific 
syndromes are classified or the classification remains uncertain.
The classification of epi[INVESTIGATOR_529348] –and alway s was – a matter of 
ongoing debate.  First published in [ADDRESS_687818] updated officially in 1981 for seizures and 1989 for epi[INVESTIGATOR_31629] (Commission on Classification and Terminology of the International League Against Epi[INVESTIGATOR_002] ([ILAE], 1981 and 1989), these ILAE classifications were based on concepts that, for the most part, predate modern technologies and concepts (Engel, 2006)ILAE ( http://ww w.ilae- epi[INVESTIGATOR_002] .org).  The availability  of these modern techniques, like long-
term video electroencephalograms (EEGs) and high-resolution magnetic resonance imaging (MRI), providing much more precise knowledge in regard to seizure t ype classifications and 
epi[INVESTIGATOR_122245], led some epi[INVESTIGATOR_529349] s ystems (like the Cleveland Clinic Epi[INVESTIGATOR_529350]) and even debating 
how useful the currentl y used ILAE classification sy stem is at all (Lüde rs et al, 2006).
This ongoing debate regarding the classification systems for epi[INVESTIGATOR_529351] (Nasreddine et al, 2010; Kwan and Brodie, 2001).
REDACTED (Nasreddine et al, 2010; Kwan and Brodie, 2001).
y is based on the recurrence of seizures.  Seizures may be caused b
REDACTED y is based on the recurrence of seizures.  Seizures may be caused b
ing brain disorder or lesion or due to genetic conditions.  Characterization of the 
REDACTED ing brain disorder or lesion or due to genetic conditions.  Characterization of the 
ndrome has profound implications for treatment and prognosis.  The major REDACTED ndrome has profound implications for treatment and prognosis.  The major COPY y if the seizure disorder remains uncontrolled.  The treatment for epi[INVESTIGATOR_529352] y if the seizure disorder remains uncontrolled.  The treatment for epi[INVESTIGATOR_122155], and there is ongoing medical need for new antiepi[INVESTIGATOR_006] (AEDs).  For 
COPY difficult, and there is ongoing medical need for new antiepi[INVESTIGATOR_006] (AEDs).  For 
eizure freedom can still not be reached with currentlyCOPY eizure freedom can still not be reached with currently
(Nasreddine et al, 2010; Kwan and Brodie, 2001).COPY (Nasreddine et al, 2010; Kwan and Brodie, 2001).
This document term video electroencephalograms (EEGs) and high
document term video electroencephalograms (EEGs) and high
(MRI), providing much more precise knowledge in regard to seizure t
document (MRI), providing much more precise knowledge in regard to seizure t
epi[INVESTIGATOR_529353], for the most part, predate modern technologies and concepts 
cannot concepts that, for the most part, predate modern technologies and concepts 
cannot ILAE (
cannot ILAE ( http://ww
cannot http://ww
term video electroencephalograms (EEGs) and highcannot term video electroencephalograms (EEGs) and highbe League Against Epi[INVESTIGATOR_002] ([ILAE], 1981 and 1989), these ILAE classifications were based on be League Against Epi[INVESTIGATOR_002] ([ILAE], 1981 and 1989), these ILAE classifications were based on 
concepts that, for the most part, predate modern technologies and concepts be concepts that, for the most part, predate modern technologies and concepts used ongoing debate.  First published in [ADDRESS_687819] updated officially
1989 for epi[INVESTIGATOR_31629] (Commused 1989 for epi[INVESTIGATOR_31629] (Comm
League Against Epi[INVESTIGATOR_002] ([ILAE], 1981 and 1989), these ILAE classifications were based on used League Against Epi[INVESTIGATOR_002] ([ILAE], 1981 and 1989), these ILAE classifications were based on to The classification of epi[INVESTIGATOR_529354].  First published in [ADDRESS_687820] updated officiallysupport  25 to 30% of all epi[INVESTIGATOR_529355]  25 to 30% of all epi[INVESTIGATOR_529356].
support or the classification remains uncertain.
The classification of epi[INVESTIGATOR_529357]  60 to 70% of all cases, and generalized epi[INVESTIGATOR_529358]  60 to 70% of all cases, and generalized epi[INVESTIGATOR_002]
 25 to 30% of all epi[INVESTIGATOR_529359]  25 to 30% of all epi[INVESTIGATOR_529360].  Characterization of the 
marketing ing brain disorder or lesion or due to genetic conditions.  Characterization of the 
ndrome has profound implications for treatment and prognosis.  The major 
marketing ndrome has profound implications for treatment and prognosis.  The major 
 for the diagnosis of epi[INVESTIGATOR_529361] (ie, 
marketing  is the differentiation between focal epi[INVESTIGATOR_31629] (ie,  for the diagnosis of epi[INVESTIGATOR_122158] (ie,  for the diagnosis of epi[INVESTIGATOR_529361] (ie,  for the diagnosis of epi[INVESTIGATOR_529362]), which are the most frequent and account for marketing ction), which are the most frequent and account for 
 60 to 70% of all cases, and generalized epi[INVESTIGATOR_529363]  60 to 70% of all cases, and generalized epi[INVESTIGATOR_529364]
(Nasreddine et al, 2010; Kwan and Brodie, 2001).
authorization (Nasreddine et al, 2010; Kwan and Brodie, 2001).
y is based on the recurrence of seizures.  Seizures may be caused b
authorization y is based on the recurrence of seizures.  Seizures may be caused b
ing brain disorder or lesion or due to genetic conditions.  Characterization of the authorization ing brain disorder or lesion or due to genetic conditions.  Characterization of the application yi
application ying cause.  Sudden 
application ng cause.  Sudden 
s in 1 to
application s in 1 to 5
application 5per 1000
application per 1000
y if the seizure disorder remains uncontrolled.  The treatment for epi[INVESTIGATOR_529365] y if the seizure disorder remains uncontrolled.  The treatment for epi[INVESTIGATOR_122155], and there is ongoing medical need for new antiepi[INVESTIGATOR_006] (AEDs).  For application difficult, and there is ongoing medical need for new antiepi[INVESTIGATOR_006] (AEDs).  For 
eizure freedom can still not be reached with currentlyapplication eizure freedom can still not be reached with currentlyand many people, particularl
and many people, particularl
children, the condition may remit, although a significant proportion will have epi[INVESTIGATOR_529366], the condition may remit, although a significant proportion will have epi[INVESTIGATOR_529367].  Sudden and ng cause.  Sudden any  with age, with high rates occurring in childhood, falling to low levels in earl
any  with age, with high rates occurring in childhood, falling to low levels in earl
many people, particularl any many people, particularlextensions The prevalence of 
extensions The prevalence of 
The annual incidence in developed countries is approximately
extensions The annual incidence in developed countries is approximately  50 to 
extensions  50 to The annual incidence in developed countries is approximately  50 to The annual incidence in developed countries is approximately
extensions The annual incidence in developed countries is approximately  50 to The annual incidence in developed countries is approximately
70 cases per 100.000.  In developi[INVESTIGATOR_14696], the figure is higher due to more limited 
extensions 70 cases per 100.000.  In developi[INVESTIGATOR_14696], the figure is higher due to more limited 
stetric services and the greater likelihood of cerebral infection and trauma.  extensions stetric services and the greater likelihood of cerebral infection and trauma.  The incidence extensions The incidence 
 with age, with high rates occurring in childhood, falling to low levels in earl extensions  with age, with high rates occurring in childhood, falling to low levels in earlor variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687821] 2015 / Page 24of 72
(Classification Task Force) which proposes a thoroughl y revised terminology  and concept for 
the diagnosis of epi[INVESTIGATOR_30989] y syndromes and also to some extent seizure ty pes (Berg et al, 2010). 
Despi[INVESTIGATOR_122173], for the purpose of this study, the seizure type classification will 
follow the 1981 ILAE classifi cation of epi[INVESTIGATOR_122174], which speaks of partial seizures, 
classified as simple partial seizures (no alteration of consciousness), complex partial seizures (with alteration of consciousness), and secondarily generalized seizures, and on the other hand defines generalized seizure ty pes, referred to as absence seizures (t ypi[INVESTIGATOR_122175]), 
myoclonic seizures, clonic seizures, tonic seizures, tonic-clonic seizures, and atonic seizures.  
Apart from m yoclonic seizures, consciousness is almost invariably impaired from the onset of 
the seizure (Commission on Classification and T erminology of the ILAE, 1981).
Likewise, the classification of epi[INVESTIGATOR_30989] y syndromes will be used according to the 1989 ILAE-
publication (Commission on Classification and Terminology of the ILAE, 1989).
6.[ADDRESS_687822]
Brivaracetam is a 2-pyrrolidone derivative. Like levetiracetam (LEV , Keppra
®), BRV
display s a high and selective interaction with a novel brain- specific binding site, SV2A 
(synaptic vesicle pro tein 2A).  However, the binding affinity  of BRV for SV2A is 
approximately  10-fold higher than with LEV.  This binding site appears to be the major target 
for its pharmacological activity .  Unlike LEV, BRV also reduces voltage-dependent sodium 
currents.  Br ivaracetam also reverses the inhibitory effects of negative allosteric modulators 
on gamma -aminobutyric acid ,and gl ycine -induced currents.  Brivaracetam is extensively  
metabolized, but seizure protection appears to be associated with the parent compound.
Brivaracetam is rapi[INVESTIGATOR_529368].  The 
extent of BRV absorption is not affected b y food.  The pharmacokinetics (PK) are 
dose-proportional (at least from 10 mg to 600 mg).  Brivaracetam is weakl y bound to plasma 
proteins (≤20%).  The volume of distribution is 0.5 L/kg, a value that is close to that of total 
body  water.  The plasma half- life of BRV is approximately  8hours in young healthy  male 
adults.  The main metabolic pathway  of BRV is by [CONTACT_122263], while a second pathway  is the ω1-hy droxylation mediated b y 
CYP2C19 (with contributions of several other isoenzymes).  The combination of these 2pathway s results in the hy droxyacid terminal metabolite.  These metabolites are not 
pharmacologically  active.  There is no evidence of chiral inversion of BRV.  Brivaracetam is 
eliminated primarily  by [CONTACT_529438].  More than 95% of the 
dose, with less than 9% as unchanged BRV, is excreted in urine within 72 hours after dosing.
Pharmacokinet ic studies in elderly  subjects and in subjects with renal impairment showed a 
similar PK profile of BRV compared to that in healthy subjects, while the elimination of the 
metabolites was marked ly slowed down.  A PK study in subjects with hepatic impairment 
showed a 50% increase in exposure to BRV associated with decreased h ydroxylation.REDACTED s a high and selective interaction with a novel brain
REDACTED s a high and selective interaction with a novel brain
tein 2A).  However, the binding affinity
REDACTED tein 2A).  However, the binding affinity
than with LEV
REDACTED than with LEV .  This binding site appears to be the major target 
REDACTED .  This binding site appears to be the major target 
.  Unlike LEV, 
REDACTED .  Unlike LEV, 
ivaracetam also reverses the inhibitory REDACTED ivaracetam also reverses the inhibitoryCOPY 6.[ADDRESS_687823]
levetiracetam (COPY levetiracetam (
s a high and selective interaction with a novel brainCOPY s a high and selective interaction with a novel brain
This document pharmacologically
document pharmacologically
eliminated primarily
document eliminated primarily
dose, with less than 9% as unchanged 
document dose, with less than 9% as unchanged cannot CYP2C19 (with contributions of several other isoenzy
cannot CYP2C19 (with contributions of several other isoenzy
pathway
cannot pathway
cannot s results in the hy
cannot s results in the hy
pharmacologicallycannot pharmacologicallybe corresponding carboxbe corresponding carbox
CYP2C19 (with contributions of several other isoenzy be CYP2C19 (with contributions of several other isoenzyused  water.  The plasma half
used  water.  The plasma half
adults.  The main metabolic pathwayused adults.  The main metabolic pathway
corresponding carboxused corresponding carboxto ≤20%).  The volume of distribution is 0.5to ≤20%).  The volume of distribution is 0.[ADDRESS_687824].  The 
absorption is not affected b
support absorption is not affected b
proportional (at least from 10
support proportional (at least from 10
≤20%).  The volume of distribution is 0.5 support ≤20%).  The volume of distribution is 0.5any y and completely absorbed throughout the gastrointestinal tract.  The any y and completely absorbed throughout the gastrointestinal tract.  The marketing .  Unlike LEV, 
marketing .  Unlike LEV, 
ivaracetam also reverses the inhibitory
marketing ivaracetam also reverses the inhibitory
and gl
marketing and gl ycine
marketing ycine
metabolized, but seizure protection appears to be associated with the parent compound.marketing metabolized, but seizure protection appears to be associated with the parent compound.authorization levetiracetam (
authorization levetiracetam (
s a high and selective interaction with a novel brain
authorization s a high and selective interaction with a novel brain
tein 2A).  However, the binding affinity
authorization tein 2A).  However, the binding affinity
.  This binding site appears to be the major target 
authorization .  This binding site appears to be the major target 
.  Unlike LEV, authorization .  Unlike LEV, BRVauthorization BRVapplication f the ILAE, 1989).
application f the ILAE, 1989).
levetiracetam (application levetiracetam (and yndromes will be used according to the 1989 ILAEand yndromes will be used according to the 1989 ILAE
f the ILAE, 1989). and f the ILAE, 1989).any  of the ILAE, 1981).
any  of the ILAE, 1981). extensions  generalized seizures, and on the other 
extensions  generalized seizures, and on the other 
cal and at
extensions cal and at ypi[INVESTIGATOR_2855]), 
extensions ypi[INVESTIGATOR_2855]), 
-clonic seizures, and atonic seizures.  
extensions -clonic seizures, and atonic seizures.  
impaired from the onset of extensions impaired from the onset of 
 of the ILAE, 1981). extensions  of the ILAE, 1981).or classified as simple partial seizures (no alteration of consciousness), complex partial seizures 
or classified as simple partial seizures (no alteration of consciousness), complex partial seizures 
 generalized seizures, and on the other or  generalized seizures, and on the other variations classified as simple partial seizures (no alteration of consciousness), complex partial seizures variations classified as simple partial seizures (no alteration of consciousness), complex partial seizures thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687825] 2015 / Page 25of 72
Brivaracetam does not impair the efficacy  of oral contraceptives containing ethinylestradiol 
30µg and levono rgestrel 150 µg.  Brivaracetam does not induce CYP3A4 using midazolam 
as a marker probe.  Brivaracetam has no interaction on lamotri gine (LTG) and topi[INVESTIGATOR_052].  
Brivaracetam plasma concentration is not increased by  [CONTACT_529439], a selective CYP2C8/9 
inhibitor, but is increased in a nonclinically relevant manner in Japanese subjects possessing 
defective CYP2C19 mutations.  Brivaracetam clearance is doubled by [CONTACT_21446][INVESTIGATOR_2513], a potent 
CYP inducer.
Trough levels of concomitant AEDs were monitored in all efficacy studies.  No significant 
change from Baseline nor dose-related trend was observed for the plasma concentrations of carbamazepi[INVESTIGATOR_050] (CBZ) , lamotrigine, LEV, oxcarbamazepi[INVESTIGATOR_122176], phenobarbital, 
pheny toin, topi[INVESTIGATOR_052], valproate, and zonisamide. Carbamazepi[INVESTIGATOR_529369] 20 mg/day , nearl y reaching the upper 
limit of normal (3.0 µg/mL ) at BRV doses of 100 and 150 mg/day .
6.3 Efficacy with BRV in fixed -dose Phase II/III studies in POS
Following completion of the Phase II studies (N01114, UCB protocol reference code RPCE02K0301; N01193, UCB protocol reference code RPCE05C2201), clinical results 
supported further development of BRV for the adjunctive treatment of POS.  Two adequate 
and well -controlled fixed -dose studies (N01252, UCB protocol reference code 
RPCE06G0704; N01253, UCB protocol reference code RPCE06G0705) were conducted to 
assess BRV across a dose range of 5 to 100 mg/day .
N01253 assessed BRV doses of 5, 20, and 50 mg/day and provided statistically significant 
and clinically relevant evidence of the efficacy  of BRV 50mg/day .  N01252 assessed BRV
doses of 20, 50, and 100mg/day.  Although N01252 was not positive, it provided supporting evidence for the efficacy  of BRV 100mg/day in subjects with epi[INVESTIGATOR_002].
6.4 Safety with BRV
In Phase II/IIIstudies, a favorable safet y and tolerability  profile has been demonstrated for 
BRV.  The discontinuation rate and the discontinuation rate due to treatment- emergent 
adverse events (TEAEs) were low and similar to placebo (PBO) for all studies. The most frequentl y reported TEAEs were headache, somnolence, dizziness, and fatigue.  The overall 
incidence of serious adverse events (SAEs) was low and similar to PBO.  There were no clinically relevant changes in laboratory  values, vital signs, or ECG abnormalities.
For additional details on safety and efficacy of BRV, please refer to the Investigator’s Brochure (UCB reference code RXCE06E2216).REDACTED II studies (N01114
REDACTED II studies (N01114
, UCB protocol reference code RPCE05C2201
REDACTED , UCB protocol reference code RPCE05C2201
for the adjunctive treatment of POS.  Two adequate 
REDACTED for the adjunctive treatment of POS.  Two adequate 
dose studies (N01252
REDACTED dose studies (N01252
, UCB protocol reference code RPCE06G0705) were conducted to REDACTED , UCB protocol reference code RPCE06G0705) were conducted to COPY II/III studies in POS
COPY II/III studies in POS
II studies (N01114COPY II studies (N01114
This document frequentl
document frequentl
incidence of serious adverse events (SAEs) was low and similar to PBO.  There were no 
document incidence of serious adverse events (SAEs) was low and similar to PBO.  There were no 
clinically
document clinicallycannot .  The discontinuation rate and the discontinuation rate due to treatment
cannot .  The discontinuation rate and the discontinuation rate due to treatment
adverse events (TEAEs) were low and s
cannot adverse events (TEAEs) were low and s
cannot frequentlcannot frequentlbe /be /IIIbe IIIstudies, a favorable safetbe studies, a favorable safet
.  The discontinuation rate and the discontinuation rate due to treatment be .  The discontinuation rate and the discontinuation rate due to treatmentused Safety with 
used Safety with 
studies, a favorable safetused studies, a favorable safetto Safety with to Safety with BRVto BRVsupport  relevant evidence of the efficacy
support  relevant evidence of the efficacy
doses of 20, 50, and 100mg/day
support doses of 20, 50, and 100mg/day
evidence for the efficacy
support evidence for the efficacy  of 
support  of evidence for the efficacy  of evidence for the efficacy
support evidence for the efficacy  of evidence for the efficacy BRV
support BRVany doses of 5, 20, and 50
any doses of 5, 20, and 50
 relevant evidence of the efficacy any  relevant evidence of the efficacymarketing dose studies (N01252
marketing dose studies (N01252
, UCB protocol reference code RPCE06G0705) were conducted to 
marketing , UCB protocol reference code RPCE06G0705) were conducted to 
across a dose range of 5 to 100
marketing across a dose range of 5 to 100
doses of 5, 20, and 50 marketing doses of 5, 20, and 50authorization II studies (N01114
authorization II studies (N01114 , UCB protocol reference code 
authorization , UCB protocol reference code 
, UCB protocol reference code RPCE05C2201
authorization , UCB protocol reference code RPCE05C2201
for the adjunctive treatment of POS.  Two adequate 
authorization for the adjunctive treatment of POS.  Two adequate 
dose studies (N01252 authorization dose studies (N01252application , nearl
application , nearl
mg/day
application mg/day .
application .
II/III studies in POSapplication II/III studies in POSand lamotrigine, LEV, oxcarbamazepi[INVESTIGATOR_122176], p
and lamotrigine, LEV, oxcarbamazepi[INVESTIGATOR_122176], p
ine epoxide was significantlyand ine epoxide was significantly
, nearland , nearlany related trend was observed for the plasma concentrations of 
any related trend was observed for the plasma concentrations of 
lamotrigine, LEV, oxcarbamazepi[INVESTIGATOR_122176], p any lamotrigine, LEV, oxcarbamazepi[INVESTIGATOR_122176], p henobarbital, any henobarbital, extensions y rifampi[INVESTIGATOR_2513], a potent 
extensions y rifampi[INVESTIGATOR_2513], a potent 
udies.  No significant extensions udies.  No significant 
related trend was observed for the plasma concentrations of extensions related trend was observed for the plasma concentrations of or but is increased in a nonclinically relevant manner in Japanese subjects possessing 
or but is increased in a nonclinically relevant manner in Japanese subjects possessing 
y rifampi[INVESTIGATOR_2513], a potent or y rifampi[INVESTIGATOR_2513], a potent variations but is increased in a nonclinically relevant manner in Japanese subjects possessing variations but is increased in a nonclinically relevant manner in Japanese subjects possessing thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687826] 2015 / Page 26of [ADDRESS_687827] participated 
in previous BRV adjunctive treatment studies in epi[INVESTIGATOR_529370] y to access adjunctive 
BRV treatment under the present protocol.  Conversion to monotherapy is not permitted
anymore ; however, subjects already on monotherapy are allowed to continue BRV
monotherap y.
The subjects allowed to enter the study  will mainly  suffer from partial onset seizure s (subjects 
coming from N01193, N01252 , N01253, and N01254 [UCB protocol reference code 
RPCE06G0706]), while a minority will present with generalized epi[INVESTIGATOR_30989] y (subjects coming 
from N01254).   The N01252, N01253 and N01254 studies aimed to test the efficacy  and 
tolerability  of BRV in POS subjects as oral therapy .Thisstudy will explore the long-term 
safet y and efficacy of BRV in such a population.
6.5.1 Dose Selection
In this study , individualized doses up to a maximum of 200 mg/day  will be used. Twice daily  
dosing is deemed necessar y to ensure more regular exposure over the 24-hour interval.
A maximum dose of 200 mg/day  was chosen following consultation with regulatory 
authorities and is evaluated in more recent BRV studies (eg, N01358 and N01379).  
According to available data, 200 mg/day  doses have been well tolerated.
6.5.2 Subjects Population
[IP_ADDRESS] Minimal Age
Subjects are allowed to participate in this study from the age of 16 where legally permitted 
and ethicall y accepted. Indeed , epi[INVESTIGATOR_529371] 16 to 18 years do not differ 
from the ones of older subjects, and efficacy of the AEDs seems to be comparable
(CPMP/EWP/566/98 rev 1, 2000).
Depending on country -specific regulations, those subjects may be considered as adolescents 
or adults (CPMP/I CH/2711/99, 2000) .In case they  are considered as adolescents, parent(s) 
or legal representative will sign the informed consent form. The consent form or a specific 
assent form, where required, will be signed and dated by  [CONTACT_25603] .
6.5.[ADDRESS_687828] udy will run throughout the duration of the clinical development 
period of BRV, and will continue until a marketing authorization is granted by  [CONTACT_529440] a maximum of 
REDACTED individualized doses up to a maximum of 
more regular exposure over the 
REDACTED more regular exposure over the 
 was chosen following consultation with regulatory
REDACTED  was chosen following consultation with regulatory
authorities and is evaluated in more recent BRV studies (eg, N01358 and N01379).  REDACTED authorities and is evaluated in more recent BRV studies (eg, N01358 and N01379).  COPY individualized doses up to a maximum of COPY individualized doses up to a maximum of 
This document or adults
document or adults
or legal representative will sign the informed consent form.
document or legal representative will sign the informed consent form.
assent form, where required, will b
document assent form, where required, will bcannot Depending on 
cannot Depending on 
or adultscannot or adultsbe (CPMP/EWP/566/98 revbe (CPMP/EWP/566/98 revused y accepted. 
used y accepted. 
from the ones of older subjects, and efficacyused from the ones of older subjects, and efficacy
(CPMP/EWP/566/98 revused (CPMP/EWP/566/98 revto Subjects are allowed to participate in this to Subjects are allowed to participate in this 
y accepted. to y accepted. support Subjects are allowed to participate in this support Subjects are allowed to participate in this any marketing  was chosen following consultation with regulatory
marketing  was chosen following consultation with regulatory
authorities and is evaluated in more recent BRV studies (eg, N01358 and N01379).  
marketing authorities and is evaluated in more recent BRV studies (eg, N01358 and N01379).  
mg/day
marketing mg/day  doses have been well tolerated.
marketing  doses have been well tolerated. mg/day  doses have been well tolerated. mg/day
marketing mg/day  doses have been well tolerated. mg/dayauthorization individualized doses up to a maximum of 
authorization individualized doses up to a maximum of 200
authorization 200
more regular exposure over the 
authorization more regular exposure over the 
 was chosen following consultation with regulatory authorization  was chosen following consultation with regulatoryapplication will explore the long
application will explore the longand while a minority will present with generalized epi[INVESTIGATOR_529372] a minority will present with generalized epi[INVESTIGATOR_30989] y (subjects coming 
and y (subjects coming 
The N01252, N01253 and N01254 studies aimed to test the efficacyand The N01252, N01253 and N01254 studies aimed to test the efficacy
will explore the longand will explore the longany UCB protocol reference code 
any UCB protocol reference code 
y (subjects coming any y (subjects coming extensions  suffer from partial onset seizureextensions  suffer from partial onset seizure
UCB protocol reference code extensions UCB protocol reference code or variations adjunctive 
variations adjunctive thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687829] 2015 / Page 27of 72
Authority  in an indication for the adjunctive treatment in adults with refractory POS, whether 
or not secondarily  generalized, until the Sponsor decides to close the study, until subjects 
transition to another BRV study, until a managed access program, named patient program, 
compassionate use program, or similar type of access program is established as allowed per country -specific requirement in addition to legal and regulatory  guidelines, or until BRV 
development is stopped by [CONTACT_1034].
Statement
The present study willbe conducted in accordance with:
This protocol.
International Conference on Harmoni zation (ICH):ICH E6 Note for Guidance on Good 
Clinical Practice [CPMP/ICH/135/95] and Code of Federal Regulations on Good Clinical Practice (GCP) Title 21 Parts 50, 54, 56, 312 and 314).
The principles that have their origin in the Declaration of Helsink i.
All applicable local laws and regulations.
7 STUDY OBJECTIVES
7.1 Primary Objective
To evaluate the long-term safet y and tolerability of BRV at individualized doses with a 
maximum of 200 mg/day in subjects suffering from epi[INVESTIGATOR_002].
7.2 Secondary Objectives
Toevaluate the maintenance of efficacy over time of BRV (for POS/PGS subjects).
7.3 Exploratory Objectives
To explore the effects of BRV on the subject’s H ealth -related Quality  of Life, anxiety ,
and depression for the first 2 years .
To explore medical re source use and indirect cost parameters for the first 2 years.
To obtain a description of the subject’s self-reported health status for the first 2 years.
To explore any  change in the subject’s socio- professional status for the first 2 years.REDACTED tolerability
REDACTED tolerability
mg/day in subjects suffering from epi[INVESTIGATOR_529373]/day in subjects suffering from epi[INVESTIGATOR_529374] a description of 
cannot To obtain a description of 
explore any
cannot explore anybe explore 
be explore 
be To obtain a description of be To obtain a description of used and depression
used and depression for the first [ADDRESS_687830] 2support Exploratory Objectives
support Exploratory Objectives
the effects of BRV support the effects of BRV any evaluate the maintenance of efficacy
any evaluate the maintenance of efficacymarketing mg/day in subjects suffering from epi[INVESTIGATOR_529375]/day in subjects suffering from epi[INVESTIGATOR_529376]/day in subjects suffering from epi[INVESTIGATOR_529377]/day in subjects suffering from epi[INVESTIGATOR_529378] i.
application i.and Clinical Practice [CPMP/ICH/135/95] and Code of Federal Regulations on Good Clinical 
and Clinical Practice [CPMP/ICH/135/95] and Code of Federal Regulations on Good Clinical 
i.and i.any H E6 Note for Guidance on Good 
any H E6 Note for Guidance on Good 
Clinical Practice [CPMP/ICH/135/95] and Code of Federal Regulations on Good Clinical any Clinical Practice [CPMP/ICH/135/95] and Code of Federal Regulations on Good Clinical extensions H E6 Note for Guidance on Good extensions H E6 Note for Guidance on Good or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687831] 2015 / Page 28of 72
8 STUDY DESIGN
8.1 Type/Design
This is a Phase III, therapeutic, long-term, follow-up, multicenter, 
noncomparative, open- label ,and single arm study .
The study design of this study and in particular the frequency  of study visits is adapted for the 
2types of studies as described below.
For those subjects coming from the therapeutic exploratory  stud y (N01193) , visits will be 
scheduled as follows:
First y ear:
 During the first 6 months there will be 1 visit/month; 1 Full Evaluation Visit 
(FEV) alternating with 1 Minimal Ev aluation Visit (MEV) .
 During the next 6 months there will be 1 visit every 3 months; 2 FEV (at V7 
and V8) .
Second and subsequent years:
 1 visit every  3 months; 1 FEV alternating with 1 MEV.
 The Yearl y Evaluation Visit (YEV) will be performed in replacement of the first 
FEV of each year.
For those subjects coming from therapeutic confirmatory  studies (N01252, N01253, 
N01254):
First y ear:
 First 3 months:  1 visit/month: FEV alternating with MEV.
 Next 9 months: 1 visit/3 months: FEV alternating with MEV.
Second and subsequent years:
 1 visit/3months: FEV alternating with MEV.
 The Yearl y Evaluation Visit will be performed in replacement of the first FEV of 
each year.REDACTED  3 months; 1 FEV alternating with 1 MEV
REDACTED  3 months; 1 FEV alternating with 1 MEV
y Evaluation Visit (YEV) will
REDACTED y Evaluation Visit (YEV) will
For those subjects coming from therapeutic REDACTED For those subjects coming from therapeutic COPY During the next 6 months there will be 1 visit every 3 months; 2 FEV (at V7 
COPY During the next 6 months there will be 1 visit every 3 months; 2 FEV (at V7 
This document cannot be used The Yearl
used The Yearl
each 
used each ye
used yeto 1 visit/3months: 
to 1 visit/3months: 
The Yearl to The Yearl y Evaluation Visit will be performed in replacement of the first FEV of to y Evaluation Visit will be performed in replacement of the first FEV of support Next 9 months: 
support Next 9 months: 1 visit/3 months:
support 1 visit/3 months:
Second and subsequent 
support Second and subsequent years:
support years:
support 1 visit/3months: support 1 visit/3months: any 1 visit/month:any 1 visit/month:
1 visit/3 months:any 1 visit/3 months:marketing For those subjects coming from therapeutic 
marketing For those subjects coming from therapeutic confirmatory
marketing confirmatoryauthorization  3 months; 1 FEV alternating with 1 MEV
authorization  3 months; 1 FEV alternating with 1 MEV
y Evaluation Visit (YEV) will
authorization y Evaluation Visit (YEV) willapplication During the first 6 months there will be 1 visit/month; [ADDRESS_687832] 6 months there will be 1 visit/month; 1 Full Evaluation Visit 
aluation Visit (MEV)
application aluation Visit (MEV)
During the next 6 months there will be 1 visit every 3 months; 2 FEV (at V7 
application During the next 6 months there will be 1 visit every 3 months; 2 FEV (at V7 and During the first 6 months there will be 1 visit/month; [ADDRESS_687833] 6 months there will be 1 visit/month; 1 Full Evaluation Visit any (N01193)
any (N01193) , visits
any , visitsextensions visits is adapted for the 
extensions visits is adapted for the 
, visitsextensions , visitsor variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687834] 2015 / Page 29of 72
8.2 Subjects/Sites Numbers
It is estimated that approximately  500 - 1,000 subjects will ente r the study based on the 
assumption that 90% of subjects having completed a previous study with BRV as adjunctive 
treatment in epi[INVESTIGATOR_529338] .
It is estimated that between [ADDRESS_687835] will be identified by [CONTACT_5657]/her initials and a subject identifier which include the 
study  number, the site number and a sequential enrollment number.  The Master CRF number 
will be used as an additional identifier on laboratory reports and at the level of the database.
8.[ADDRESS_687836] in this study , an Independent Ethics 
Committee/I nstitutional Review Board (IEC/IRB) approved written informed consent form 
will be properly executed and documented.9.[ADDRESS_687837] be met:
An IEC/I RB approved written informed consent signed and dated by [CONTACT_529441] b y 
parent(s) or legall y acceptable representative. The consent form or a specific assent form, 
where required, will be signed and dated b y minors.REDACTED will continue until a marketing authorization is granted b
REDACTED will continue until a marketing authorization is granted b
djunctive treatment in adults with refractory
REDACTED djunctive treatment in adults with refractory
generalized, until the Sponsor decides to close the study
REDACTED generalized, until the Sponsor decides to close the study
until a managed access program, named patient program, 
REDACTED until a managed access program, named patient program, 
e program, or similar ty REDACTED e program, or similar tyCOPY  will run throughout the duration of the clinical development period of COPY  will run throughout the duration of the clinical development period of 
will continue until a marketing authorization is granted bCOPY will continue until a marketing authorization is granted b
This document 9.[ADDRESS_687838] Inclusion Criteriacannot Committee/I
cannot Committee/I
will be properl
cannot will be properlbe y studbe y stud
Committee/I be Committee/I nstitutional Review Board (IEC/Ibe nstitutional Review Board (IEC/Iused SELECTION AND WITHDR
used SELECTION AND WITHDR
y studused y stud y procedures are initiated for anused y procedures are initiated for anto SELECTION AND WITHDR to SELECTION AND WITHDRsupport y is defined as th
support y is defined as thany marketing until a managed access program, named patient program, 
marketing until a managed access program, named patient program, 
e program, or similar ty
marketing e program, or similar ty pe of access program is established as allowed per 
marketing pe of access program is established as allowed per e program, or similar ty pe of access program is established as allowed per e program, or similar ty
marketing e program, or similar ty pe of access program is established as allowed per e program, or similar ty
specific requirement in addition to legal and regulatory
marketing specific requirement in addition to legal and regulatory
development is stopped by [CONTACT_1034].marketing development is stopped by [CONTACT_1034].authorization  will run throughout the duration of the clinical development period of 
authorization  will run throughout the duration of the clinical development period of 
will continue until a marketing authorization is granted b
authorization will continue until a marketing authorization is granted b
djunctive treatment in adults with refractory
authorization djunctive treatment in adults with refractory
generalized, until the Sponsor decides to close the study
authorization generalized, until the Sponsor decides to close the study
until a managed access program, named patient program, authorization until a managed access program, named patient program, application reports and at the level of the database.
application reports and at the level of the database.
 will run throughout the duration of the clinical development period of application  will run throughout the duration of the clinical development period of and  his/her initials and a subject identifier which include the 
and  his/her initials and a subject identifier which include the 
The Master CRF number and The Master CRF number 
reports and at the level of the database. and reports and at the level of the database.any  his/her initials and a subject identifier which include the any  his/her initials and a subject identifier which include the extensions or variations as adjunctive 
variations as adjunctive thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687839] 2015 / Page 30of 72
Male/female subjects from 16 years or older. Subjects under 18 years may  only  be 
included where legal ly permitted and ethicall y accepted.
Subjects with epi[INVESTIGATOR_122149] .
Subjects from whom the Investigator believes a reasonable benefit from the long- term 
administration of BRV may be expected.
Female subjects without childbearing potential (premenarcheal; 2 years postmenopausal 
bilateral oophorectomy or ovariectomy, bilateral salpi[INVESTIGATOR_1656] , complete hy sterectom y, 
congenital sterility) are eligible. Female subjects with childbearing potential are eligible 
if they  use a medically  accepted contraceptive method for the duration of the study (Intra 
Uterine Device, diaphragm with spermicide, male or female condom with spermicide; 
oral hormonal contraceptive, non-oral hormonal contraceptive m edication, bilateral tubal 
ligation, bilateral tubal implant, monogamous relationship with vasectomized partner). 
Oral or depot contraceptive treatment with at least 30 µg [or 50 µg if associated with other antiepi[INVESTIGATOR_122150]] ethiny lestradiol per intake must be used in 
conjunction with a barrier method. The subject must understand the consequences and potential risks of inadequately  protected sexual activity , be educated about and understand 
the proper use of contraceptive methods, and undertake to inform the Investigator of an y 
potential change in status.  According to the judgment of the Investigator, sexual inactivity  might be accepted on a case by [CONTACT_413].
Subject/legall y acceptable representative considered as reliable and capable of adhering to 
the protocol (e.g. able to understand and complete diaries and questionnaires), visit schedule or medication intake according to the judgment of the Investigator.
9.[ADDRESS_687840] be excluded if they  meet any  ofthe following criteria :
Severe medical, neurological and psychiatric disorders or laboratory  values which may  
have an impac t on the safety  of the subject.
Poor compliance with the visit schedule or medication intake in the previous BRV study .
Participatio n in any clinical study of another investigation drug or device during the 
study .
Pregnant or lactating woman.
If the Investigator has any  medically  valid reason to doubt the eligibility  of a subject, the 
subject should not be included into the study .If, however, the Investigator has an y other kind 
of doubts concerning the subject’s eligibility , he/she should consult the UCB Study  Physician
(SP) or representative for clarification.
9.[ADDRESS_687841] WithdrawalInvestigators should attempt to obtain information on subjects, in case of withdrawal or 
discontinuation. The Investigator should make every  effort, and document his/her effort, to REDACTED the proper use of contraceptive methods, and
REDACTED the proper use of contraceptive methods, and
According to the judgment of the Investigator, sexual 
REDACTED According to the judgment of the Investigator, sexual 
 might be accepted on a case by
[CONTACT_529442] a case by  [CONTACT_413].
REDACTED  case basis.  might be accepted on a case by  [CONTACT_413].  might be accepted on a case by
[CONTACT_529442] a case by  [CONTACT_413].  might be accepted on a case by
y acceptable representative considered as reliable and capa
REDACTED y acceptable representative considered as reliable and capa
the protocol (e.g. able to understand and complete diaries and questionnaires), visit REDACTED the protocol (e.g. able to understand and complete diaries and questionnaires), visit 
schedule or medication intake according to the judgment of the REDACTED schedule or medication intake according to the judgment of the COPY The subject must understand the consequences and 
COPY The subject must understand the consequences and 
 protected sexual activity
COPY  protected sexual activity
undertake to inform the Investigator of anCOPY undertake to inform the Investigator of an
This document subject should not be included into 
document subject should not be included into 
of doubts concerning the 
document of doubts concerning the 
(SP)
document (SP)cannot Pregnant or lactating woman.
cannot Pregnant or lactating woman.
If the cannot If the Investigatorcannot Investigator
subject should not be included into cannot subject should not be included into be Pregnant or lactating woman. be Pregnant or lactating woman.used Poor compliance with 
used Poor compliance with 
Participatio
used Participatio n in any
used n in anyto Poor compliance with to Poor compliance with support Subjects must be excluded if they
support Subjects must be excluded if they
Severe medical, neurological and ps
support Severe medical, neurological and ps
t on the safetysupport t on the safety
Poor compliance with support Poor compliance with any Subjects must be excluded if they any Subjects must be excluded if theymarketing the protocol (e.g. able to understand and complete diaries and questionnaires), visit 
marketing the protocol (e.g. able to understand and complete diaries and questionnaires), visit 
schedule or medication intake according to the judgment of the 
marketing schedule or medication intake according to the judgment of the 
Subject Exclusion Criteriamarketing Subject Exclusion Criteriaauthorization  protected sexual activity
authorization  protected sexual activity
undertake to inform the Investigator of an
authorization undertake to inform the Investigator of an
According to the judgment of the Investigator, sexual 
authorization According to the judgment of the Investigator, sexual 
 case basis.
authorization  case basis.
y acceptable representative considered as reliable and capaauthorization y acceptable representative considered as reliable and capa
the protocol (e.g. able to understand and complete diaries and questionnaires), visit authorization the protocol (e.g. able to understand and complete diaries and questionnaires), visit application ligation, bilateral tubal implant, monogamous relationship with vasectomized 
application ligation, bilateral tubal implant, monogamous relationship with vasectomized 
Oral or depot contraceptive treatment with at least 30 µg [or [ADDRESS_687842] 30 µg [or [ADDRESS_687843] 30 µg [or [ADDRESS_687844] 30 µg [or 50 µg if associated with any Uterine Device, diaphragm with spermicide, male or female condom with spermicide; 
any Uterine Device, diaphragm with spermicide, male or female condom with spermicide; 
edication, bilateral tubal any edication, bilateral tubal extensions ars postmenopausal 
extensions ars postmenopausal 
sterectom
extensions sterectom
tential are eligible 
extensions tential are eligible 
 accepted contraceptive method for the duration of the extensions  accepted contraceptive method for the duration of the studyextensions study
Uterine Device, diaphragm with spermicide, male or female condom with spermicide; extensions Uterine Device, diaphragm with spermicide, male or female condom with spermicide; or ars postmenopausal or ars postmenopausal variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687845] 2015 / Page 31of 72
complete the Earl y Discontinuation Visit and preferabl y also the Down -Titration Phone Call 
and the Final Visit. All results o f these evaluations and observations, together with a 
narrative description of the reason(s) for removing the subject, must be recorded in the source 
documents. The Case Report Form (CRF) must document the primary reason for withdrawal or discontinuation.
The study medication will be progressivel y down -titrated. During the down-titration period, 
the dose may  be decreased in steps of a maximum of 50 mg/day  on a weekly  basis. A last 
down -titration step at 20mg/day for 1 week will be included prior to the study  -drug free 
period. The down -titration period will be followed by a period free of study drug of a 
minimum of 2 weeks and a maximum of 4 weeks and subsequently, the Final Visit will occur.
9.3.1 Withdrawal Criteria
Subjects are free to withdraw from the study  at any  time, without prejudice to their continued 
care.Stoppi[INVESTIGATOR_529379]:
Withdrawal for safety  reasons by  [CONTACT_737] : occurrence of status epi[INVESTIGATOR_7397], 
appearance of a more severe t ype of seizure, liver enzymes significant increase, and an y 
other significant safety  reason.
Subject and/or Investigator does not think that the investigational drug is effective (i.e., 
lack or loss of efficacy ).
Lost to follow-up.
Withdrawal of consent for personal reasons; not related to AE or lack/loss of efficacy.
Other reason that has to be specified in the CRF.
Withdrawal criteria for already enrolled subjects who did not complete a C- SSRS assessment 
at screening:
Subject has a lifetime his tory (prior to study  entry  or since study  start) of suicide attempt 
(including an active attempt, interrupted attempt, or aborted attempt) of the “Alread y 
Enrolled Subjects” version of the C- SSRS. The I nvestigator must withdraw the subject 
from the study  and immediately  refer the subject to a Mental Healthcare Professional.
Subject had active suicidal ideation prior to study  entry  or since study  start as indicated by  
a positive response (‘Yes’) to either Question 4 or Question 5 of the “Already Enrolled 
Subjects” version of the C- SSRS. The Investigator must immediately  refer the subject to a 
Mental Healthcare Professional and use clinical judgment as to whether to withdraw the subject from the stud y. 
Subject has active suicidal ideation as indicated by a positive response (‘Yes’) to either 
Question 4 or Question 5 of the “Since Last Visit” version of the C-SSRS.  The subject 
should be referred immediately to a Mental Healthcare Professional and must be withdrawn from the study.REDACTED Investigator
REDACTED Investigator
ype of seizure, liver enzy
REDACTED ype of seizure, liver enzy
Subject and/or Investigator does not think that the investigational drug is effective (i.e., 
REDACTED Subject and/or Investigator does not think that the investigational drug is effective (i.e., COPY Stoppi[INVESTIGATOR_529380]
a positive response (‘Yes’) to either Question 4 or Question 5 of the “Alreadycannot a positive response (‘Yes’) to either Question 4 or Question 5 of the “Already
Subcannot Subbe Enrolled Subjec
be Enrolled Subjec
from the studybe from the studyused Subject has a lifetime his
used Subject has a lifetime his
(including an active attempt, interrupted attempt, or aborted attempt) of the “Alread
used (including an active attempt, interrupted attempt, or aborted attempt) of the “Alread
Enrolled Subjec used Enrolled Subjecto Subject has a lifetime histo Subject has a lifetime his
(including an active attempt, interrupted attempt, or aborted attempt) of the “Alreadto (including an active attempt, interrupted attempt, or aborted attempt) of the “Alreadsupport Withdrawal criteria for already enrolled subjects who did not complete a C
support Withdrawal criteria for already enrolled subjects who did not complete a C
support Subject has a lifetime hissupport Subject has a lifetime hisany Other reason that has to be specified in the CRF.
any Other reason that has to be specified in the CRF.marketing Subject and/or Investigator does not think that the investigational drug is effective (i.e., 
marketing Subject and/or Investigator does not think that the investigational drug is effective (i.e., 
consent for personal reasons; not related to AE or lack/loss of efficacymarketing consent for personal reasons; not related to AE or lack/loss of efficacy
Other reason that has to be specified in the CRF.marketing Other reason that has to be specified in the CRF.authorization Stoppi[INVESTIGATOR_529381] : occurrence of status epi[INVESTIGATOR_7397], 
authorization : occurrence of status epi[INVESTIGATOR_7397], 
ype of seizure, liver enzy
authorization ype of seizure, liver enzy
Subject and/or Investigator does not think that the investigational drug is effective (i.e., authorization Subject and/or Investigator does not think that the investigational drug is effective (i.e., application  time, without prejudice to their continued 
application  time, without prejudice to their continued 
Stoppi[INVESTIGATOR_529382] y, the Final Visit will occur.
any y, the Final Visit will occur. extensions -titration period, 
extensions -titration period, 
A last 
extensions A last 
drug free 
extensions drug free 
drugextensions drug of a extensions of a 
y, the Final Visit will occur. extensions y, the Final Visit will occur.or -titration period, or -titration period, variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687846] 2015 / Page 32of [ADDRESS_687847]’s discontinuation, the Investigator will provide the subject with 
information about available alternative treatments.
9.3.[ADDRESS_687848] Replacement Policy
Not applicable.
10 TREATMENT OF SUBJECTS (INVESTIGATIONAL PRODUCT AND 
CONCOMITANT MEDICATI ONS)
10.[ADDRESS_687849] (tablets containing 10 or 25 mg BRV) will be supplied under 
the responsibility  of the Sponsor Clinical Trial Supply  Department for all subjects. The 
frequency  at which investigational product will be supplied to each individual site will be 
adapted to the recruitment capacity of that site and to the expi[INVESTIGATOR_529383].
10.1.[ADDRESS_687850] the opportunity to access BRV treatment at a 
flexible dose of up to a maximum of 200 mg/day  in b.i.d. administration.  I t is recommended 
that the daily  dose be divided equall y,taken with or without food, and that t he first intake will
be in the evening of the day  of the dispensation of the study medication.
The individual starting dose of each subject will be the one defined/reached at the end of the 
previous study .  It isrecommended that the dosing be done in even increments such as 20mg, 
30 mg, 40 mg, etc. with the implementation of the IVRS /IWRS .  
At each subject visit, if necessary, the dosage can be adapted:
Up-titration can be made by [CONTACT_529443] 50 mg/day on a weekly  basis and 
this to a maximum of 200 mg/day.
Dose decreases can be made b y steps of maxim um 50 mg/day  on a weekly  basis .  A last 
down -titration step at 20mg/day for 1 week will be included prior to the study-drug free 
period.
At each visit , an IVRS /IWRS will be responsible for issuing subjects kits of study 
medication, as appropriate, according to the visit schedule and according to the supplies 
needed b y the subject in terms of number of containers of each size (80 or 200) and of each 
dosage (10 mg or 25 mg tablets) according to the dose prescribed and the possibility  to down-REDACTED y of that site and to the expi[INVESTIGATOR_529384] y of that site and to the expi[INVESTIGATOR_529385] [ADDRESS_687851] will be the one defined/reached at the end of the 
support The individual starting dose of each subject will be the one defined/reached at the end of the 
recommended that the dosing be done in even increments such support recommended that the dosing be done in even increments such any  dose be divided equall
any  dose be divided equall
 of the diany  of the dimarketing studies have the opportunity
marketing studies have the opportunity
flexible dose of up to a maximum of marketing flexible dose of up to a maximum of 200marketing [ADDRESS_687852] AND or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687853] 2015 / Page 33of 72
titrate/up- titrate by a maximum of 50mg/day  steps.  Containers of [ADDRESS_687854] will not continue with BRV, the Investigator will plan the progressive 
down -titration of the study drug. The down-titration period will be fo llowed by  a period free 
of study drug of minimum 2 weeks and a maximum of 4 weeks and subsequently  the Final 
Visit will occur.
At the time of study termination by  [CONTACT_1034] (as defined in Section 8.4), subjects will 
discontinue the study  drug following the described down-titration process or will be 
converted without down-titration to commercial BRV, when and where available.  
Alternativel y,subjects may  transition into another BRV study , or be initiated without 
down -titration in a managed access program, named patient program, compassionate use 
program, or similar type of access program as allowed per country-specific legal and regulatory  requirements.
10.1.[ADDRESS_687855] via the IVRS/ IWRS , the
Investigator will be supplied with a sufficient number of containers. Each container will have 
a unique, pre -printed identification number. 
The Investigator will inform each subject on how to take the drug and that an excess of drug is present in the investigational product container.
10.1.4 Labeling
Clinical drug supplies will be labeled in accordance with the current ICH guidelines on GCP 
and Good Manufacturing Practice ( GMP ) and will include an y locall y required statements.
The labels and the size of the investigational product package will be adapted to local 
regulatory  requirements. The labels willbe translated as appropriate.
The label will consist of [ADDRESS_687856] container.authorization will be packaged in bottles 
authorization will be packaged in bottles 
y removed.
authorization y removed.
Investigator will be supplied with a sufficient number of containers. 
authorization Investigator will be supplied with a sufficient number of containers. application ype of access program as allowed per country-
application ype of access program as allowed per country- specific legal and 
application specific legal and and be initiated 
and be initiated 
m, named patient program, compassionate use and m, named patient program, compassionate use 
specific legal and and specific legal and any -titration to commercial BRV, when and where available.  
any -titration to commercial BRV, when and where available.  
be initiated any be initiated extensions subjects will 
extensions subjects will 
will be extensions will be 
-titration to commercial BRV, when and where available.  extensions -titration to commercial BRV, when and where available.  or  the Final 
or  the Final variations  a period free 
variations  a period free 
 the Final variations  the Final thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687857] 2015 / Page 34of 72
are not controlled (with recording), a temperature log should be completed at least once a 
week with the minimal and the maximal temperatures reached in the week preceding the record. Any excursion from the allowed temperature range will be communicated to the 
Sponsor or representative.
Storage should be in a pharmacy  or in a locked facility . Supplies for this study will be stored 
in such a way  that they  may  not be mixed up with supplies being used for another study . A 
standard storage statement will appear on each investigational product package label of study
medication.The Investigator or the hospi[INVESTIGATOR_122189].  The Investigator will instruct the subject/legally  acceptable representative to store the medication at the storage temperature 
specified on the investigational product package label, in a secure place out of t he reach of 
children.
10.1.[ADDRESS_687858] package (even if empty ). Drug reconciliation must be done in 
the subject’s presence in order to obtain explanations regarding discrepancies in compliance with the dosing regimen.
The number of tablets as well as explanations of non-compliance must all be recorded on the 
CRF.Compliance with study medication is defined as investigational product consumption by  [CONTACT_479749] 80% - 120% of the prescribed dosage.
10.1.[ADDRESS_687859] (due to breakage or wastage), not used, 
disposed of at the study site or returned must also be recorded.  All supplies and pharmacy 
documentation must be made available throughout the study for the Sponsor or designee to review.
The Drug Accountability Form should include the following:
Number of tablets dispensed to and return b y each subject, with the subject’s number and 
carton or bottle number.
Initials of the person who actuall y disp ensed and/or received the return tablets.
Dates of the above.REDACTED At each visit after drug is dispensed, subjects must return all unused medication and 
REDACTED At each visit after drug is dispensed, subjects must return all unused medication and 
(even if empty
REDACTED (even if empty
presence in order to obtain explanations regarding discrepancies in compliance 
REDACTED presence in order to obtain explanations regarding discrepancies in compliance COPY At each visit after drug is dispensed, subjects must return all unused medication and COPY At each visit after drug is dispensed, subjects must return all unused medication and 
This document documentation must
document documentation must
document review.
document review.cannot released for subject use.
cannot released for subject use.
cannot disposed of at the study
cannot disposed of at the study
documentation mustcannot documentation mustbe y recording all study drug rbe y recording all study drug r
released for subject use. be released for subject use.used The Sponsor or its representatives will supplyused The Sponsor or its representatives will supply
y recording all study drug rused y recording all study drug rto Investigational Products Accountabilityto Investigational Products Accountability support medication is defined as invest
support medication is defined as invest
120% of the prescribed dosage.
support 120% of the prescribed dosage.
Investigational Products Accountability support Investigational Products Accountabilityany medication is defined as invest any medication is defined as investmarketing as well as explanations of non
marketing as well as explanations of nonauthorization At each visit after drug is dispensed, subjects must return all unused medication and 
authorization At each visit after drug is dispensed, subjects must return all unused medication and 
(even if empty
authorization (even if empty
presence in order to obtain explanations regarding discrepancies in compliance 
authorization presence in order to obtain explanations regarding discrepancies in compliance application specified on the investigational product package label, in a secure place out of t
application specified on the investigational product package label, in a secure place out of t and The Investigator will instruct 
and The Investigator will instruct 
 acceptable representative to store the medication at the storage temperature and  acceptable representative to store the medication at the storage temperature 
specified on the investigational product package label, in a secure place out of t and specified on the investigational product package label, in a secure place out of tany The Investigator or the hospi[INVESTIGATOR_529386] . 
extensions . 
standard storage statement will appear on each investigational product package label of 
extensions standard storage statement will appear on each investigational product package label of study
extensions study
The Investigator or the hospi[INVESTIGATOR_529387] 
A or A variations will be stored variations will be stored thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687860] 2015 / Page 35of 72
Explanations for non- compliance.
Periodically and after completion of the study, all used (including empty  cartons and bottles ) 
and unused investigational product package must be reconciled and returned (preferabl y in 
their original package) to the Sponsor or designee according to a procedure to be defined at 
the time . Clinical drug supplies designated for the study  cannot be used for any  other purpose 
than that described in this protocol.
10.[ADDRESS_687861] be kept in the clinic chart (source 
documentation) and the Case Report Form. This record should include the brand name [CONTACT_214842], the dose, frequency, route, the indication for use and the date(s) of administration.
10.2.1 Permitted Concomitant Treatments (Medications and Therapi[INVESTIGATOR_014])
Investigator may  adapt the AED drug/dosage for safet y or efficacy reasons.   Benzodiazepi[INVESTIGATOR_050] s 
(BZD) taken more than once a week (for any indication) will be considered as a concomitant 
AED. 
10.2.2 Prohibited Concomitant Treatments (Medications and Therapi[INVESTIGATOR_014])
Vigabat rin
11 STUDY PROCEDURES
11.1 Description of Procedures11.1.1 Informed Consent
Prior to any  study activities, subjects will be asked to read and sign an informed consent form 
that has been approved by [CONTACT_18369]/IRBand which complies with regulatory requirements. 
Subjects will be given adequate time to consider any information concerning the stud y, give n 
to them by  [CONTACT_18370].  As part of the informed consent procedure, subjects 
will be given the opportunity to ask the Investigator any questions regarding potential risks 
and benefits of participation in the study.Where legall y accepta ble, a P artner Pregnancy  Consent Form will be issued in case the 
partner of a male subject becomes pregnant (Section 12.1.6).REDACTED Prohibited Concomitant Treatments (Medications and Therapi[INVESTIGATOR_014])
REDACTED Prohibited Concomitant Treatments (Medications and Therapi[INVESTIGATOR_014])COPY  adapt the AED drug/dosage for safet
COPY  adapt the AED drug/dosage for safet y or efficacy reasons.
COPY y or efficacy reasons.
y indication) will be considered as a concomitant COPY y indication) will be considered as a concomitant 
This document and benefits of participation in the study
document and benefits of participation in the study
Where legall
document Where legallcannot to them by
[CONTACT_529444], subjects will be asked to read and sign an informed consent form 
used activities, subjects will be asked to read and sign an informed consent form 
that has been approved by [CONTACT_529445], subjects will be asked to read and sign an informed consent form to activities, subjects will be asked to read and sign an informed consent form support Description of Procedures
support Description of Procedures
Informed Consent
support Informed Consentany Description of Procedures any Description of Proceduresmarketing STUDY PROCEDURESmarketing STUDY PROCEDURESauthorization y indication) will be considered as a concomitant 
authorization y indication) will be considered as a concomitant 
Prohibited Concomitant Treatments (Medications and Therapi[INVESTIGATOR_014])
authorization Prohibited Concomitant Treatments (Medications and Therapi[INVESTIGATOR_014])application 10.2.1 Permitted Concomitant Treatments (Medications and Therapi[INVESTIGATOR_014])
application 10.2.1 Permitted Concomitant Treatments (Medications and Therapi[INVESTIGATOR_014])
y or efficacy reasons.application y or efficacy reasons.
y indication) will be considered as a concomitant application y indication) will be considered as a concomitant and This record should include the 
and This record should include the 
the date(s) of administration.and the date(s) of administration.any accurate record must be kept in the clinic chart (source 
any accurate record must be kept in the clinic chart (source 
This record should include the any This record should include the brand any brand extensions accurate record must be kept in the clinic chart (source extensions accurate record must be kept in the clinic chart (source or  other purpose 
or  other purpose variations ) to the Sponsor or designee according to a procedure to be defined at 
variations ) to the Sponsor or designee according to a procedure to be defined at 
 other purpose variations  other purpose thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687862] 2015 / Page 36of [ADDRESS_687863] study cards 
that contains the Investigator ’s contact [CONTACT_122275] .These subject 
cards will be in the language of the subject. The Investigator will fill in each card with 
his/her contact [CONTACT_8972] (name [CONTACT_41319]) and the subject ’sidentifier. This card 
will be distributed to the subject at the Entry  Visit .The Investigator will instruct the subject 
to keep the card with them at all times.
11.1.[ADDRESS_687864]’s status change. A pregnancy  
test will be performed as specified in the S tudy Flowchart (see Table 5:1).
11.1.[ADDRESS_687865] visit, information on childbearing potential and contraceptive method used by
[CONTACT_529446] 
e that birth control remains optimal should COPY e that birth control remains optimal should the COPY the 
owchart (seeCOPY owchart (see
This document will be recorded on the concomitant AED medication page of the CRF.
document will be recorded on the concomitant AED medication page of the CRF.
11.1.[ADDRESS_687866]’s status change. 
authorization subject’s status change. 
owchart (see
authorization owchart (see
General Medical and Procedure History
authorization General Medical and Procedure Historyapplication At the first visit, information on childbearing potential and contraceptive method used by
[CONTACT_529447], information on childbearing potential and contraceptive method used by
[CONTACT_529448]’s status change. application subject’s status change. and oup will be recorded.
and oup will be recorded. any extensions will instruct the subject 
extensions will instruct the subject or This card 
or This card 
will instruct the subject or will instruct the subject variations This card variations This card thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687867] 2015 / Page 37of 72
11.1.9 Weight and Height
Body we ight (subject wearing light clothing without shoes and rounded to the nearest 
kilogram) will be obtained at the following visits: Entry  Visit, each Full Evaluation Visit, 
each Yearly Evaluation Visit, Early Discontinuation Visit , and at the Final Visit. Height will 
be obtained at the Entry  Visit. For subjects that are still potentially  growing , height will also 
be measured at each Yearly  Evaluation Visit and the Final V isit.
11.1.[ADDRESS_687868] ph ysical examination will be performed at the following visits: every Full 
Evaluation Visit, each Yearl y Evaluation Visit, Early Discontinuation Visit and at the Final 
Visit. This examination may  include investigation of skin, ey es, ear, nose, throat, 
cardiovascular s ystem, respi[INVESTIGATOR_36517], gastro -intestinal sy stem, musculoskeletal sy stem 
and optionally  genitourinary  system. At the Entry Visit, the phy sical examination will be 
obtained electronically from the last Evaluation Visit of the previous study and should not be 
recorded in the CRF.
11.1.[ADDRESS_687869] neurological examination will be performed at the following visits: every Full 
Evaluation Visit, each Yearl y Evaluation Visit , Early  Discontinuation Visit and at the Final 
Visit. This examination will consist of a brief review of cortical functions, cranial nerves, 
motor function, reflex function, sensory function, gait and stance. Psychiatric and mental 
status will be reported by [CONTACT_529449], mental 
impairments and behavior al symptoms. At the Entry  Visit, the neurological examination will 
be obtained electronically  from the last Evaluation Visit of the previous study  and should not 
be recorded in the CRF.11.1.[ADDRESS_687870] 12- lead 
ECGs will be reduced to once per year at the following visits: Yearl y Evaluation Visit, Early  
Discontinuation Visit, and Final Visit (in case the FV follows an EDV and the EDV ECG is 
normal, no additional ECG has to be performed a t FV). At the Entry  Visit, the ECG will be 
obtained electronically from the last Evaluation Visit of the previous study and should not be recorded in the CRF.  The Investigator will determine whether the results of the ECG are normal or abnormal and assess the clinical significance of an y abnormalities.  The original 
ECG tracing will be signed or initialed and dated by [CONTACT_529450].REDACTED A standard neurological examination will be performed at the following visits:
REDACTED A standard neurological examination will be performed at the following visits:
y Evaluation Visit REDACTED y Evaluation VisitCOPY At the Entry Visit, the phy
COPY At the Entry Visit, the phy
y from the last Evaluation Visit of the previous study and should not be 
COPY y from the last Evaluation Visit of the previous study and should not be 
This document normal, no additional ECG has to be performed a
document normal, no additional ECG has to be performed a
obtained electronicall
document obtained electronicall
recorded in the CRF.  
document recorded in the CRF.  cannot ECGs will be reduced to once per 
cannot ECGs will be reduced to once per 
Discontinuation Visit
cannot Discontinuation Visit
cannot normal, no additional ECG has to be performed acannot normal, no additional ECG has to be performed abe Once the subject has signed the updated Informed Consent, the nbe Once the subject has signed the updated Informed Consent, the n
ECGs will be reduced to once per be ECGs will be reduced to once per used Once the subject has signed the updated Informed Consent, the nused Once the subject has signed the updated Informed Consent, the nto support al sy
support al sy
be obtained electronically
support be obtained electronically  from the last Evaluation Visit of the previous study
support  from the last Evaluation Visit of the previous study be obtained electronically  from the last Evaluation Visit of the previous study be obtained electronically
support be obtained electronically  from the last Evaluation Visit of the previous study be obtained electronically
be recorded in the CRF.
support be recorded in the CRF.any y recording the presence or absence of ps
any y recording the presence or absence of ps
any al syany al symptomsany mptomsal symptomsal syany al symptomsal symarketing A standard neurological examination will be performed at the following visits:
marketing A standard neurological examination will be performed at the following visits:
y Evaluation Visit
marketing y Evaluation Visit
of a brief
marketing of a brief
motor function, reflex function, sensorymarketing motor function, reflex function, sensory  function, gait and stance. marketing  function, gait and stance. motor function, reflex function, sensory  function, gait and stance. motor function, reflex function, sensorymarketing motor function, reflex function, sensory  function, gait and stance. motor function, reflex function, sensory
y recording the presence or absence of ps marketing y recording the presence or absence of psauthorization A standard neurological examination will be performed at the following visits: authorization A standard neurological examination will be performed at the following visits:application es, ear, nose, throat, 
application es, ear, nose, throat, 
stem, musculoskeletal sy
application stem, musculoskeletal sy
At the Entry Visit, the phy
application At the Entry Visit, the phy sical examination will be 
application sical examination will be 
y from the last Evaluation Visit of the previous study and should not be application y from the last Evaluation Visit of the previous study and should not be and following visits:
and following visits:
y Evaluation Visit, Early Discontinuation Visit and at the Final and y Evaluation Visit, Early Discontinuation Visit and at the Final 
es, ear, nose, throat, and es, ear, nose, throat, any following visits: any following visits: everyany everyextensions will also 
extensions will also or Height will 
or Height will 
will also or will also variations Height will variations Height will thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687871] 2015 / Page 38of [ADDRESS_687872] (DRC)
At the Entry  Visit, every  Full Evaluation Visit, ever y Minimal Evaluation Visit, Yearl y 
Evaluation Visit, and the Early Discontinuation Visit, the subject will receive a Dail y Record 
Card (DRC) and will be asked to come back at the next visit with the completed DRC.
The following information will be recorde d on the DRC:
Date and the number (where possible) of epi[INVESTIGATOR_122174]
Type of seizure (according to individual description of epi[INVESTIGATOR_122174])
Occurrence of seizure clusters
All unusual events concerning the subject’s health
Changes in concomitant medication (dosage and/or product)
Changes in investigational product (dosage)
The written information will be discussed with the subject at each visit in order to ensure 
completeness and accuracy.  As a result of the discussion, the Investigator will assess the epi[INVESTIGATOR_529388] t ypes and frequency on 
the CRF; he/she will also confirm the presence of adverse events (if applicable).  The concomitant medication changes and adverse events will be reported by [CONTACT_122279].
The DRC will be considered part of the CRF as well as source documentation.  The subject 
should be educated to complete the DRC on a regular basis (each time that a seizure, an undesirable event, a modification of medication or investigational product, or a medical visit occurs).
11.1.[ADDRESS_687873] 
Evaluation Visit of the previous study and should not be recorded on the CRF.  The central 
laboratory  will provide the Investi gator with dedicated, standardized sampling equipment 
(labels, needles, tubes), and a study -specific laboratory manual, which will explain how to 
use the equipment and how to ship the samples back to the central laboratory. 
Results for hematology , chemistry , urinal ysis and pregnancy tests will be provided by [CONTACT_529451] 72 hours after sample receipt. 
The t otal blood volume drawn for the clinical laboratory  assessments will be a maximum of 
20 ml/sampling. The subject should preferabl ybe fasting. Study medication intake must not 
be delay ed.REDACTED the CRF; he/she will also confirm the presence of adverse events (if applicable).  The 
REDACTED the CRF; he/she will also confirm the presence of adverse events (if applicable).  The 
concomitant medication changes and adverse events will be reported by
[CONTACT_529452].  The subject REDACTED The DRC will be considered part of the CRF as well as source documentation.  The subject 
should be educated to complete the DRC on a regular basis (each time that a seizure, an REDACTED should be educated to complete the DRC on a regular basis (each time that a seizure, an COPY .  As a result of the discussion, the Investigator will asses
COPY .  As a result of the discussion, the Investigator will asses
epi[INVESTIGATOR_529388] t
COPY epi[INVESTIGATOR_529388] t
the CRF; he/she will also confirm the presence of adverse events (if applicable).  The COPY the CRF; he/she will also confirm the presence of adverse events (if applicable).  The 
This document Results for hematology
document Results for hematology
the 
document the cannot laboratory
cannot laboratory  will provide the 
cannot  will provide the laboratory  will provide the laboratory
cannot laboratory  will provide the laboratory
(labels, needles, tubes), and a 
cannot (labels, needles, tubes), and a 
use the equipment and how to ship the samples back to the central laboratorycannot use the equipment and how to ship the samples back to the central laboratorybe Evaluation Visit of the previous study
be Evaluation Visit of the previous study
 will provide the be  will provide the used Visit, and Final Visit, 
used Visit, and Final Visit, 
central laboratory
used central laboratory
used . 
used . At the Entry
used At the Entry
Evaluation Visit of the previous study used Evaluation Visit of the previous studyto Visit, and Final Visit, to Visit, and Final Visit, laboratoryto laboratory
At the Entryto At the Entrysupport Laboratory Assessments
support Laboratory Assessments
At the following visitssupport At the following visits ,support ,Full Evaluation Visit, Yearlysupport Full Evaluation Visit, Yearly
laboratorysupport laboratoryany Laboratory Assessments any Laboratory Assessmentsmarketing The DRC will be considered part of the CRF as well as source documentation.  The subject 
marketing The DRC will be considered part of the CRF as well as source documentation.  The subject 
should be educated to complete the DRC on a regular basis (each time that a seizure, an 
marketing should be educated to complete the DRC on a regular basis (each time that a seizure, an 
cation of medication or investigational product, or a medical visit 
marketing cation of medication or investigational product, or a medical visit authorization epi[INVESTIGATOR_529388] t
authorization epi[INVESTIGATOR_529388] t
the CRF; he/she will also confirm the presence of adverse events (if applicable).  The 
authorization the CRF; he/she will also confirm the presence of adverse events (if applicable).  The 
concomitant medication changes and adverse events will be reported by
[CONTACT_529453].  The subject authorization The DRC will be considered part of the CRF as well as source documentation.  The subject application The written information will be discussed with the subject at each visit in order to ensure 
application The written information will be discussed with the subject at each visit in order to ensure 
.  As a result of the discussion, the Investigator will asses
application .  As a result of the discussion, the Investigator will asses
epi[INVESTIGATOR_529388] t application epi[INVESTIGATOR_529389] (according to individual description of epi[INVESTIGATOR_122174])
extensions pe of seizure (according to individual description of epi[INVESTIGATOR_122174])or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687874] 2015 / Page 39of 72
The following laboratory assessments will be conducted:
Blood chemistry : glucose, urea, creatinine, sodium, potassium, calcium, phosphorus 
(inorganic), total protein, albumin, total bilirubin, alkaline phosphatase (ALP) , aspartate 
aminotransferase/serum glutamic oxaloacetic transaminase (ASAT/SGOT), alanine 
aminotransferase/serum glutamic p yruvic transaminase (ALAT /SGPT), gamma -
glutam yltranspeptidase ( GGT ), anduric acid.
The creatinine clearance (Cr Cl) will be calculated by [CONTACT_94486]’s formula (only  at the 
Entry  Visit) : 
 male: Cr Cl ml/min = [(140 -age) x body  weight] / (72 x serum creatinine 
(mg/dl)] .
 female: Cr Cl ml/min =[(140 -age) x body  weight] / [ 72 x serum creatinine 
(mg/dl)] x 0.85.
Hematology : white blood cells (WBC), red blood cells (RBC), hemoglobin, hematocrit, 
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC), platelet count, lymphocytes (number, %), monocy tes (number, %), neutrophils (number, %), eosinophils (number, %), 
basophils (number, %).
Urinalysis: specific gravity , pH, glucose, bilirubin, ketones, occult blood, protein, 
nitrites, leukocy tes. If the test for protein, blood or leukocytes shows a trace or is 
positive, sediment and microscopic anal yses (erythrocy te cast, leukocyte casts, 
hemoglobin casts, uric acid cry stals, bihy drate calcium oxalate cry stals, monohy drate 
calcium oxalate crystals, triple phosphate cry stals and bacteria) will be conducted.
Where applicable (women of childbearing potential), a urine pregnancy test will be 
conducted. 
Plasma samples to analyze BRV and concomitant AED plasma concentrations will no longer 
be obtained.
11.1.15 Adverse Events (AEs)
At the Entry Visit, the Investigator will record any  adverse event that was still ongoing at the 
end of the previous study .From the entry  Visit onwards, adverse events will be assessed at 
each visit and recorded in the CRF and in the source documents. T he study participant will 
be given the opportunity to report AEs spontaneously . A general prompt will also be given to 
detect AEs, e.g., “Did you notice an ything unusual about your health (since your last visit)?” 
In addition, the Investigator should review an y self-assessment procedures (e. g. dail y record 
cards) used in the study .
11.1.16 Assessment of S uicidality
Suicidality  will be assessed by  [CONTACT_122281] C-SSRS.  This scale will be 
used to assess suicidal ideation and behavior that may  occur during the study .  The C -SSRS 
will be completed according to the tabular schedule of assessments (Section 5.1).REDACTED , pH, glucose, bilirubin, ketones, occult blood, protein, 
REDACTED , pH, glucose, bilirubin, ketones, occult blood, protein, 
If the test for protein, blood or leukocy
REDACTED If the test for protein, blood or leukocy
positive, sediment and microscopic anal
REDACTED positive, sediment and microscopic anal ys
REDACTED yses 
REDACTED es 
REDACTED stals, bihy
REDACTED stals, bihy
stals, triple phosphate cryREDACTED stals, triple phosphate cry
childbearing potential), a REDACTED childbearing potential), a COPY umber, %), neutrophils (number, %), eosinophils (number, %), 
COPY umber, %), neutrophils (number, %), eosinophils (number, %), 
, pH, glucose, bilirubin, ketones, occult blood, protein, COPY , pH, glucose, bilirubin, ketones, occult blood, protein, 
This document In addition, the 
document In addition, the 
cards) used in the 
document cards) used in the cannot each visit and recorded in the CRF and in the source documents. 
cannot each visit and recorded in the CRF and in the source documents. 
be given the
cannot be given the
detect AEs, e.g., “Did cannot detect AEs, e.g., “Did 
In addition, the cannot In addition, the be previous 
be previous 
each visit and recorded in the CRF and in the source documents. be each visit and recorded in the CRF and in the source documents. used  Visit, the 
used  Visit, the 
used previous used previous to support 11.1.15 Adverse Events (AEs)support 11.1.15 Adverse Events (AEs)any BRVany BRV and concomitant AED plasma concentrations will no longer any and concomitant AED plasma concentrations will no longer marketing stals, triple phosphate cry
marketing stals, triple phosphate cry
childbearing potential), a 
marketing childbearing potential), a 
and concomitant AED plasma concentrations will no longer marketing and concomitant AED plasma concentrations will no longer authorization , pH, glucose, bilirubin, ketones, occult blood, protein, 
authorization , pH, glucose, bilirubin, ketones, occult blood, protein, 
If the test for protein, blood or leukocy
authorization If the test for protein, blood or leukocy
es 
authorization es (ery
authorization (ery
authorization stals, bihyauthorization stals, bihy drate calcium oxalate cryauthorization drate calcium oxalate cry
stals, triple phosphate cry authorization stals, triple phosphate cryapplication white blood cells (WBC), red blood cells (RBC), hemoglobin, hematocrit, 
application white blood cells (WBC), red blood cells (RBC), hemoglobin, hematocrit, 
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean 
application mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC), platelet count, lymphocytes (number, 
application corpuscular hemoglobin concentration (MCHC), platelet count, lymphocytes (number, 
umber, %), neutrophils (number, %), eosinophils (number, %), 
application umber, %), neutrophils (number, %), eosinophils (number, %), and white blood cells (WBC), red blood cells (RBC), hemoglobin, hematocrit, and white blood cells (WBC), red blood cells (RBC), hemoglobin, hematocrit, 
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean and mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean any 72 x serum creatinine 
any 72 x serum creatinine extensions (only
extensions (only  at the 
extensions  at the (only  at the (only
extensions (only  at the (only
 weight] / (72 x serum creatinin
extensions  weight] / (72 x serum creatinin
72 x serum creatinine extensions 72 x serum creatinine or  at the or  at the variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687875] 2015 / Page 40of 72
11.1.17 Medical Procedures
From the Entry  Visit onwards, collection of data on medical procedures (surgery, therapeutic 
and/or diagnostic, hospi[INVESTIGATOR_602]) undertaken during the study will be obtained. ECGs 
specific to this study will not be recorded on the Medical Procedures page of the CRF but in 
the modules specificall y designed for this purpose.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or page of the CRF but in 
or page of the CRF but in variations page of the CRF but in variations page of the CRF but in thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687876] 2015 / Page 41of [ADDRESS_687877] all Non-Antiepi[INVESTIGATOR_529390] .All 
medications (including over- the-counter preparations) taken during the course of the study
must be documented in the CRF (brand name, indication, dosage, and the dates of start and 
discontinuation).
At each visit, a complete listing of all medications currently being taken will be obtained. 
Any changes, a dditions or deletions in the administration of non-antiepi[INVESTIGATOR_122195]-Antiepi[INVESTIGATOR_529391]. In case of intake of prohibited concomitant medication ( see Section 10.2.2) during the 
study period, the Investigator will contact [CONTACT_122285] .
Changes, additions or deletions in the administration of antiepi[INVESTIGATOR_122197].
11.1.19 Patient Reported Outcomes
A Patient Reported Outcomes (PRO) booklet per visit will be created for the FEV, YEV as 
well as for EDV. The assessment of the Patient Reported Outcomes will be limited to the first 2 yearsafter study  entry , which includes the YEV of Year 3.  These booklets will 
include, in order of appearance: T he Patient Weighted Quality  of Life in Epi[INVESTIGATOR_122198]  -
31 item form (QOLIE -31-P -Version 2), the Hospi[INVESTIGATOR_74017] 
(HADS ), and t he EQ -5D self report questionnaire. The PRO booklet is to be provided to 
subjects that are not mentally  impaired, at the very beginning of the study visit. The subject 
will be asked to complete the questionnaires on his/her own. Once completed, the subject will hand back the booklet to the Investigator who will check that all questions have been answered.
Subjects coming from N01193 will not have to complete the PRO booklet. All other subjects 
that are not mentally impaired will complete the PRO booklet at FEV, YEV and/or EDV for 
the first 2 years.
The PRO booklets will be considered as part of the CRF as well as source documentation.
11.1.20 Quality of Life in Epi[INVESTIGATOR_56005] (QOLIE -31-P)
QOLIE -31-P (Cramer and Van Hammée, 2003) is an adaptation of the original QOLIE-31 
instrument (Cramer et al, 1998) that includes 7 subscales (seizure worry , overall quality  of 
life, emotional well- being, energy -fatigue, cognitive functioning, medication effects, social 
function) and the health status item. Subscale scores as well as Total score range from 0 to REDACTED A Patient Reported Outcomes (PRO) booklet per visit will be created for the FEV, YEV as 
REDACTED A Patient Reported Outcomes (PRO) booklet per visit will be created for the FEV, YEV as 
The assessment of the Patient Reported Outcomes will be limited to the 
REDACTED The assessment of the Patient Reported Outcomes will be limited to the 
, which includes the YEV of Year REDACTED , which includes the YEV of YearCOPY Changes, additions or deletions in the administration of antiepi[INVESTIGATOR_529392], additions or deletions in the administration of antiepi[INVESTIGATOR_529393].
COPY omitant Medications page of the CRF.
This document The PRO booklets will be considered as part of the CRF as well as source documentation.
document The PRO booklets will be considered as part of the CRF as well as source documentation.
11.1.[ADDRESS_687878] to complete the PRO booklet. 
that are not mentally impaired will complete the PRused that are not mentally impaired will complete the PRto support subjects that are not mentally
support subjects that are not mentally  impaired, at the very beginning of the stud
support  impaired, at the very beginning of the stud subjects that are not mentally  impaired, at the very beginning of the stud subjects that are not mentally
support subjects that are not mentally  impaired, at the very beginning of the stud subjects that are not mentally
will be asked to complete the questionnaires on his/her own. 
support will be asked to complete the questionnaires on his/her own. 
will hand back the booklet to the I
support will hand back the booklet to the Iany -5D self report questionnaire. The PRO booklet is to be provided to 
any -5D self report questionnaire. The PRO booklet is to be provided to 
 impaired, at the very beginning of the studany  impaired, at the very beginning of the studmarketing The assessment of the Patient Reported Outcomes will be limited to the 
marketing The assessment of the Patient Reported Outcomes will be limited to the 
, which includes the YEV of Year
marketing , which includes the YEV of Year
he Patient Weighted Quality
marketing he Patient Weighted Quality
Version 2), the Hospi[INVESTIGATOR_529394] 2), the Hospi[INVESTIGATOR_198442]
-5D self report questionnaire. The PRO booklet is to be provided to marketing -5D self report questionnaire. The PRO booklet is to be provided to authorization A Patient Reported Outcomes (PRO) booklet per visit will be created for the FEV, YEV as 
authorization A Patient Reported Outcomes (PRO) booklet per visit will be created for the FEV, YEV as 
The assessment of the Patient Reported Outcomes will be limited to the authorization The assessment of the Patient Reported Outcomes will be limited to the application will contact [CONTACT_529454] .
application .
Changes, additions or deletions in the administration of antiepi[INVESTIGATOR_529395], additions or deletions in the administration of antiepi[INVESTIGATOR_529393].application omitant Medications page of the CRF.and Antiepi[INVESTIGATOR_529396] (brand name, indication, dosage, and the dates of start and 
extensions must be documented in the CRF (brand name, indication, dosage, and the dates of start and 
y being taken will be obtained. extensions y being taken will be obtained. 
antiepi[INVESTIGATOR_529397] (brand name, indication, dosage, and the dates of start and or must be documented in the CRF (brand name, indication, dosage, and the dates of start and variations study variations studythereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687879] 2015 / Page 42of 72
100 with higher scores indicating better health related quality  of life. In addition to the 31 
items of the QOLIE-31, the QOLIE-31- P contains 7 items asking the subjects to grade his or 
her overall "distress" related to the topic of each subscale.  The QOLIE -31-P also contains an 
item asking about the relative importance of each subscale topic. The subjects will complete 
the QOLIE-31-P at every Full Evaluation Visit and Yearly Evaluation Visit for the first 2years, and at the Early  Discontinuation Visit if the Early Discontinuation Visit occurs 
within the first 2 years.
11.1.21 Hospi[INVESTIGATOR_5620] (HADS)
The Hospi[INVESTIGATOR_74017] (HADS) (Herrmann, 1997) will be used to 
evaluate anxiety  and depression/depressed feelings. The HADS was developed as a self 
administered scale to assess the presence and severity  of both anxiety and depression 
simultaneously . It consists of 14 items that are scored on a 4- point severit y scale ra nging 
from 0 to 3. A score per dimension (anxiety , depression) will be calculated as recommended 
by [CONTACT_529455] 0 to 21 and higher scores indicating higher 
depression/anxiety .The subjects will complete the HADS at every  Full Evaluation Visit and 
Yearl y Evaluation Visit for the first [ADDRESS_687880] 2 years.
11.1.22 EQ-5D Questionnaire
The EQ -5D(EuroQol Group, 2000) is a self-administered questionnaire designed to measure 
health status. EQ-5D defines health in terms of 5 dimensions (mobility , self -care, usual 
activities, pain/discomfort and anxiety /depression). Each dimension is divided into 3 levels:
no problem = 1.
some or moderate problems = 2.
extreme problems = 3.
EQ-5D also captures a self-rating of health status on a 20 cm vertical visual analogue scale, 
anchored at 100 (best imaginable health state) at the top and 0 (worst imaginable health state) 
at the bottom.
The EQ -5D questionnaire will be assessed at every Full Evaluation Visit and Yearl y 
Evaluation Visit for the first [ADDRESS_687881] 2be 5D questionnbe 5D questionnused anchored at 100 (best imaginable health state) at the top and 0 (worst imaginable health state) 
used anchored at 100 (best imaginable health state) at the top and 0 (worst imaginable health state) to 5D also captures a selfto 5D also captures a self
anchored at 100 (best imaginable health state) at the top and 0 (worst imaginable health state) to anchored at 100 (best imaginable health state) at the top and 0 (worst imaginable health state) support some or moderate problems = 2
support some or moderate problems = 2
extreme problems = 3
support extreme problems = 3 .
support .
5D also captures a self support 5D also captures a selfany some or moderate problems = 2 any some or moderate problems = 2marketing is a self
marketing is a self -
marketing - is a self - is a self
marketing is a self - is a self administered qu
marketing administered qu
marketing 5D defines health in terms of 5 dimensions (mobility
marketing 5D defines health in terms of 5 dimensions (mobility
activities, pain/discomfort and anxietymarketing activities, pain/discomfort and anxiety /depression). marketing /depression). activities, pain/discomfort and anxiety /depression). activities, pain/discomfort and anxietymarketing activities, pain/discomfort and anxiety /depression). activities, pain/discomfort and anxietyauthorization years, and at the Earl
authorization years, and at the Earl
y Discontinuation Visit occurs within the first [ADDRESS_687882] 2 ye
authorization years.
authorization ars.application point severit
application point severit
, depression) will be calculated as recommended 
application , depression) will be calculated as recommended 
 the authors with each score ranging from 0 to 21 and higher scores indicating higher 
application  the authors with each score ranging from 0 to 21 and higher scores indicating higher 
The subjects will complete the HADS at everyapplication The subjects will complete the HADS at every
years, and at the Earlapplication years, and at the Earl y Discontinuation Visit if the application y Discontinuation Visit if the and The HADS was developed as a self 
and The HADS was developed as a self 
 of both anxietyand  of both anxiety  and depression and  and depression  of both anxiety  and depression  of both anxietyand  of both anxiety  and depression  of both anxiety
point severit and point severitany will be used to 
any will be used to 
The HADS was developed as a self any The HADS was developed as a self extensions will be used to extensions will be used to or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687883] 2015 / Page 43of [ADDRESS_687884] 2 years.
11.1.24 Healthcare Provider Consultation not Foreseen by [CONTACT_529456], healthcare provider consultation not foreseen by  [CONTACT_529457]. It will include the ty pe of provider [general practitioner 
(GP), specialist ph ysician, nurse], site of care (office-private, office- hospi[INVESTIGATOR_307], home, 
emergency  room) and t he reason leading to the consultation.  Healthcare provider 
consultations not foreseen by [CONTACT_529458], 
Minimal Evaluation Visit, and Yearly  Evaluation Visit for the first [ADDRESS_687885] 2 years 
and/or at the Early  Discontinuation Visit if the Early Discontinuation Visit occurs within the 
first [ADDRESS_687886]’s participation in the study will be confirmed on the subject’s status 
evaluation section of the CRF.  All data about the subject’s status ( study completion or reason 
for early  study termination) will be recorded. It will be specified:
Whether the subject completed (participated until the study was stopped) or prematurel y 
discontinued the study .
A subject will be considered lost to follow- up following [ADDRESS_687887] (e.g. b y telepho ne).
If a subject will not continue with the study drug, the Investigator will first schedule an Earl y 
Discontinuation Visit which will be followed by a progressive down-titration of the study
drug. The dose decrease can be made by [CONTACT_122288] a maximum of 50mg/day on a weekl y 
basis. A last down-titration step at 20 mg/day  for 1 week will be included prior to the study -
drug free period.  At the end of the down-titration period, a Down -Titration P hone Call will 
occur for subjects having down-titrated from d oses higher than 20 mg/day . The Down -
Titration Period will be followed by a period free of study drug at the minimum of 2weeks 
and a maximum of 4 weeks and subsequentl y the Final Visit will occur. 
When the time point is reached at which the stud y will be terminated b y the sponsor (as 
defined in Section 8.4), subjects will discontinue the study drug, following the above REDACTED collects information such as education level, housing status, emplo
REDACTED collects information such as education level, housing status, emploCOPY Evaluation 
COPY Evaluation 
if the Early
COPY if the Early Discontinuation Visit occurs within the 
COPY Discontinuation Visit occurs within the 
from N01252, N01253 and N01254COPY from N01252, N01253 and N01254
collects information such as education level, housing status, emploCOPY collects information such as education level, housing status, emplo
This document basis.
document basis.
document drug free period.  
document drug free period.  
occur for 
document occur for cannot Discontinuation Visit which will be followed by
[CONTACT_529459]. 
cannot drug. The dose decrease can be made by
[CONTACT_529460].cannot basis. A last downcannot A last downbe If a subject will not continue with be If a subject will not continue with 
Discontinuation Visit which will be followed by[CONTACT_529461] (e.g. b
used to contact [CONTACT_423] (e.g. b
If a subject will not continue with used If a subject will not continue with to A subject will be considered lost to follow-to A subject will be considered lost to follow-
to contact [CONTACT_423] (e.g. b to to contact [CONTACT_423] (e.g. bsupport Whether the subject completed (participated until the 
support Whether the subject completed (participated until the 
study
support study .
support .
A subject will be considered lost to follow- support A subject will be considered lost to follow-any termination) will be recorded.
any termination) will be recorded.
Whether the subject completed (participated until the any Whether the subject completed (participated until the marketing The end of the subject’s participation in 
marketing The end of the subject’s participation in the 
marketing the 
marketing All data about the subject’s status (marketing All data about the subject’s status (
termination) will be recorded. marketing termination) will be recorded.authorization from N01252, N01253 and N01254
authorization from N01252, N01253 and N01254
collects information such as education level, housing status, emplo
authorization collects information such as education level, housing status, emploapplication Evaluation 
application Evaluation 
Discontinuation Visit occurs within the application Discontinuation Visit occurs within the 
from N01252, N01253 and N01254application from N01252, N01253 and N01254and ation Visit and the Final Visit if these visits occur within the first [ADDRESS_687888] 2extensions pe of provider [general practitioner 
extensions pe of provider [general practitioner 
hospi[INVESTIGATOR_307], home, 
extensions hospi[INVESTIGATOR_307], home, 
Healthcare provider 
extensions Healthcare provider 
 Full Evaluation Visit, extensions  Full Evaluation Visit, 
ars, and at the Early extensions ars, and at the Earlyor  protocol will be 
or  protocol will be 
pe of provider [general practitioner or pe of provider [general practitioner variations  protocol will be variations  protocol will be thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687889] 2015 / Page 44of [ADDRESS_687890] visit of 
the previous study  and the entry  visit in the present study , the Sponsor’s Study  Physician or 
representative should be contact[CONTACT_122289]. The Adverse Events, Medical Procedures, 
Non-Antiepi[INVESTIGATOR_529398], on specific pages.
Each visit will be planned within a “window” of ± [ADDRESS_687891] an additional study visit/phone call if the Investigator of 
the subject deems it necessary . All information, including the reason for the visit/phone call, 
any information on adverse events, etc., should be collected in the source documents and 
recorded in the appropriate section of the CRF.
11.2.1 Entry Visit
Signing and dating of written informed consent.
Dispensation of “clinical study subject card” (participation in the study ).
Verification of the Inclusion/exclusion criteria.
Demograph y data: date of birth, gender and racial group.
Childbearing potential.
Medical and procedure history .
Epi[INVESTIGATOR_122208] .
AED history .
Vital signs including blood pressure and pulse rate.
Body weight and height.
Physical and neurological examination.
ECG.
Dispensation of subject DRC and instruction on proper completion.
Recording of seizures.
Concomitant medications (AED and Non- AED) documentation .
Laboratory  assessment including safety (hematology, blood chemistry, and urinalysis), 
pregnancy test (if applicable) .
Recording of Adverse E vents .REDACTED All information, including the reason for the visit/phone call, 
REDACTED All information, including the reason for the visit/phone call, 
 information on adverse events, etc., should be collected in the source documents and 
REDACTED  information on adverse events, etc., should be collected in the source documents and 
recorded in the appropriate section of the CRF.
REDACTED recorded in the appropriate section of the CRF.COPY 7 day
COPY 7 day
studyCOPY study
All information, including the reason for the visit/phone call, COPY All information, including the reason for the visit/phone call, 
This document 
document ECG.
document ECG.

document cannot Vital signs
cannot Vital signs
cannot Bod
cannot Body weight and height.
cannot y weight and height.
Phycannot Physical and neurological examination.cannot sical and neurological examination.
ECG.cannot ECG.be AED history
be AED history
Vital signs be Vital signsused dical and procedure history
used dical and procedure history
 history
used  history
AED history used AED historyto dical and procedure historyto dical and procedure historysupport Inclusion
support Inclusion
date of birth, gender and racial group.
support date of birth, gender and racial group.
Childbearing potential.support Childbearing potential.
dical and procedure historysupport dical and procedure historyany study
any study
any Inclusion any Inclusion /exclusion criteria.any /exclusion criteria.marketing gning and dating of written informed consent.marketing gning and dating of written informed consent.
subject card” (participation in the marketing subject card” (participation in the authorization visit/phone call if the 
authorization visit/phone call if the 
All information, including the reason for the visit/phone call, 
authorization All information, including the reason for the visit/phone call, 
 information on adverse events, etc., should be collected in the source documents and 
authorization  information on adverse events, etc., should be collected in the source documents and 
recorded in the appropriate section of the CRF.
authorization recorded in the appropriate section of the CRF.application s from the previous visit.
application s from the previous visit.
visit/phone call if the application visit/phone call if the and representative should be contact[CONTACT_122289]. The Adverse Events, Medical Procedures, 
and representative should be contact[CONTACT_122289]. The Adverse Events, Medical Procedures, 
n belonging to the interim period and n belonging to the interim period any tudy
any tudy
representative should be contact[CONTACT_122289]. The Adverse Events, Medical Procedures, any representative should be contact[CONTACT_122289]. The Adverse Events, Medical Procedures, extensions  as the last visit of the previous study in 
extensions  as the last visit of the previous study in 
 between the extensions  between the 
tudyextensions tudy Pextensions Por variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687892] 2015 / Page 45of 72
Medical procedures.
Dispensation of study medication (only  dispensed once all inclusion/exclusion criteria 
have been met).
Appointment for the next visit according to the schedule described in Section 5.2.
The following data will be transferred from the database of the baseline visit of the previous 
study and should not be recorded in the CRF:
General medical and procedure h istory .
AED history .
Epi[INVESTIGATOR_122208] .
The following data will be transferred from the database of the last evaluation visit o f the 
previous study andshould not be recorded in the CRF /DRC :
Vital s igns including blood pressure and pulse rate.
Physical examination.
Neurological examination.
ECG.
Laboratory  assessment including safet y (hematology, bl ood chemistry , and urinaly sis).
Pregnancy test (if applicable) .
Recording of seizures.
11.2.2 Full Evaluation Visit
Vital signs including blood pressure and pulse rate.
Body weight.
Physical and neurological examination.
Retrieval of previous subject DRC.
Recording of seizures.
Laboratory  assessment including safety (hematology, blood chemistry, and urinalysis), 
urine pre gnancy  test (if applicable) .
Recording of Adverse Events.
Assessment of suicidality (C- SSRS).
Medical procedures.
Concomitant medications (AED and Non-AED) documentation.
Drug return/accountability including study medication intake and compliance check.
Dispensation of new DRC.
Dispensation of study medication .
Appointment for the next visit according to the schedule described in Section 5.2.
The following assessments will be performed during the first 2 years which includes the YEV 
in Year 3.REDACTED y (hematology, bl
REDACTED y (hematology, bl COPY y (hematology, bl COPY y (hematology, bl
This document Drug
document Drug

document cannot Assessment of suicidality (C
cannot Assessment of suicidality (C
Medical procedures.
cannot Medical procedures.
Concomitant medications (AED and Noncannot Concomitant medications (AED and Non
Drugcannot Drugbe Recording of Adverse Events
be Recording of Adverse Events
Assessment of suicidality (Cbe Assessment of suicidality (Cused gnancy
used gnancy  test (if applicable)
used  test (if applicable) gnancy  test (if applicable) gnancy
used gnancy  test (if applicable) gnancy
Recording of Adverse Eventsused Recording of Adverse Eventsto essment including safetto essment including safet
 test (if applicable)to  test (if applicable)support sical and neurological examination.
support sical and neurological examination.
Retrieval of previous subject DRC.
support Retrieval of previous subject DRC.
Recording of seizures.support Recording of seizures.
essment including safetsupport essment including safetany sical and neurological examination. any sical and neurological examination.marketing Vital signs including blood pressure and pulse rate.
marketing Vital signs including blood pressure and pulse rate.authorization y (hematology, bl
authorization y (hematology, blapplication and last evaluation visit o
and last evaluation visit o any last evaluation visit o any last evaluation visit oextensions or m the database of the baseline visit of the previous or m the database of the baseline visit of the previous variations m the database of the baseline visit of the previous variations m the database of the baseline visit of the previous thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687893] 2015 / Page 46of 72
QOLIE -31-P questionnaire (except if subject mentally impaired and except for all 
subjects coming from N01193).  The questionnaire should be filled in at the beginning of 
the Visit.
HADS questionnaire (except if subject mentall y impaired and except for all subjects 
coming from N01193).  The questionnaire should be filled in at the beginning of the Visit, after the QOLIE -31-P.
Healthcare provider consultation not foreseen b y protocol
Recording of workday s and schoolday s lost and day s subject received help from a 
caregiver (paid or not) at home.
Hospi[INVESTIGATOR_4408] .
EQ-5D questionnaire (except if subject mentall y impaired and except for all subjects 
coming from N01193).
11.2.3 Minimal Evaluation Visit
Vital signs including blood pressure and pulse rate.
Retrieval of previous subject DRC.
Recording of seizures.
Recording of workday s and schoolday s lost and day s subject received help from a 
caregiver (paid or not ) at home during the first 2 years .
Hospi[INVESTIGATOR_529399] 2 years.
Healthcare provider c onsultation not foreseen by [CONTACT_529462] 2 years.
Recording of Adverse Events.
Assessment of suicidality (C- SSRS).
Medical procedures.
Concomitant medications (AED and Non -AED) documentation.
Drug return/accountability  including study medication intake and compliance check.
Dispensation of new DRC.
Dispensation of study medicatio n.
Appointment for the next visit according to the schedule described i n Section 5.2.
11.2.4 Yearly Evaluation Visit (replaces the first FEV of each year)
Vital signs including blood pressure and pulse rate.
Body weight and height (only for those subjects still potentially  growing ).
Physical and neurological examination.
ECG.
Retrieval of previous subject DRC.
Recording of seizures.REDACTED s and schoolday
REDACTED s and schoolday s lost and day
REDACTED s lost and day
during the first [ADDRESS_687894] 2
yeREDACTED yearsREDACTED arsCOPY Vital signs including blood pressure and pulse rate.
COPY Vital signs including blood pressure and pulse rate.
This document Vital signs including blood pressure and pulse rate.
document Vital signs including blood pressure and pulse rate.

document cannot Yearly Evaluation Visit (replaces 
cannot Yearly Evaluation Visit (replaces 
Vital signs including blood pressure and pulse rate.cannot Vital signs including blood pressure and pulse rate.be Appointment for the next visit according to the schedule described i
be Appointment for the next visit according to the schedule described i
Yearly Evaluation Visit (replaces be Yearly Evaluation Visit (replaces used Dispensation of 
used Dispensation of 
Appointment for the next visit according to the schedule described iused Appointment for the next visit according to the schedule described ito Dispensation of new DRC.to Dispensation of new DRC.
studyto studysupport medications (AED and Non
support medications (AED and Non
Drug return/accountability
support Drug return/accountability
Dispensation of new DRC. support Dispensation of new DRC.any Assessment of suicidality (C
any Assessment of suicidality (C -
any -SSRS).
any SSRS).marketing onsultation not 
marketing onsultation not f
marketing foreseen
marketing oreseenforeseenf
marketing foreseenf
SSRS).marketing SSRS).authorization s lost and day
authorization s lost and day
during the first 2authorization during the first 2application and mpaired and except for all subjects 
and mpaired and except for all subjects any mpaired and except for all subjects any mpaired and except for all subjects extensions s subject received help from a 
extensions s subject received help from a or coming from N01193).  The questionnaire should be filled in at the beginning of the Visit, or coming from N01193).  The questionnaire should be filled in at the beginning of the Visit, variations coming from N01193).  The questionnaire should be filled in at the beginning of the Visit, variations coming from N01193).  The questionnaire should be filled in at the beginning of the Visit, thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687895] 2015 / Page 47of 72
Laboratory  assessment including safety (hematology, blood chemistry, and urinalysis), 
urine pregnancy  test (if a pplicable).
Recording of Adverse Events.
Asses sment of suicidality (C- SSRS).
Medical procedures.
Concomitant medications (AED and Non-AED) documentation.
Drug return/accountability  including study medication intake and compliance check.
Dispensation of new DRC.
Dispensation of study medication.
Appointment for the next visit according to the schedule described in Section 5.2.
The following assessments will be performed during the first 2 years which includes the YEV 
in Year 3.
QOLIE -31-P questionnaire (excep t if subject mentally  impaired and except for all 
subjects coming from N01193).  The questionnaire should be filled in at the beginning of 
the Visit.
HADS questionnaire (except if subject mentall y impaired and except for all subjects 
coming from N01193).  The questionnaire should be filled in at the beginning of the Visit, after the QOLIE -31-P.
Healthcare provider consultation not foreseen b y protocol
Recording of workdays and school days lost and day s subject received help from a 
caregiver (paid or not) at home.
Hospi[INVESTIGATOR_4408] .
EQ-5D questionnaire (except if subject mentall y impaired and except for all subjects 
coming from N01193).
Socio -professional data.
11.2.5 Early Discontinuation Visit
Vital signs including blood pressure and pulse rate.
Body weight.
Physical and neurological examination.
ECG.
Retrieval of previous subject DRC.
Recording of seizures.
Laboratory  assessment including safety (hematology, blood chemistry, and urinalysis), 
urine pregnancy  test (if applicable).
Recording of Adverse Events.
Assessment of suicidality (C- SSRS).
Medical procedures.
Concomitant medications (AED and Non-AED) documentation.REDACTED The questionnaire should be filled in at the beginning of the Visit, 
REDACTED The questionnaire should be filled in at the beginning of the Visit, 
Healthcare provider consultation not foreseen b
REDACTED Healthcare provider consultation not foreseen b
s and school day
REDACTED s and school day s lost and day
REDACTED s lost and dayCOPY HADS questionnaire (except if subject mentall
COPY HADS questionnaire (except if subject mentall y i
COPY y impaired and except for all subjects 
COPY mpaired and except for all subjects 
The questionnaire should be filled in at the beginning of the Visit, COPY The questionnaire should be filled in at the beginning of the Visit, 
This document Recording of seizures.
document Recording of seizures.

document cannot ECG.
cannot ECG.
Retrieval of previous subject DRC.
cannot Retrieval of previous subject DRC.
Recording of seizures.cannot Recording of seizures.be sicabe sical and neurological examination.be l and neurological examination.used Vital signs including blood pressure and pulse rate.
used Vital signs including blood pressure and pulse rate.
y weight.used y weight.
l and neurological examination.used l and neurological examination.to Vital signs including blood pressure and pulse rate. to Vital signs including blood pressure and pulse rate.support 11.2.[ADDRESS_687896] and day
5D questionnaire (except if subject mentallmarketing 5D questionnaire (except if subject mentallauthorization mpaired and except for all subjects 
authorization mpaired and except for all subjects 
The questionnaire should be filled in at the beginning of the Visit, 
authorization The questionnaire should be filled in at the beginning of the Visit, 
Healthcare provider consultation not foreseen b
authorization Healthcare provider consultation not foreseen b y protocol
authorization y protocol
s lost and dayauthorization s lost and dayapplication  impaired and except for all 
application  impaired and except for all 
The questionnaire should be filled in at the beginning of 
application The questionnaire should be filled in at the beginning of 
mpaired and except for all subjects application mpaired and except for all subjects and ars which includes the YEV 
and ars which includes the YEV any ars which includes the YEV any ars which includes the YEV extensions medication intake and compliance check.
extensions medication intake and compliance check.
Section extensions Section or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687897] 2015 / Page 48of 72
Drug return/accountability  including study medication intake and compliance check.
Dispensation of new DRC.
Dispensation of study medication with down-titration dosing schedule.
Appointment for the next visit according to the schedule described in Section 5.2.
Down -titration may  not be applicable to subjects who may transition to another BRV study  or 
may be in itiated in a managed access pro gram or similar ty pe of program.   
The following assessments will be performed only if the EDV occurs within the first 2 years.
QOLIE -31-P questionnaire (except if subject mentally impaired and except for all 
subjects coming from N01193).  The questionnaire should be filled in at the beginning of 
the Visit.
HADS questionnaire (except if subject mentall y impaired and except for all subjects 
coming from N01193).  The questionnaire should be filled in at the beginning of the Vi sit, 
after the QOLIE -31-P.
Healthcare provider consultation not foreseen b y protocol
Recording of workday s and schoolday s lost and day s subject received help from a 
caregiver (paid or not) at home.
Hospi[INVESTIGATOR_4408] .
EQ-5D questionnaire (except if subject mentall y impaired and except for all subjects 
coming from N01193).
Socio -professional data.
11.2.6 Down- Titration Phone Call
Recording of Adverse Events.
Reminder of appointment for the next visit according to the schedule described in
Section 5.2.
11.2.7 Final Visit (FV  following a Study Drug Free Period after an EDV or FV initiated 
upon Sponsor request at the end of the program)
Vital signs including blood pressure and pulse.
Body weight and height (only for those subjects s till potentially  growing ).
Physical and neurological examination.
ECG (except after an EDV when EDV ECG results were normal).
Retrieval of previous subject DRC.
Recording of seizures.
Recording of workday s and school days lost and day s subject received hel p from a 
caregiver (paid or not) at home during the first 2 years .
Hospi[INVESTIGATOR_529399] 2 years.REDACTED 5D questionnaire (except if subject ment
REDACTED 5D questionnaire (except if subject mentCOPY y protocol
COPY y protocol
s lost and day
COPY s lost and day
This document 
document Phy
document Phy

document cannot Vital signs including blood pressure and pulse.
cannot Vital signs including blood pressure and pulse.
Bodcannot Bodbe upon Sponsor request at the end of the program)
be upon Sponsor request at the end of the program) used Final Visit used Final Visit (FVused (FV
upon Sponsor request at the end of the program) used upon Sponsor request at the end of the program)to support Recording of Adverse Events.
support Recording of Adverse Events.
support ppointment for the next visit according to the schedule described in
support ppointment for the next visit according to the schedule described inany Phone Call
any Phone Call
Recording of Adverse Events.any Recording of Adverse Events.marketing Phone Call marketing Phone Callauthorization s lost and day
authorization s lost and day s subject received help from a 
authorization s subject received help from a 
5D questionnaire (except if subject ment
authorization 5D questionnaire (except if subject ment all
authorization ally i
authorization y iapplication mpaired and except for all subjects 
application mpaired and except for all subjects 
The questionnaire should be filled in at the beginning of the Vi
application The questionnaire should be filled in at the beginning of the Vi
y protocol
application y protocol
s subject received help from a application s subject received help from a and mpaired and except for all subjects and mpaired and except for all subjects any The questionnaire should be filled in at the beginning of 
any The questionnaire should be filled in at the beginning of extensions y if the EDV occurs within the first [ADDRESS_687898] 2
 impaired and except for all extensions  impaired and except for all 
The questionnaire should be filled in at the beginning of extensions The questionnaire should be filled in at the beginning of or  transition to another BRV studyor  transition to another BRV study  or or  or  transition to another BRV study  or  transition to another BRV studyor  transition to another BRV study  or  transition to another BRV study variations  transition to another BRV study variations  transition to another BRV study  or variations  or thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687899] 2015 / Page 49of 72
Healthcare provider c onsultation not foreseen by [CONTACT_529462] 2 years.
Laboratory  assessment including safety (hematology, blood chemistry , and urinaly sis), 
urine pregnancy  test (if applicable) .
Recording of Adverse Events.
Assessment of suicidality (C- SSRS).
Medical procedures.
Concomitant medications (AED and Non-AED) documentation.
Drug return/accountability including study medication i ntake and compliance check.
Completion of end of study status.
Retrieval of “Clinical Study  Subject Card”.
11.2.[ADDRESS_687900] an additional study visit/phone call if the Investigator or 
the subject deems it necessary . All information, including reason for visit/phone call, an y 
information on AEs, etc., should be collected in the source documents and recorded in the 
appropriate section of the CRF.  Study  medication can be dispensed if required.
11.[ADDRESS_687901] es
The safet y samples (hematology, biochemistry , urinaly sis, pregnancy  test) will be routinely  
assay ed and the results sent by [CONTACT_122290] 11.1.14.
11.4 Other Supplie s
Not applicable.
12 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS
12.1 Adverse Events
12.1.1 Definition of Adverse Event (AE)
An adverse event is an y untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product which does not necessaril y have a causal 
relationship with this treatment. An adverse event can therefore be an y unfavorable and 
unintended sign (including an abnormal laboratory finding), s ymptom, or disease temporally  
associated with the use of a medicinal (investigational) product, whether or not related to the 
medicinal (investigational) product.
In order to ensure complete safety data collection, all AEs or undesirable experiences 
occurring during the study (i.e., after signature [CONTACT_122330]), including an y pre -REDACTED , biochemistry
REDACTED , biochemistry
d and the results sent by [CONTACT_529463] d and the results sent by [CONTACT_529464], etc., should be collected in the source documents and recorded in the 
COPY information on AEs, etc., should be collected in the source documents and recorded in the 
 medication can be dispensed if required.
COPY  medication can be dispensed if required.
This document subject administered a pharmaceutical product which 
document subject administered a pharmaceutical product which 
relationship with this treatment. 
document relationship with this treatment. 
unintended sign (including an abnormal laboratory finding), s
document unintended sign (including an abnormal laboratory finding), scannot 12.1.1 Definition of Adverse Event (AE)
cannot 12.1.1 Definition of Adverse Event (AE)
An adverse event is ancannot An adverse event is an
subject administered a pharmaceutical product which cannot subject administered a pharmaceutical product which be 12.1.1 Definition of Adverse Event (AE) be 12.1.1 Definition of Adverse Event (AE)used Adverse Events
used Adverse Eventsto support ADVERSE EVENTS AND Ssupport ADVERSE EVENTS AND Sany marketing d and the results sent by [CONTACT_529465] I
marketing d and the results sent by [CONTACT_529466].
authorization  medication can be dispensed if required.
, biochemistryauthorization , biochemistry , urinalyauthorization , urinaly
d and the results sent by [CONTACT_529467] d and the results sent by [CONTACT_529468]/phone call if the 
application visit/phone call if the 
information, including reason for visit/phone call, an
application information, including reason for visit/phone call, an
information on AEs, etc., should be collected in the source documents and recorded in the 
application information on AEs, etc., should be collected in the source documents and recorded in the 
 medication can be dispensed if required. application  medication can be dispensed if required.and any extensions ntake and compliance check.
extensions ntake and compliance check.or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687902] 2015 / Page 50of [ADDRESS_687903] was taken but specific study procedures were conducted. These 
include all AEs not present prior to the initial visit and all AEs which recurred or wor sened 
after the initial visit.
Signs or s ymptoms of the condition/disease for which the investigational product is being 
studied should be recorded as AEs only if their nature changes considerably or their 
frequency  or intensit y increas es in a clinically significant manner as compared to the clinical 
profile known to the Investigator from the subject’s history  or the baseline period.
12.1.[ADDRESS_687904] adverse events, e.g.,
“Did y ou notice any thing unusual about your health (since your last visit)?”
In addition, the Investigator should review an y self-assessment procedures (e.g., diary  cards) 
employ ed in the study .
12.1.3 Description of AEs
The following guidelines and definitions should be used b y the Investigator for the 
description of an AE when reporting information:
Nature of the AE: Preferably  an overall diagnosis or s yndrome, rather 
than individual symptoms or signs. The Investigator
must report adverse events using standard medical 
terminology . The CRF and source documents should 
be consistent. Any discrepancies between the 
subject’s own words on his/her own records (e.g., 
diary  card) and the corresponding medical 
terminology  should be clarified in the source 
documentation.
Date of onset: Date the AE started.
Pattern:
Intermittent The AE recurs with the same intensity at various intervals throughout the entire time period specified. There were intervals within the specified time period when the AE was not present.
Continuous The AE is present at the same intensity for the entire time period specified. There was no time at which the event abated or was not present during the time period 
specified.REDACTED The following guidelines and definitions should be used b
REDACTED The following guidelines and definitions should be used b
description of an AE when reporting information: REDACTED description of an AE when reporting information:COPY our health (since y
COPY our health (since y
elfCOPY elf-COPY -elf-elfCOPY elf-elfassessment COPY assessment 
This document cannot Date of onset:
cannot Date of onset:
Pattern:
cannot Pattern:be Date of onset: be Date of onset:used to support any marketing The following guidelines and definitions should be used b
marketing The following guidelines and definitions should be used b
description of an AE when reporting information:
marketing description of an AE when reporting information:
Preferablymarketing Preferablyauthorization assessment 
authorization assessment 
The following guidelines and definitions should be used b authorization The following guidelines and definitions should be used bapplication A general prompt will also be given to detect adverse events, e.g.,
application A general prompt will also be given to detect adverse events, e.g.,
our health (since y
application our health (since y
assessment application assessment and  to report Adverse Events spontaneouslyand  to report Adverse Events spontaneouslyany extensions y significant manner as compared to the clinical 
extensions y significant manner as compared to the clinical 
 or the baseline period.
extensions  or the baseline period.or ptoms of the condition/disease for which the investigational product is being 
or ptoms of the condition/disease for which the investigational product is being variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687905] 2015 / Page 51of 72
Intensit y:
Mild The subject is aware of the sign or s ymptom 
(syndrome), but it does not interfere with his/her 
usual activities and/or it is of no clinical consequence.
Moderate The AE interferes with the usual activities of the 
subject or it is of some clinical consequence.
Severe The subject is unable to work normall y or to carry out 
his/her usual activities, or the AE is of definite 
clinical consequence.
Action taken with investigational product:
Not applicable For AEs occurring during the study  drug free period.
No change Investigational product dosing remained the same in 
spi[INVESTIGATOR_122212].
Dosage increased Investigational product dose was increased because of this AE.
Dosage decreased Investigational product dose was decreased because 
of this AE.
Temporarily discontinued Investigational product was temporaril y discontinued 
because of this AE, either because the subject chose to discontinue the study drug or the physician felt it was in the subject’s best interest to temporaril y 
discontinue the investigational product.
Permanently  discontinued Investigational product was permanently  discontinued 
because of this AE, either because the subject chose to discontinue the study drug or the physician felt it was in the subject’s best interest to discontinue the investigational product.
Other actions taken: If action taken other than study  drug, the appropriate 
sections should be completed: Medications, Medical procedures.
Outcome:
Resolved TheAE is no longer present at any  intensity  -
completely  abated.
Resolved with sequela The AE is resolved but residual effects are still 
present.
Ongoing The AE is still present at the last contact [CONTACT_1155]. If the AE is marked “ongoing”, the outc ome 
date should be blank.
Worsened The AE is still present but at a heightened intensity. The rule of repetition of AE reporting should be applied.REDACTED Investigational product was temporaril
REDACTED Investigational product was temporaril
because of this AE, either because the subject chose 
REDACTED because of this AE, either because the subject chose 
to discontinue the study
REDACTED to discontinue the study
was in th
REDACTED was in th
discontinue the investigational product.REDACTED discontinue the investigational product.COPY estigational product dose was decreased because 
COPY estigational product dose was decreased because 
Investigational product was temporarilCOPY Investigational product was temporaril
This document cannot Resolved with sequela
cannot Resolved with sequelabe Resolvedbe Resolvedused Resolvedused Resolvedto support any marketing was in th
marketing was in th
discontinue the investigational product.
marketing discontinue the investigational product.
Investigational product was permanently
marketing Investigational product was permanently
because of this AE, either because the subject chose marketing because of this AE, either because the subject chose authorization estigational product dose was decreased because 
authorization estigational product dose was decreased because 
Investigational product was temporaril
authorization Investigational product was temporaril
because of this AE, either because the subject chose 
authorization because of this AE, either because the subject chose 
to discontinue the study
authorization to discontinue the study
was in th authorization was in th e subject’s best interest to temporarilauthorization e subject’s best interest to temporarilapplication spi[INVESTIGATOR_122212].
application spi[INVESTIGATOR_122212].
Investigational product dose was increased because of 
application Investigational product dose was increased because of 
estigational product dose was decreased because application estigational product dose was decreased because and study
and study  drug free period.
and  drug free period. study  drug free period. study
and study  drug free period. study
Investigational product dosing remained the same in and Investigational product dosing remained the same in any  drug free period.any  drug free period.extensions y or to carry out 
extensions y or to carry out 
his/her usual activities, or the AE is of definite 
extensions his/her usual activities, or the AE is of definite or variations usual activities and/or it is of no clinical consequence.
variations usual activities and/or it is of no clinical consequence.thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687906] 2015 / Page 52of [ADDRESS_687907]’s death.
Date of outcome: Date the AE abat ed.  If the AE consists of several 
signs and s ymptoms (sy ndromes), the sign or 
symptom with the longest duration determines the 
duration of the AE.  If the AE is marked “ongoing”, the outcome date should be blank.
Relationship to study  drug:
None Only  applicable when no investigational product was 
taken or when the subject is taking single- blind 
placebo, or when the AE can be ascribed with reasonable certainty  to another cause (e.g., a gun shot 
wound).
Unlikely There are good reasons to think that there is no 
relationship (e.g., the AE is a known adverse drug reaction of a concomitant medication).
Possible Equally  valid arguments can be considered for or 
against an implication of the investigational product, For example, the AE:
follows a reasonable temporal sequence from the 
administration of the investigational product.
follows a known or expected response pattern to 
the investigational product.
but could readil y have been produced b y a number 
of other factors.
Probable The relationship is likely .For example, the AE:
follows a reasonable temporal sequence from administration of the investigational product.
follows a known or expected response pattern to 
the investigational product.
is confirmed b y improvement on stoppi[INVESTIGATOR_529400].
could not be reasonably explained by  [CONTACT_93735]’s clinical state.REDACTED Equally
REDACTED Equally  valid arguments can be considered for or 
REDACTED  valid arguments can be considered for or Equally  valid arguments can be considered for or Equally
REDACTED Equally  valid arguments can be considered for or Equally
against an implication of the investigational product, 
REDACTED against an implication of the investigational product, 
For example, the AE:
REDACTED For example, the AE:
REDACTED COPY There are good reasons to think that there
COPY There are good reasons to think that there
relationship (e.g., the AE is a known adverse drug 
COPY relationship (e.g., the AE is a known adverse drug 
reaction of a concomitant medication).COPY reaction of a concomitant medication).
This document cannot be used to support any marketing For example, the AE:
marketing For example, the AE:
follows a reasonable te
marketing follows a reasonable te
administration of the investigational product
marketing administration of the investigational product
marketing authorization reaction of a concomitant medication).
authorization reaction of a concomitant medication).
 valid arguments can be considered for or 
authorization  valid arguments can be considered for or 
against an implication of the investigational product, 
authorization against an implication of the investigational product, 
For example, the AE: authorization For example, the AE:application There are good reasons to think that there
application There are good reasons to think that there
relationship (e.g., the AE is a known adverse drug application relationship (e.g., the AE is a known adverse drug 
reaction of a concomitant medication).application reaction of a concomitant medication).and placebo, or when the AE can be ascribed with 
and placebo, or when the AE can be ascribed with 
 to another cause (e.g., a gun shot and  to another cause (e.g., a gun shot any taken or when the subject is taking single-
any taken or when the subject is taking single-
placebo, or when the AE can be ascribed with any placebo, or when the AE can be ascribed with extensions duration of the AE.  If the AE is marked “ongoing”, 
extensions duration of the AE.  If the AE is marked “ongoing”, 
plicable when no investigational product was extensions plicable when no investigational product was 
taken or when the subject is taking single- extensions taken or when the subject is taking single-or duration of the AE.  If the AE is marked “ongoing”, or duration of the AE.  If the AE is marked “ongoing”, variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687908] 2015 / Page 53of 72
Highly probable There is a strong relationship. For example, the AE:
follows a reasonable temporal sequence from 
administration of the investigational product.
follows a known or expected response pattern to 
the investigational product.
is confirmed b y improvement on stoppi[INVESTIGATOR_22019], 
and reappearance on repeated exposure (re-challenge ).
12.1.[ADDRESS_687909] of 
supplementary  measurements and/or evaluations (e.g., re-challenge procedure).
A serious AE or an AE leading to premature discontinuation from the study must alway s be 
followed up until it has r esolved or the Investigator no longer feels it is clinically significant.
12.1.5 Rule for Repetition of an AE
An unexpected increase in the intensity of an AE should lead to the repetition of the AE 
reporting with:
the outcome date of the first AE that is not related to the natural course of the disease 
being the same as the start date of the repeated AE.
the Investigator ’s original description of the AE being the same for the first and repeated 
AE.
12.1.[ADDRESS_687910] should be excluded from the study as soon as 
pregnancy  is known (immediate start of down- titration of investigational product intake).
The pregnancy  will be documented in the AE section of the CRF. The Investigator must 
inform the subject about the potential risk of malformations that may  be caused by  [CONTACT_529469], 
and about the available alternatives, eg, voluntary  termination with medical indication.  The 
progression of the pregnancy must be followed up using the standard Sponsor Pregnancy  
form. The Investigator has to report on the health of the mother and of the offspring.REDACTED perform or arrange for the conduct of 
REDACTED perform or arrange for the conduct of 
 measurements and/or evaluations (e.g., re-
REDACTED  measurements and/or evaluations (e.g., re-
A serious AE or an AE leading to premature discontinuation from the study must alway
REDACTED A serious AE or an AE leading to premature discontinuation from the study must alway
esolved or the 
REDACTED esolved or the Investigator
REDACTED InvestigatorCOPY perform or arrange for the conduct of COPY perform or arrange for the conduct of 
 measurements and/or evaluations (e.g., re-COPY  measurements and/or evaluations (e.g., re-
This document should be informed immediatel
document should be informed immediatel
pregnancy
document pregnancycannot 12.1.[ADDRESS_687911] become pregnant durin
should be informed immediatelcannot should be informed immediatelbe 12.1.6 Pregnancybe 12.1.6 Pregnancyused vestigator
used vestigatorto vestigatorto vestigator ’s original description of the AE being the same for the first and repeated to ’s original description of the AE being the same for the first and repeated support the outcome date of the first AE that is not r
support the outcome date of the first AE that is not r
being the same as the start date of the repeated AE.support being the same as the start date of the repeated AE.
’s original description of the AE being the same for the first and repeated support ’s original description of the AE being the same for the first and repeated any An unexpected increase in the intensity
any An unexpected increase in the intensitymarketing Investigator
marketing Investigator
Rule for Repetition of an AE
marketing Rule for Repetition of an AE
An unexpected increase in the intensitymarketing An unexpected increase in the intensityauthorization perform or arrange for the conduct of 
authorization perform or arrange for the conduct of 
 measurements and/or evaluations (e.g., re-
authorization  measurements and/or evaluations (e.g., re-
A serious AE or an AE leading to premature discontinuation from the study must alway
authorization A serious AE or an AE leading to premature discontinuation from the study must alway
Investigatorauthorization Investigatorapplication If an AE is still ongoing at the time the CRF is collected, a follow
application If an AE is still ongoing at the time the CRF is collected, a follow -up report should be 
application -up report should be 
up report is provided, the 
application up report is provided, the Investigator
application Investigator
perform or arrange for the conduct of application perform or arrange for the conduct of and -up report should be and -up report should be any extensions y improvement on stoppi[INVESTIGATOR_529401] y improvement on stoppi[INVESTIGATOR_22019], 
extensions reducing the dosage of the investigational product, 
and reappearance on repeated exposure (re-
extensions and reappearance on repeated exposure (re-or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687912] 2015 / Page 54of [ADDRESS_687913]’s partner for completion.
12.1.[ADDRESS_687914]
For this protocol, any daily intake of more than 200 mg/day will be considered as an 
overdose. Symptoms associated with an overdose must be recorded as AEs. Overdose 
without signs or symptoms will be documented in the “Study  Medication Intake” section of 
the CRF.
12.2 Serious Adverse Events
12.2.1 Definition of Serious Adverse Event (SAE)
A Serious Adverse Event is any untoward medical occurrence that occurs at any  dose :
results in death.
is life threatenin g, (an immediate risk of death).
requires in-patient hospi[INVESTIGATOR_1081].
results in persistent or significant disability /incapacity  (any  severe or long- lasting inability  
to carry  out normal work or normal activitie s).
or
is a congenital anomal y/birth defect (in a child of a subject/patient who took the 
investigational product, especially  of a mother who was pregnant during the study ).
In this context, the term life threatening refers to an event in which the subject was at 
immediate risk of death at the time of the event; it does NOT refer to an event which might have caused death if it would have been more severe.
Any important medical event that may not be immediately  life threatening or result in dea th 
or hospi[INVESTIGATOR_313], based upon appropriate medical judgment, may  jeopardize the subject 
or may  require medical or surgical intervention to prevent 1 of the other outcomes listed in 
the definition above should also be reported as a SAE. Examples of such events are intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; or development of drug dependency or drug abuse.
Any event reported by  [CONTACT_529470] a “Serious Adverse Event”.REDACTED  untoward medical occurrence that occurs at any
REDACTED  untoward medical occurrence that occurs at any
g, (an immediate risk of death).
REDACTED g, (an immediate risk of death).
patient hospi[INVESTIGATOR_529402] 12.2.1 Definition of Serious Adverse Event (SAE)
COPY 12.2.1 Definition of Serious Adverse Event (SAE)
 untoward medical occurrence that occurs at anyCOPY  untoward medical occurrence that occurs at any
This document the definition above should also be reported as a SAE. 
document the definition above should also be reported as a SAE. 
treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
document treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; or development of drug dependency
document convulsions that do not result in hospi[INVESTIGATOR_059]; or development of drug dependencycannot  important medical event that may
cannot  important medical event that may
or hospi[INVESTIGATOR_313], based upon appropriate medical 
cannot or hospi[INVESTIGATOR_313], based upon appropriate medical 
or may
cannot or may  require medical or surgical intervention to prevent 
cannot  require medical or surgical intervention to prevent or may  require medical or surgical intervention to prevent or may
cannot or may  require medical or surgical intervention to prevent or may
the definition above should also be reported as a SAE. cannot the definition above should also be reported as a SAE. be  important medical event that maybe  important medical event that mayused immediate risk of death at the time of the event; it does NOT refer to an event which might 
used immediate risk of death at the time of the event; it does NOT refer to an event which might 
have caused death if it would have been more severe.
used have caused death if it would have been more severe.to immediate risk of death at the time of the event; it does NOT refer to an event which might to immediate risk of death at the time of the event; it does NOT refer to an event which might 
have caused death if it would have been more severe.to have caused death if it would have been more severe.support investigational product, especially
support investigational product, especially
In this context, the term life threatening refers to an event in whicsupport In this context, the term life threatening refers to an event in whic
immediate risk of death at the time of the event; it does NOT refer to an event which might support immediate risk of death at the time of the event; it does NOT refer to an event which might any birth defect (in a child of a subject/patient who took the 
any birth defect (in a child of a subject/patient who took the 
investigational product, especially any investigational product, especiallymarketing patient hospi[INVESTIGATOR_529403] (in a child of a subject/patient who took the marketing birth defect (in a child of a subject/patient who took the authorization  untoward medical occurrence that occurs at any
authorization  untoward medical occurrence that occurs at any
g, (an immediate risk of death).
authorization g, (an immediate risk of death).
patient hospi[INVESTIGATOR_529404]” section of 
and  Medication Intake” section of any ptoms associated with an overdose must be recorded as AEs.
any ptoms associated with an overdose must be recorded as AEs. Overdose 
any Overdose 
 Medication Intake” section of any  Medication Intake” section of extensions  will be considered as an extensions  will be considered as an 
Overdose extensions Overdose or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687915] 2015 / Page 55of 72
Cases involving cancer as an Adverse Event could be reported as serious using the criterion 
“medicall y important”.
Hospi[INVESTIGATOR_529405] a SAE, except when otherwise required by [CONTACT_18332]. This also applies to situation of scheduled elective surgery where no 
AE is present.  Non -complicated, preplanned elective surgery  will not be considered an AE or 
SAE even if it involves hospi[INVESTIGATOR_059]. However, if a hospi[INVESTIGATOR_122221] a result of an adverse event, this will be considered an SAE.
12.2.2 Procedures for Reporting Serious Adverse E vents (SAE)
The Sponsor (or its representatives) must be informed about an SAE within 24 hours of the 
site knowing about the event (see contact [CONTACT_529471] 2).  The 
Investigator must prom ptly forward to the Sponsor (or its representatives) a duly  completed 
“Investigator SAE report form” provided by  [CONTACT_1034], even if the data are incomplete or if 
it is obvious that more data will be needed to make an y conclusions.
Additional information (e.g., autops y or lab reports…) should be provided to the sponsor in a 
timely  fashion to ensure accurate follow-up of each case. All documents in the local 
language must be accompanied by a translation in English, or the relevant information included in the same document must be summarized in the SAE report form.
The Sponsor (or its representatives) will communicate safety information to the appropriate 
agency (ies) and all active I nvestigators, in accordance with applicable regulatory 
requirements. The appropriate IRB/IEC will also be informed b y the Investigator or the 
Sponsor, as specified b y the applicable regulatory  requirements in each concerned country. 
Investigators are to provide the Sponsor or its representatives with evidence of such IEC/IRB notification.
A cop y of the Investigator SAE report form and completion guide will be provided to the 
Investigator. The SAE report form has to be completed in English.If known b y the Investigator, Serious Adverse Events up to [ADDRESS_687916] be reported to the Sponsor regardless of the time 
between the event and the end of the stud y.
The reference document for the assessment of the expectedness of the SAEs is the Investigator ’s Brochure (IB ).REDACTED y or lab reports…) should be provided to 
REDACTED y or lab reports…) should be provided to 
up of each case.
REDACTED up of each case.
y a translation in English, or the relevant information 
REDACTED y a translation in English, or the relevant information 
REDACTED the same document must be summarized in the SAE report form.
REDACTED the same document must be summarized in the SAE report form.COPY ponsor
COPY ponsor
it is obvious that more data will be needed to make an
COPY it is obvious that more data will be needed to make an y conclusions.
COPY y conclusions.
y or lab reports…) should be provided to COPY y or lab reports…) should be provided to 
This document no way
document no way
document associated with the stud
document associated with the stud
between the event and the end of the stud
document between the event and the end of the studcannot If known b
cannot If known b y the 
cannot y the 
medication must be reported to the Sponsor, even if the 
cannot medication must be reported to the Sponsor, even if the 
no waycannot no way  associated with the studycannot  associated with the studybe y the be y the used Investigator
used Investigator
. The SAE report form has to be completed in English.used . The SAE report form has to be completed in English.to Investigatorto Investigatorsupport the applicable regulatory
support the applicable regulatory
Investigators are to provide the Sponsor or its representatives with evidence of such IEC/IRB 
support Investigators are to provide the Sponsor or its representatives with evidence of such IEC/IRB any appropriate IRB/IEC will also be informed b
any appropriate IRB/IEC will also be informed b
the applicable regulatoryany the applicable regulatorymarketing the same document must be summarized in the SAE report form.
marketing the same document must be summarized in the SAE report form.
(or its representatives) will communicate safet
marketing (or its representatives) will communicate safet
nvestigators, in accordance with applicable regulatorymarketing nvestigators, in accordance with applicable regulatory
appropriate IRB/IEC will also be informed b marketing appropriate IRB/IEC will also be informed bauthorization y or lab reports…) should be provided to 
authorization y or lab reports…) should be provided to 
up of each case.
authorization up of each case.
y a translation in English, or the relevant information 
authorization y a translation in English, or the relevant information 
the same document must be summarized in the SAE report form. authorization the same document must be summarized in the SAE report form.application SAEs listed in 
application SAEs listed in S
application Section 
application ection 
(or its representatives) a duly
application (or its representatives) a duly
, even if the data are incomplete or if 
application , even if the data are incomplete or if 
y conclusions.application y conclusions.and (or its representatives) must be informed about an SAE within 24 hours of the and (or its representatives) must be informed about an SAE within 24 hours of the 
ection and ection any extensions  will not be considered an AE or 
extensions  will not be considered an AE or 
However, if a hospi[INVESTIGATOR_122221] a 
extensions However, if a hospi[INVESTIGATOR_122221] a or  where no 
or  where no 
 will not be considered an AE or or  will not be considered an AE or variations  where no variations  where no thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687917] 2015 / Page 56of [ADDRESS_687918] of Anticipated SAEs has been identified as these events are anticipated to 
occur in the population studied in this protocol at some frequency that is independent of drug exposure: convulsion.  This original list will remain in effect for the duration of the protocol.
The list does not change the investigator’s obligation to report allserious AEs (including 
Anticipated SAEs) as detailed in Section 12.2.2.
13 STATISTICS
A general description of statistical methods is presented below.  Additio nal details will be 
described in the Statistical Anal ysis Plan (SAP).
13.1 Statistical and Analytical Plans
13.1.1 Study Population(s)
 Subpopulations
There are 2 mutuall y exclusive subpopulations.  They are defined based upon enrollment.
1. Partial onset seizure: Subjects enrolled from prior studies N01193, N01252, N01253, 
and subjects from N01254 with a diagnosis of POS at N01254 study  entry
2.Primary generalized seizure: Subjects enrolled from prior study  N01254 with a 
diagnosis of PGS at N01254 study  entry
The Effi cacy Population will consist of all subjects who took at least [ADDRESS_687919] 1 dose of study  
medication.
13.1.2 Efficacy and Safety Variables
Primary  safet y variables :
Occurrence of a TEAE
Withdrawal due to an AE
Occurrence of an SAEREDACTED y exclusive subpopulations.  They
REDACTED y exclusive subpopulations.  They
Partial onset seizure: Subjects enrolled from prior studies REDACTED Partial onset seizure: Subjects enrolled from prior studies COPY 
This Primary
document Primary
document Primary
document Primary
document cannot 13.1.[ADDRESS_687920] 1any diagnosis of PGS at N01254 study
any diagnosis of PGS at N01254 study marketing Partial onset seizure: Subjects enrolled from prior studies 
marketing Partial onset seizure: Subjects enrolled from prior studies 
and subjects from N01254 with a diagnosis of POS at N01254 study
marketing and subjects from N01254 with a diagnosis of POS at N01254 study
 generalized seizure: Subjects enrolled from prior studymarketing  generalized seizure: Subjects enrolled from prior study
diagnosis of PGS at N01254 study marketing diagnosis of PGS at N01254 studyauthorization y exclusive subpopulations.  They
authorization y exclusive subpopulations.  Theyapplication and A general description of statistical methods is presented below.  Additio
and A general description of statistical methods is presented below.  Additio nal detail
and nal detailany nal detailany nal detailextensions serious AEs (including 
extensions serious AEs (including or serious AEs (including or serious AEs (including variations exposure: convulsion.  This original list will remain in effect for the duration of the protocol.
variations exposure: convulsion.  This original list will remain in effect for the duration of the protocol.thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687921] 2015 / Page 57of 72
Other safety  variables:
Laboratory  tests (hematology , blood chemistry , urinaly sis)
Vital signs (s ystolic blood pressure [SBP]), diastolic blood pressure [DBP], pulse rate) 
and body weight
Electrocardiogram (ECG)
Physical and neurological examinations
Change in Hospi[INVESTIGATOR_5620] (HADS) scores from the Baseline 
of the previous study to each assessment for the first [ADDRESS_687922] 2 years
Secondary  efficacy  variables:
POS (ty pe I) frequency  per 28 day s during the Evaluation Period
Percent reduction in POS (ty pe I)frequency  per 28 day s from Baseline of the previous 
study to the Evaluation Period
Responder rate for POS (ty pe I) frequency  over the Evaluation Period. A responder is
defined as a subject with a ≥50% reduction in seizure frequency  from the Baseline 
Period of the previous study
Other efficacy  variables:
For subjects with focal- onset epi[INVESTIGATOR_002] :
Percentage of subjects continuously  seizure -free for all seizure types (I+II+II I) for at 
least [ADDRESS_687923] 12 months during the Evaluation Period
For subjects with generalized epi[INVESTIGATOR_002]:
Generalized (type II) seizure day s per 28 day s during the Evaluation Period
Percent reduction in generalized (ty pe II) seizure day s per 28 day s from Baseline of the 
previous study to the Evaluation Period
Responder rate for generalized (ty pe II) seizure days over the Evaluation Period. A 
responder is defined as a subject with a ≥50% reduction in seizure day s from the 
Baseline Period of the previous studyREDACTED I)frequency
REDACTED I)frequency  per 28 day
REDACTED  per 28 day I)frequency  per 28 day I)frequency
REDACTED I)frequency  per 28 day I)frequency
pe I) frequency
REDACTED pe I) frequency
≥50% reduction in seizure frequencyREDACTED ≥50% reduction in seizure frequencyCOPY s during the Evaluation Period
COPY s during the Evaluation Period
This document cannot Generalized (ty
cannot Generalized (ty
cannot Percent reduction in generalized (tycannot Percent reduction in generalized (tybe For subjects with generalized epi[INVESTIGATOR_529406] [ADDRESS_687924] 12 months during the Evaluation Periodany onset epi[INVESTIGATOR_529407] I) frequency
marketing pe I) frequency
≥50% reduction in seizure frequency
marketing ≥50% reduction in seizure frequencyauthorization s during the Evaluation Period
authorization s during the Evaluation Period
 per 28 day
authorization  per 28 day
pe I) frequency authorization pe I) frequencyapplication s during the Evaluation Period application s during the Evaluation Periodand s and to the last Evaluation 
and s and to the last Evaluation any  and Depression Scale (HADS) scores from the Baseline any  and Depression Scale (HADS) scores from the Baseline 
s and to the last Evaluation any s and to the last Evaluation extensions or variations c blood pressure [DBP], pulse rate) 
variations c blood pressure [DBP], pulse rate) thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687925] 2015 / Page 58of 72
Percentage of subjects continuously  seizure -free for all seizure ty pes (I+II+III) for at 
least [ADDRESS_687926] 12 months during the Evaluation Period
The following will be evaluated separatel y for subjects with focal -onset epi[INVESTIGATOR_529347] y:
Change in Patient Weighted Quality  of Life in Epi[INVESTIGATOR_122146] (QOLIE-31- P)
scores from Baseline of the previ ous study  to each assessment for the first [ADDRESS_687927] 2 years
EuroQol 5 Dimensions (EQ-5D) questionnaire response for each assessment for the first 
2years for the Evaluation Period and for the las t assessment during the first 2 y ears of 
theEvaluation Period
Pharmacoeconomic variables
The following will be evaluated separatel y for subjects with focal -onset epi[INVESTIGATOR_529347] y:
Direct costs (healthcare provider consultations not foreseen b y the protocol, concurrent 
medical procedures, concomitant medications, hospi[INVESTIGATOR_602], and emergency  room 
[ER] visits) during the first 2 y ears of the Evaluation Period
Indirect costs (work day s or school days lost by  [CONTACT_122252] s subject received 
help from a caregiver) during the first 2 years of the Evaluation Period
Socio -professional data for each assessment for the first [ADDRESS_687928] 2 years of the Evaluation Period
13.1.3 Statistical Evalu ation
General considerations:
Summary  statistics will consist of frequency  tables for categorical variables and descriptive 
statistics (number of available observations, mean, median, standard deviation, minimum, 
maximum, 25thand 75thpercentiles) for c ontinuous variables.
The periods considered are: 
Evaluation Period (V1 until the last Evaluation Visit)
Down -Titration Period
Post-Treatment Period
Efficacy  summaries will be created separately  for the POS and PGS subpopulations within 
the efficacy  population, and safety summaries will be created for the safet y population.REDACTED Direct costs (healthcare provider consultations not foreseen b
REDACTED Direct costs (healthcare provider consultations not foreseen b
medical procedures, concomitant medications, hospi[INVESTIGATOR_602], and emergency
REDACTED medical procedures, concomitant medications, hospi[INVESTIGATOR_602], and emergency
ears of the Evaluation Period
REDACTED ears of the Evaluation Period
s or school day
REDACTED s or school day
help from a caregiver) during the first 2 y REDACTED help from a caregiver) during the first [ADDRESS_687929] costs (healthcare provider consultations not foreseen b COPY Direct costs (healthcare provider consultations not foreseen b
This document 
document cannot maximum, 25
cannot maximum, 25
The periods considered are: cannot The periods considered are: be statistics (number of available observations, mean, median, standard deviation, minimum, 
be statistics (number of available observations, mean, median, standard deviation, minimum, 
maximum, [ADDRESS_687930] of frequency
statistics (number of available observations, mean, median, standard deviation, minimum, used statistics (number of available observations, mean, median, standard deviation, minimum, to General considerations:
to General considerations: support ation
support ation
General considerations: support General considerations:any assessment during the first [ADDRESS_687931] 2 y marketing s or school day
marketing s or school day
help from a caregiver) during the first 2 y
marketing help from a caregiver) during the first [ADDRESS_687932] costs (healthcare provider consultations not foreseen b
authorization Direct costs (healthcare provider consultations not foreseen b
medical procedures, concomitant medications, hospi[INVESTIGATOR_602], and emergency
authorization medical procedures, concomitant medications, hospi[INVESTIGATOR_602], and emergency
ears of the Evaluation Period
authorization ears of the Evaluation Period
s or school day authorization s or school day s lost by[CONTACT_214728] s lost by[CONTACT_529472] y for subjects with focal
application y for subjects with focaland t assessment during the first [ADDRESS_687933] 2 yany 5D) questionnaire response for each assessment for the first 
any 5D) questionnaire response for each assessment for the first 
t assessment during the first [ADDRESS_687934] 2 yextensions  Questionnaire (QOLIE-31
extensions  Questionnaire (QOLIE-[ADDRESS_687935] 2 y ears and 
extensions ears and 
5D) questionnaire response for each assessment for the first extensions 5D) questionnaire response for each assessment for the first or -or -P)or P)variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687936] 2015 / Page 59of 72
Baseline:
Baseline, whether efficacy  or safet y, will always refer to the original prior study pretreatment 
Baseline value.  Baselines created and validated, as part of the prior st udy SAPs, will be 
copi[INVESTIGATOR_529408] b y this study  for all changes from baseline anal yses.
Study  entry /disposition:
Subjects will be sufficiently  described to enable a clear understanding of the populations and 
subpopulations and relevant demographics, dise ase, medical history , current treatment(s), as 
well as disposition.  Historical and Baseline data will be copi[INVESTIGATOR_529409] b y the SAP.
Seizure efficacy variables:
Analy ses will be based upon the Efficacy  Population.  Summaries will be over the entire 
Evaluation Period and b y 3-month periods over the Evaluation Period.
QOLIE-31-P, HADS, EQ -5D, and socio- professional efficacy  variables:
Analy ses will be based upon the Efficacy Population and summarized by  [CONTACT_529473] 2 years. Data 
collected after Year 2 are not planned to be summarized.
Medical resource and indirect cost efficacy variables:
Analy ses will be based upon the Efficacy  Population and sum marized by  3-month periods.  
Data collected after Year 2 are not planned to be summarized.Safety variables:
Analy ses will be based upon the Safety Population.  Summary tables will be presented over 
the Evaluation Period b y time windows, by  [CONTACT_32795], and by  [CONTACT_529474].
Treatment -emergent AEs will be summarized by  [CONTACT_529475], 
period, and Medical Dictionary  for Regulatory Activities (MedDRA
®) Primary  System Organ 
Class (SOC), and Preferred Term in incidence tables.  Separate tables will be provided b y 
categories of total duration of exposure, for AEs leading to withdrawal from the study , and 
for SAEs.REDACTED -month periods over the Evaluation Period.
REDACTED -month periods over the Evaluation Period.
5D, and socio
REDACTED 5D, and socio -
REDACTED -professional efficacy
REDACTED professional efficacy
ses will be based upon the EfficacyREDACTED ses will be based upon the Efficacy  Population and summarized by[CONTACT_529476] [ADDRESS_687937] 2COPY  Population.  Summaries will
COPY  Population.  Summaries will
-month periods over the Evaluation Period.COPY -month periods over the Evaluation Period.
This document Treatment
document Treatment
period, and Medical Dictionary
document period, and Medical Dictionarycannot ses will be based upon the Safet
cannot ses will be based upon the Safet
the Evaluation Period b
cannot the Evaluation Period b
exposure.cannot exposure.be ses will be based upon the Safetbe ses will be based upon the Safetused Safety variables:
used Safety variables:to support ses will be based upon the Efficacy
support ses will be based upon the Efficacy
Data collected after Yearsupport Data collected after Year [ADDRESS_687938] efficacyauthorization  Population.  Summaries will
authorization  Population.  Summaries will
-month periods over the Evaluation Period.
authorization -month periods over the Evaluation Period.
professional efficacy
authorization professional efficacy
 Population and summarized by[CONTACT_529477].  Summaries willapplication  Population.  Summaries will
-month periods over the Evaluation Period.application -month periods over the Evaluation Period.and well as disposition.  Historical and Baseline data will be copi[INVESTIGATOR_529410].  Historical and Baseline data will be copi[INVESTIGATOR_529411] , current treatment(s), as 
any , current treatment(s), as 
well as disposition.  Historical and Baseline data will be copi[INVESTIGATOR_529412].  Historical and Baseline data will be copi[INVESTIGATOR_529413] a clear understanding of the populations and extensions  described to enable a clear understanding of the populations and 
, current treatment(s), as extensions , current treatment(s), as or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687939] 2015 / Page 60of 72
Laboratory  values, vital signs, and weight will be summarized by  [CONTACT_319790].  Possibly  
clinically  significant treatment -emergent abnormalities for laboratory values, vital signs, and 
weight will be listed and summarized by [CONTACT_319790].  Electrocardiogram abnormalities, 
as well as ph ysical and neurological abnormalities, will also be listed b y period and visit.
Hospi[INVESTIGATOR_529414].
13.2 Determination of the Sample Size
No sample size calculation has been made . Sample size will depend upon recruitment into 
and completion of preceding studies; approximately 500 - 1000 subjects are expected.
13.3 Statistical and Analytical Issues
13.3.1 Handling of Dropouts of Missing Data
Safety  and efficacy  variables will be anal yzed as they  are available. Days with missing 
information will be ignored in the calculation of the seizure frequency  and seizure days.   
Since subjects will drop out at different times from the study, results will be presented b y 
categories of duration of exposure.
13.3.2 Interim Analysis and Data Monitoring
Due to the single -arm ope n-label nature of this study, no interim analy sis as such will be 
performed. However, interim database snapshots may  beperformed to allow safet y and 
efficacy  anal yses in support of submission activities or to allow optimization of the 
development program. In addition, an ongoing medical review (Safet y Data Review) 
apply ing to the entire BRV program is organized.
13.3.[ADDRESS_687940] data according to similar BRV exposure times.
13.3.4cannot 13.3.4be ded into 2
be ded into 2
Additionally be Additionally , as needed, the POS and the PGS subjects maybe , as needed, the POS and the PGS subjects mayused  population will be a subset of the safety
used  population will be a subset of the safety
ded into 2used ded into 2to 13.3.3 Use of an Efficacy Subset of Subjects
to 13.3.3 Use of an Efficacy Subset of Subjectssupport ing to the entire BRV program is organized.
support ing to the entire BRV program is organized.
13.3.3 Use of an Efficacy Subset of Subjectssupport 13.3.3 Use of an Efficacy Subset of Subjectsany es in support of submission activities or to allow optimization of the 
any es in support of submission activities or to allow optimization of the 
In addition, an ongoing medical review (Safetany In addition, an ongoing medical review (Safet
ing to the entire BRV program is organized. any ing to the entire BRV program is organized.marketing label nature of this study
marketing label nature of this study
database 
marketing database snapshots may
marketing snapshots may
es in support of submission activities or to allow optimization of the marketing es in support of submission activities or to allow optimization of the 
In addition, an ongoing medical review (Safetmarketing In addition, an ongoing medical review (Safetauthorization in the calculation of the seizure 
authorization in the calculation of the seizure 
Since subjects will drop out at different times from the study
authorization Since subjects will drop out at different times from the study
and Data Monitoringauthorization and Data Monitoringapplication  are available. 
application  are available. 
in the calculation of the seizure application in the calculation of the seizure frequencyapplication frequencyand any 1000 subjects are expected.
any 1000 subjects are expected.extensions ample size will depend upon recruitment into 
extensions ample size will depend upon recruitment into 
1000 subjects are expected.extensions 1000 subjects are expected.or  and depression scales will be analyzed for the POS and PGS subpopulations.
or  and depression scales will be analyzed for the POS and PGS subpopulations. variations  and depression scales will be analyzed for the POS and PGS subpopulations. variations  and depression scales will be analyzed for the POS and PGS subpopulations.thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687941] 2015 / Page 61of [ADDRESS_687942] be signed by [CONTACT_079] [INVESTIGATOR_529415], the Sponsor Study Physician, the Sponsor Clinical Lead , the Sponsor Clinical Trial 
Manager (CTM) and the Sponsor Statistician .
The final protocol must be submitted to and approved by:
a duly constituted I ndependent Ethics Committee (IEC ) or Institutional Review Board 
(IRB).
the relevant Regulatory  Authorities, according to local regulations.
If any alterations to the protocol are required by [CONTACT_529478], they can be implemented only  
with the written agreement of the Investigator , the Study  Physician, the Clinical Lead , the 
Statistician, and C TM, and thesponsors’ approvers before further submission to the 
requesting bod y.
A copy of the IEC/IRB’s written approval with clear identification of the submitted 
document(s) and a list of members attending the meeting (listed by [CONTACT_122306] ) 
should be forwarded b y the Investigator to the CTM. 
The usual composition of the IRB/IEC (or DHHS number) along with an IRB/IEC Statement 
of Compliance should also be forwarded to the CTM.
Before submission to an IRB/IEC, the consent form and an y other written information to be 
provided to subjects (e.g., advertisement) must be submitted for internal Sponsor approval. 
The study  is not allowed to start until the protocol and related documents (informed consent, 
advertisement, etc.) have received written approval from the IEC/I RB and Regulatory  
Authorities, if applicable, as well as until other GCP prerequisites are fulfilled. If new 
information becomes available, it should be communicated without delay to the subject, the Investigator , the IEC/IRB, and regulatory  authorities, wherever required.REDACTED ndependent Ethics Committee (IEC
REDACTED ndependent Ethics Committee (IEC
 Authorities, according to local regulations.
REDACTED  Authorities, according to local regulations.
terations to the protocol are required by [CONTACT_529479] (IECCOPY ndependent Ethics Committee (IEC
This document provided to subjects (e.g., ad
document provided to subjects (e.g., ad
document The study
document The study
advertisement, etc.) have received written approval from the IEC/I
document advertisement, etc.) have received written approval from the IEC/Icannot Before submission to an IRB/IEC, the consent form and an
cannot Before submission to an IRB/IEC, the consent form and an
provided to subjects (e.g., adcannot provided to subjects (e.g., adbe Compliance should also be forwarded to the CTM.be Compliance should also be forwarded to the CTM.used e usual composition of the Iused e usual composition of the I
Compliance should also be forwarded to the CTM.used Compliance should also be forwarded to the CTM.to should be forwarded bto should be forwarded b y tto y tsupport y of the IEC/IRB’s written approval 
support y of the IEC/IRB’s written approval 
document(s) and a list of members attending the meeting (listed by[CONTACT_529480](s) and a list of members attending the meeting (listed by
[CONTACT_529481] b support should be forwarded b y tsupport y the support he any marketing terations to the protocol are required by
[CONTACT_529482]’ approversmarketing sponsors’ approversauthorization The final protocol must be submitted to and approved by
[CONTACT_529483] :
authorization :
ndependent Ethics Committee (IEC
authorization ndependent Ethics Committee (IEC
 Authorities, according to local regulations.
authorization  Authorities, according to local regulations.application  the Principal 
application  the Principal 
the 
application the Sponsor 
application Sponsor and  the Principal and  the Principal any extensions or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687943] 2015 / Page 62of 72
The IEC/I RB must be notified promptly  by [CONTACT_737] (or Sponsor, if applicable) in 
writing of the following:
Deviations from, or changes to the protocol to eliminate immediate hazards to all the 
study  subjects.
Significant changes to the conduct of the stud y.Significant changes to the protocol can 
only be affected b y a formal protocol amendment that must be submitted to the IEC/I RB 
and approved prior to implementation at the site.
New information that may adversel y affect subject safety or the conduct of the stu dy.
The Investigator (or Sponsor, if applicable) should comply  with the applicable regulatory  
requirements related to the reporting of safety information to the I EC/IRB and Regulatory  
Authorities.
14.[ADDRESS_687944] Information and Consent
The original Informed Consent form can be amended as appropriate.  If the Informed Consent 
form is amended during the study, the Investigator (or the Sponsor, if applicable) must follow all applicable regulatory  requirements pertaining to the approval of the amended Informed 
Consent form by [CONTACT_1201]/IEC and use of the amended form.
All studies conducted at centers in the [LOCATION_002] must include the use of a Health Insurance Portability and Accountability Act Authorization form.
Adequate information will be provided to the subject in both oral and written form and 
consent will be obtained in writing prior to performance of an y study specific procedure. The 
content and process of obtaining informed consent will be in accordance with all applicable regulatory  and IEC/IRB requirements.
For subjects alread y ongoing in the study , a new informed consent will be issued and need to 
be signed covering the increased risk of suicidality or suicidal thoughts to comply with the warning issued b y the FDA subsequent to anal ysis performed on m arketed anti-epi[INVESTIGATOR_132385].  Although data from BRV studies were not included in FDA’s analysis, this risk may 
be expected because BRV belongs to this class of medication.
The Sponsor may  provide a sample informed consent form and a subject information sheet . 
The final consent form must be approved b y the IEC/I RB and should contain the applicable 
ICH-GCP elements in a language readily understood by [CONTACT_423] (i.e., lay terminology).
The Investigator , or a person designated by  [CONTACT_737] , should full y inform the subject 
about all pertinent aspects of the study including the fact that the protocol has been granted the approval of the IRB/IEC and local regulatory authorities if required.REDACTED  requirements pertaining to the approval of the amended Informed 
REDACTED  requirements pertaining to the approval of the amended Informed 
EC and use of the amended form.
REDACTED EC and use of the amended form.
All studies conducted at centers in the [LOCATION_002] must include the use of a Health 
REDACTED All studies conducted at centers in the [LOCATION_002] must include the use of a Health 
 and Accountability
REDACTED  and Accountability  Act Authorization form.
REDACTED  Act Authorization form.  and Accountability  Act Authorization form.  and Accountability
REDACTED  and Accountability  Act Authorization form.  and AccountabilityCOPY nsent form can be amended as appropriate.  If the I
COPY nsent form can be amended as appropriate.  If the I
Investigator (or the Sponsor, if applicable) must follow 
COPY Investigator (or the Sponsor, if applicable) must follow 
 requirements pertaining to the approval of the amended Informed COPY  requirements pertaining to the approval of the amended Informed 
EC and use of the amended form.COPY EC and use of the amended form.
This document The final consent form must be approved b
document The final consent form must be approved b
document ICH
document ICHcannot The Sponsor may
cannot The Sponsor may
The final consent form must be approved bcannot The final consent form must be approved bbe drugs.  Although data from 
be drugs.  Although data from 
be expected because be be expected because used warning issued b
used warning issued b y the FDA subsequent to anal
used y the FDA subsequent to anal
used drugs.  Although data from used drugs.  Although data from 
be expected because used be expected because to be signed covering the increased risk of suicidality or suicidal thoughts to complyto be signed covering the increased risk of suicidality or suicidal thoughts to comply
y the FDA subsequent to analto y the FDA subsequent to analsupport RB requirem
support RB requirem
y ongoing in the support y ongoing in the 
be signed covering the increased risk of suicidality or suicidal thoughts to comply support be signed covering the increased risk of suicidality or suicidal thoughts to complyany content and process of obtaining informed consent will be in accordance with all applicable 
any content and process of obtaining informed consent will be in accordance with all applicable 
RB requirem any RB requiremmarketing  Act Authorization form.
marketing  Act Authorization form.
marketing Adequate information will be provided to the subj
marketing Adequate information will be provided to the subj
consent will be obtained in writing prior to performance of anmarketing consent will be obtained in writing prior to performance of an
content and process of obtaining informed consent will be in accordance with all applicable marketing content and process of obtaining informed consent will be in accordance with all applicable authorization Investigator (or the Sponsor, if applicable) must follow 
authorization Investigator (or the Sponsor, if applicable) must follow 
 requirements pertaining to the approval of the amended Informed 
authorization  requirements pertaining to the approval of the amended Informed 
EC and use of the amended form.
authorization EC and use of the amended form.
All studies conducted at centers in the [LOCATION_002] must include the use of a Health 
authorization All studies conducted at centers in the [LOCATION_002] must include the use of a Health 
 Act Authorization form.authorization  Act Authorization form.application nsent form can be amended as appropriate.  If the I
application nsent form can be amended as appropriate.  If the I
Investigator (or the Sponsor, if applicable) must follow application Investigator (or the Sponsor, if applicable) must follow 
 requirements pertaining to the approval of the amended Informed application  requirements pertaining to the approval of the amended Informed and any EC/IRB and Regulatory
any EC/IRB and Regulatoryextensions affect subject safety or the conduct of the stu
extensions affect subject safety or the conduct of the stu dy
extensions dy
 with the applicable regulatoryextensions  with the applicable regulatory
EC/IRB and Regulatoryextensions EC/IRB and Regulatoryor a formal protocol amendment that must be submitted to the IEC/Ior a formal protocol amendment that must be submitted to the IEC/I RB or RB variations gnificant changes to the protocol can 
variations gnificant changes to the protocol can 
RB variations RB thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687945] 2015 / Page 63of [ADDRESS_687946]’s medical records.  The subject will receive a c opy of the signed and dated consent 
form and the original will be filed in the Investigator ’s Study  File. The consent form or a 
specific assent form, where required, will be signed and dated b y minors.
If the signature [CONTACT_4007] a witness is required, the witness should sign and personally date the consent form after the subject has signed. By [CONTACT_17317], the witness attests 
that the information in the consent form and in any  other written information was accurately  
explained to, and apparently understood by, the subject and that informed consent was freel y 
given b y the subject.
The subject may  withdraw their consent to participate in the study  at any  time. A subject is 
considered as enrolled in the study when he/she has signed the informed consent form. A 
Case Report Form must not be started, nor may  any study  specific procedure be performed 
for a given subject, without obtain ing his/her written consent to participate in the study .
If any new information that could influence the subject’s decis ion to stay in the study  
becomes available, this information will be transmitted to the subject without delay. In 
addition, the informed consent form must be amended accordingly or a separate consent form be created and submitted to the I EC/IRB for approval prior to being implemented for
re-consent of all ongoing subjects in the study  and for use in consenting all subjects entering 
the study  from that point forward.
14.[ADDRESS_687947] confidentiality  will be maintained at all times. Personnel from the Sponsor (or its 
representative) from Regulatory  Authorities and members of the IRB/IEC may inspect 
medical records and Case Report Forms for verification of the accuracy of data. These 
groups are obliged to respect medical confidentiality  and to refrain from divulging the 
subject’s identity  or any  other personal information. Sites will be required to obliterate an y REDACTED  signing the consent form, the witness attests 
REDACTED  signing the consent form, the witness attests 
that the information in the consent form and in any
REDACTED that the information in the consent form and in any
derstood b
REDACTED derstood b y, the subject and that informed consent was freel
REDACTED y, the subject and that informed consent was freelCOPY specific assent form, where required, will be signed and dated b
COPY specific assent form, where required, will be signed and dated b
If the signature [CONTACT_4007] a witness is required, the witneCOPY If the signature [CONTACT_4007] a witness is required, the witne ss should sign and personally date the COPY ss should sign and personally date the 
 signing the consent form, the witness attests COPY  signing the consent form, the witness attests 
This document 14.[ADDRESS_687948]’s decis
support y new information that could influence the subject’s decis
becomes available, this information will be transmitted to the subject without delay support becomes available, this information will be transmitted to the subject without delayany Case Report Form must not be started, nor may
any Case Report Form must not be started, nor may
for a given subject, without obtain any for a given subject, without obtainmarketing  withdraw their consent to participate in the study
marketing  withdraw their consent to participate in the study
considered as enrolled in the studymarketing considered as enrolled in the study  when he/she has signed the informed consemarketing  when he/she has signed the informed conse considered as enrolled in the study  when he/she has signed the informed conse considered as enrolled in the studymarketing considered as enrolled in the study  when he/she has signed the informed conse considered as enrolled in the study
Case Report Form must not be started, nor may marketing Case Report Form must not be started, nor mayauthorization ss should sign and personally date the 
authorization ss should sign and personally date the 
 signing the consent form, the witness attests 
authorization  signing the consent form, the witness attests 
that the information in the consent form and in any
authorization that the information in the consent form and in any  other written information was accurately
authorization  other written information was accurately that the information in the consent form and in any  other written information was accurately that the information in the consent form and in any
authorization that the information in the consent form and in any  other written information was accurately that the information in the consent form and in any
y, the subject and that informed consent was freel
authorization y, the subject and that informed consent was freelapplication  of the signed and dated consent 
application  of the signed and dated consent 
 File.
application  File. The consent form or a 
application The consent form or a 
specific assent form, where required, will be signed and dated b
application specific assent form, where required, will be signed and dated b y minors.
application y minors.
ss should sign and personally date the application ss should sign and personally date the and the person who obtained the informed 
and the person who obtained the informed 
Obtaining of consent will be confirmed iand Obtaining of consent will be confirmed i
 of the signed and dated consent and  of the signed and dated consent any formed Consent 
any formed Consent 
the person who obtained the informed any the person who obtained the informed extensions After having received extensive information about the purpose and risks of the study
extensions After having received extensive information about the purpose and risks of the study  and 
extensions  and After having received extensive information about the purpose and risks of the study  and After having received extensive information about the purpose and risks of the study
extensions After having received extensive information about the purpose and risks of the study  and After having received extensive information about the purpose and risks of the study
or their legal extensions or their legal 
formed Consent extensions formed Consent or variations  will receive complete written information in the Subject 
variations  will receive complete written information in the Subject thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687949] 2015 / Page 64of 72
possibly  identify inginformation (e.g., name, social security number, address, etc.) on any  
materials, forms, or report prior to sending them to the sponsor or its designee.
Medical records will be handled by [CONTACT_122313].
14.4 Informing the General Practitioner (or Pediatrician)
If the subject agrees, the Investigator may inform the subject’s regular physician of his/her 
participation in the stud y.
[ADDRESS_687950] monitor. The Monitor (the individual responsible for monitoring) will advise 
the Investigator regarding the practical conduct of the study and maintaining compliance with 
the protocol, GCP, and all applicable regulatory requirements.
The Investigator will allow the Sponsor or its representatives to review periodically , at 
mutually  convenient times during the stud y and after the stud y has been completed, all CRFs 
and corresponding source documents (e.g., portions of office, hospi[INVESTIGATOR_529416]). Therefore, the monitor will have direct access to these records.
The monitoring visits provide the sponsor or its representatives with the opportunity  to 
evaluate the progress of the study , to verify  the accuracy  and completeness of CRFs, ensure 
that all protocol requirements, applicable authorities’ regulations and Investigator’s 
obligations are being fulfilled, and resolve any inconsistencies in the study records.If the monitoring and/or auditing process identifies serious and/or persistent non- compliance 
by [CONTACT_39595] /Institution, the Sponsor may  terminate the Investigator’s/ Institution’s 
participation in the study.
15.[ADDRESS_687951] Access to Source Data/Documents
The Investigator (s)/Institution(s) will permit study -related monitoring, audits by  [CONTACT_529484] , IEC/I RB review, and regulatory inspection(s), providing direct access to 
source data/documents.
Source documents are original records in which raw data are first recorded. These may  be:
hospi[INVESTIGATOR_307]/clinic/GP records, charts, diaries, x- rays, laboratory  results, printouts, pharmacy  
records, care records, ECG or other printouts, completed scales, etc. Source documents 
should be kept in a secure, limited access area.REDACTED will allow the Sponsor or its representatives to review
REDACTED will allow the Sponsor or its representatives to review
 convenient times during the stud
REDACTED  convenient times during the stud y and after the stud
REDACTED y and after the stud
and corresponding source documents (e.g., portions of office, hospi[INVESTIGATOR_529417] (e.g., portions of office, hospi[INVESTIGATOR_529418], the monitor REDACTED Therefore, the monitorCOPY The Monitor (the individual responsible fo
COPY The Monitor (the individual responsible fo
regarding the practical conduct of the study
COPY regarding the practical conduct of the study
 requirements.COPY  requirements.
This document the 
document the 
document source data/documents.
document source data/documents.cannot Investigator
cannot Investigator
the cannot the sponsorcannot sponsorbe Direct Access to Source Data/Documentsbe Direct Access to Source Data/Documentsused participation in the study
used participation in the study
Direct Access to Source Data/Documentsused Direct Access to Source Data/Documentsto nstitution, the Sponsor mayto nstitution, the Sponsor may
participation in the study to participation in the studysupport obligations are being fulfilled, and resolve an
support obligations are being fulfilled, and resolve an
If the monitoring and/or auditing process identifies serious and/or persistent non
support If the monitoring and/or auditing process identifies serious and/or persistent non
nstitution, the Sponsor maysupport nstitution, the Sponsor mayany applicable 
any applicable 
any obligations are being fulfilled, and resolve an any obligations are being fulfilled, and resolve anmarketing and corresponding source documents (e.g., portions of office, hospi[INVESTIGATOR_529419] (e.g., portions of office, hospi[INVESTIGATOR_529418], the monitor
marketing Therefore, the monitor
The monitoring visits provide the sponsor or its representatives with the opportunity
marketing The monitoring visits provide the sponsor or its representatives with the opportunity
, to verifymarketing , to verify
applicable marketing applicable authorization  requirements.
authorization  requirements.
will allow the Sponsor or its representatives to review
authorization will allow the Sponsor or its representatives to review
y and after the stud
authorization y and after the stud
and corresponding source documents (e.g., portions of office, hospi[INVESTIGATOR_529420] (e.g., portions of office, hospi[INVESTIGATOR_529421] t
application  be delegated t  of the Sponsor and may  be delegated t  of the Sponsor and may
application  of the Sponsor and may  be delegated t  of the Sponsor and may
The Monitor (the individual responsible fo
application The Monitor (the individual responsible fo r monitoring) will advise 
application r monitoring) will advise 
regarding the practical conduct of the studyapplication regarding the practical conduct of the study  and maintaining compliance with application  and maintaining compliance with regarding the practical conduct of the study  and maintaining compliance with regarding the practical conduct of the studyapplication regarding the practical conduct of the study  and maintaining compliance with regarding the practical conduct of the study
 requirements.application  requirements.and any extensions physician of his/her 
extensions physician of his/her or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687952] 2015 / Page 65of [ADDRESS_687953] be, accurate, clear, unambiguous, permanent and capable of being 
audited.  They  should be made using some permanent form of recording (ink, typi[INVESTIGATOR_007], 
printing, optical disc). They  should not be obscured by [CONTACT_122318] (such as removable self- stick notes).   Photocopi[INVESTIGATOR_529422]. Photocopi[INVESTIGATOR_529423]-permanent media.
Source documents that are computer generated and stored electronicall y must be printed for 
review b y the monitor (e.g., ECG reports). Once printed, these copi[INVESTIGATOR_529424] b y the Investigator and become a permanent part of the subject’s source documents. 
The Investigator will authorize the monitor to compare the content of the printout and the 
data stored in the computer to ensure all data are consistent.
For subjects exposed to investigation product(s), the minimum requirements for source 
documents used in clinical studies are that they  should contain the identity  of the subject and 
study  related identifiers (such as treatment numbers, CRF number, or similar), they should 
mention the subject’s participation in the study  and identification of that study  (study  title or 
number), they  should record the obtaining of consent (date of consent), the subject’s medical 
history , the concomitant medication treatments and dates (including contraceptive treatment), 
AEs and SAEs and the dates of th e visits. The source documents should provide evidence 
that inclusion/ex clusion criteria have been met. Information recorded in the CRF must be 
consistent with entries in the source documents. The monitor will perform source documents verification (SDV) according to the SDV plan prepared for the study.
15.[ADDRESS_687954] been protected, that enrolled subjects (i.e., signing consent and undergoing 
study  procedures) are appropriate for the study, and that all data relevant for the evaluation of 
the investigational product have been processed and reported in compliance with the planned arrangements, the protocol, facility  and IEC/I RB SOPS, I CH/GCP and appl icable regulatory
requirements. The Investigator will provide direct access to all study documents, source 
records and source data. If an inspection b y a regulatory authority is announced, the 
Investigator will immediately  inform the Sponsor.
15.4 Case Report Forms (CRF)REDACTED documents used in clinical studies are that they
REDACTED documents used in clinical studies are that they  should contain the identity
REDACTED  should contain the identity documents used in clinical studies are that they  should contain the identity documents used in clinical studies are that they
REDACTED documents used in clinical studies are that they  should contain the identity documents used in clinical studies are that they
 related identifiers (such as treatment numbers, CR
REDACTED  related identifiers (such as treatment numbers, CR
mention the subject’s participation in the study
REDACTED mention the subject’s participation in the study
 should record the obtaining of consent (date of consent), the subject’s medical 
REDACTED  should record the obtaining of consent (date of consent), the subject’s medical 
cation treatments and dates (including contraceptive treatment), REDACTED cation treatments and dates (including contraceptive treatment), COPY are consistent.
COPY are consistent.
For subjects exposed to investigation product(s), theCOPY For subjects exposed to investigation product(s), the minimum requirements for source COPY minimum requirements for source 
 should contain the identityCOPY  should contain the identity
This document the investigational product have been processed and reported in compliance with the planned 
document the investigational product have been processed and reported in compliance with the planned 
document arrangements, the protocol, facility
document arrangements, the protocol, facility
requirements.
document requirements.cannot enrolled have been protected, that enrolled subjects (i.e., signin
cannot enrolled have been protected, that enrolled subjects (i.e., signin
study
cannot study  procedures) are appropriate for the study
cannot  procedures) are appropriate for the study study  procedures) are appropriate for the study study
cannot study  procedures) are appropriate for the study study
the investigational product have been processed and reported in compliance with the planned cannot the investigational product have been processed and reported in compliance with the planned be s of an audit or inspection be s of an audit or inspection 
enrolled have been protected, that enrolled subjects (i.e., signin be enrolled have been protected, that enrolled subjects (i.e., signinused will permit study
used will permit study
inspections by[CONTACT_529485]
s of an audit or inspection used s of an audit or inspection to will permit studyto will permit studysupport verification (SDV) according to the SDV plan prepared for the study
support verification (SDV) according to the SDV plan prepared for the study
Audit and Inspection
support Audit and Inspectionany tries in the source documents. 
any tries in the source documents. 
verification (SDV) according to the SDV plan prepared for the study any verification (SDV) according to the SDV plan prepared for the studymarketing  should record the obtaining of consent (date of consent), the subject’s medical 
marketing  should record the obtaining of consent (date of consent), the subject’s medical 
cation treatments and dates (including contraceptive treatment), 
marketing cation treatments and dates (including contraceptive treatment), 
e visits.
marketing e visits. The source documents should provide evidence 
marketing The source documents should provide evidence 
clusion criteria have been met.marketing clusion criteria have been met.
tries in the source documents. marketing tries in the source documents. authorization minimum requirements for source 
authorization minimum requirements for source 
 should contain the identity
authorization  should contain the identity
 related identifiers (such as treatment numbers, CR
authorization  related identifiers (such as treatment numbers, CR
mention the subject’s participation in the study
authorization mention the subject’s participation in the study  and identification of that study
authorization  and identification of that study mention the subject’s participation in the study  and identification of that study mention the subject’s participation in the study
authorization mention the subject’s participation in the study  and identification of that study mention the subject’s participation in the study
 should record the obtaining of consent (date of consent), the subject’s medical authorization  should record the obtaining of consent (date of consent), the subject’s medical application and become a permanent part of the subject’s source documents. 
application and become a permanent part of the subject’s source documents. 
will authorize the monitor to compare the content of the printout and the 
application will authorize the monitor to compare the content of the printout and the 
minimum requirements for source application minimum requirements for source and y must be printed for 
and y must be printed for 
copi[INVESTIGATOR_529425] a permanent part of the subject’s source documents. and and become a permanent part of the subject’s source documents. any y must be printed for any y must be printed for extensions   Photocopi[INVESTIGATOR_529426]. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687955] 2015 / Page 66of 72
Data reflecting participant experience with the drug(s) under investigation will be reported to 
the Sponsor. These data will be recorded on the CRF .The CRF is essentially a data entry  
form and may  not routine ly constitute the original (or source) medical record. CRFs should 
be kept in a secure, limited access area.
The CRF will be organized in Yearl y Books. CRFs will be signed and dated by  [CONTACT_9532] [INVESTIGATOR_529427].The Investigator ’s or Principal Investigator ’s signature [CONTACT_529496]. Paper CRFs will be completed in dark ballpoint pen, and must be legible. If 
an entry  in a CRF needs to be changed, the correction will be made as follows:
Draw a single l ine through the incorrect entry .
Enter the correct data, explain the correction (if necessary), date and initial the change. 
Correcting fluid, erasure or any form of obliteration of data in CRFs is not permitted except to obliterate information that could specifically  identify  a subject (i.e., a name 
[CONTACT_122332] a subject diary).
The Sponsor cannot interpret a blank answer as “NONE” or “N/A”; therefore, all fields must be completed. If the data are not available, a straight line should be drawn through al l 
applicable fields.
Data reported in the CRF, which are derived from source documents, should be consistent 
with the source documents or the discrepancies should be explained in those source documents.
The Investigator must submit to the Sponsor or its representatives a completed CRF for each 
participant exposed to the investigational product.All supportive documentation submitted to the Sponsor in addition to the CRF , such as 
laboratory  results or hospi[INVESTIGATOR_78685], must be clearly identified wi th the study  number, 
subject’s number, subject’s initials and visit number where relevant; any personal 
information, including the subject’s name, must be removed or rendered illegible to preserve 
individual confidentiality. All original lab oratory report s will remain at the study  site.
Copi[INVESTIGATOR_262054] s will be placed in the CRF binder (where directed) and forwarded to the 
sponsor.
15.5 Adherence to Protocol
The Investigator /Institution should conduct the study  in compliance with the protocol agreed 
to by [CONTACT_1052], if applicable, by [CONTACT_122321] y(ies) and which 
has been approved b y the I EC/IRB. The Investigator /Institution and the Sponsor should sign 
the protocol to confirm agreement.REDACTED If the data are not available, a straight line should be drawn through al
REDACTED If the data are not available, a straight line should be drawn through al
Data reported in the CRF, which are derived from source documents, should be consistent 
REDACTED Data reported in the CRF, which are derived from source documents, should be consistent 
with the source documents or the discrepancies should be explained in those source REDACTED with the source documents or the discrepancies should be explained in those source COPY The Sponsor cannot interpret a blank answer as “NONE” or “N/A”; therefore, all fields must COPY The Sponsor cannot interpret a blank answer as “NONE” or “N/A”; therefore, all fields must 
If the data are not available, a straight line should be drawn through alCOPY If the data are not available, a straight line should be drawn through al
This document 15.[ADDRESS_687956]’s number, 
used subject’s number, subject’s
used subject’s
information, including the used information, including the 
individual confidentiality. used individual confidentiality. to  results or hospi[INVESTIGATOR_78685], must be clearlyto  results or hospi[INVESTIGATOR_78685], must be clearly
subject’sto subject’ssupport participant exposed to the investigational product.
support participant exposed to the investigational product.
All supportive documentation submitted to the Sponsor in addition to the support All supportive documentation submitted to the Sponsor in addition to the 
 results or hospi[INVESTIGATOR_78685], must be clearly support  results or hospi[INVESTIGATOR_78685], must be clearlyany must submit to the Sponsor or its 
any must submit to the Sponsor or its 
participant exposed to the investigational product. any participant exposed to the investigational product.marketing Data reported in the CRF, which are derived from source documents, should be consistent 
marketing Data reported in the CRF, which are derived from source documents, should be consistent 
with the source documents or the discrepancies should be explained in those source 
marketing with the source documents or the discrepancies should be explained in those source 
must submit to the Sponsor or its marketing must submit to the Sponsor or its authorization The Sponsor cannot interpret a blank answer as “NONE” or “N/A”; therefore, all fields must 
authorization The Sponsor cannot interpret a blank answer as “NONE” or “N/A”; therefore, all fields must 
If the data are not available, a straight line should be drawn through al
authorization If the data are not available, a straight line should be drawn through al
Data reported in the CRF, which are derived from source documents, should be consistent authorization Data reported in the CRF, which are derived from source documents, should be consistent application y form of obliteration of data in CRFs is not permitted 
application y form of obliteration of data in CRFs is not permitted 
 identify
application  identify  a subject (i.e., a name 
[CONTACT_529472]  a subject (i.e., a name  [CONTACT_529497]  a subject (i.e., a name  [CONTACT_529498]  a subject (i.e., a name  [CONTACT_529499] a blank answer as “NONE” or “N/A”; therefore, all fields must application The Sponsor cannot interpret a blank answer as “NONE” or “N/A”; therefore, all fields must and Enter the correct data, explain the correction (if necessary), date and initial the change. and Enter the correct data, explain the correction (if necessary), date and initial the change. 
y form of obliteration of data in CRFs is not permitted and y form of obliteration of data in CRFs is not permitted any  in a CRF needs to be changed, the correction will be made as follows:
any  in a CRF needs to be changed, the correction will be made as follows: extensions ’s signature [CONTACT_529500] ’s signature [CONTACT_529501], and must be legible.extensions point pen, and must be legible.
 in a CRF needs to be changed, the correction will be made as follows: extensions  in a CRF needs to be changed, the correction will be made as follows:or  the Principal 
or  the Principal variations  the Principal variations  the Principal thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687957] 2015 / Page 67of [ADDRESS_687958] to their health and safety . In this case, this 
action should be taken immediately , without prior notification of the regulatory  authorit y, 
IRB/IEC or sponsor. After implementation of such measure, the investigator must notify the 
CPM of the sponsor within [ADDRESS_687959] be approved by [CONTACT_1034], the I RB/IEC and the appropriate regulatory  authorities, if 
applicable prior to being implemented.
Any significant protocol deviation will be documented and explained by  [CONTACT_529486] b y the Investigator and will be included in the final Clinical Study  
Report.
15.[ADDRESS_687960] of the study  as specified in the I CH GCP guidelines 
will be maintained by  [CONTACT_37888] a norderly  manner and made available for 
monitoring and/or auditing by [CONTACT_4885].
15.7 Data Handling
The Sponsor will be responsible for data processing.
CRF data will be entered in a validated electronic database using a Clinical D ata Management 
System (CDMS). Computerized data cleaning checks will be used in addition to manual 
review to check for discrepancies and to ensure consistency of the data. An electronic audit 
trail sy stem will be used to track all data changes in the database subsequent to the 
reconciliation of the double-entered data.  The SAS system will be used for the statistical 
analysis of the data. Regular back-ups of the electronic data will be performed.
15.[ADDRESS_687961] the following activities in 
conjunction with the Investigator, as appropriate:
Return of all study data to the sponsor or its representatives while maintaining original source documents.
Dataclarification and/or resolution.
Accountability , reconciliation and arrangements for used and unused study drugs.
Review of site study records for completeness.
Discussion/reminder on archiving responsibilities.
Discussion of IEC/I RB requirements for study termination.
Arrangements for unused CRFs, lab supplies and any other stud y related supplies.REDACTED y the Sponsor or its designee.
REDACTED y the Sponsor or its designee.
The Sponsor will be responsible for data processing. REDACTED The Sponsor will be responsible for data processing.COPY All documents required for the conduct of the study
COPY All documents required for the conduct of the study  as specified in the I
COPY  as specified in the I All documents required for the conduct of the study  as specified in the I All documents required for the conduct of the study
COPY All documents required for the conduct of the study  as specified in the I All documents required for the conduct of the study
orderlyCOPY orderly  manner and made available for COPY  manner and made available for orderly  manner and made available for orderlyCOPY orderly  manner and made available for orderly
y the Sponsor or its designee.COPY y the Sponsor or its designee.
This document 
document D
document D

document cannot conjunction with the 
cannot conjunction with the 
R
cannot Return of all study
cannot eturn of all study
source documentscannot source documentsbe Upon completion of the studybe Upon completion of the study
conjunction with the be conjunction with the used Terminationused Termination
Upon completion of the studyused Upon completion of the studyto is of the data. to is of the data. Regular backto Regular backsupport review to check for discrepancies and to ensure consistency
support review to check for discrepancies and to ensure consistency
be used to track all data changes in the database subsequent to the 
support be used to track all data changes in the database subsequent to the 
reconciliation of the double-entered data.  The SAS
support reconciliation of the double-entered data.  The SAS
Regular backsupport Regular backany Computerized data cleaning checks will be used in addition to manual 
any Computerized data cleaning checks will be used in addition to manual 
review to check for discrepancies and to ensure consistency any review to check for discrepancies and to ensure consistencymarketing The Sponsor will be responsible for data processing.
marketing The Sponsor will be responsible for data processing.
idatmarketing idated electronic database using a Cmarketing ed electronic database using a C
Computerized data cleaning checks will be used in addition to manual marketing Computerized data cleaning checks will be used in addition to manual authorization  manner and made available for 
authorization  manner and made available for 
y the Sponsor or its designee.
authorization y the Sponsor or its designee.application  as specified in the Iapplication  as specified in the I
 manner and made available for application  manner and made available for and and will be included in the final Clinical Study
and and will be included in the final Clinical Study any  the 
any  the Investigator
any Investigator
and will be included in the final Clinical Study any and will be included in the final Clinical Studyextensions ficant changes to the protocol will ONLY be made as an amendment to the protocol and 
extensions ficant changes to the protocol will ONLY be made as an amendment to the protocol and 
 authorities, if 
extensions  authorities, if 
Investigatorextensions Investigatoror ficant changes to the protocol will ONLY be made as an amendment to the protocol and or ficant changes to the protocol will ONLY be made as an amendment to the protocol and variations  the 
variations  the thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687962] 2015 / Page 68of [ADDRESS_687963] to quality or quantity .
If the stud y isprematurely terminated or suspended, the Sponsor or its representatives will 
inform the Investigator s/Institutions, and the regulatory  authorit y(ies) of the termination or 
suspension and the reason(s) for the termination or suspension, in accordance with applicable 
regulatory  requirement(s). The IEC/IRB should also be informed and provided with 
reason(s) for the termination or suspension by  [CONTACT_122323] /Institution, 
as specified b y the applicable regulatory requirement(s). In additi on, arrangements will be 
made for the return of all unused study drugs and other material in accordance with the Sponsor procedures for the study.
15.[ADDRESS_687964] is requested to 
inform the treating ph ysician responsible for the study without delay .Information as to 
insurance policies held by [CONTACT_529487]/IRB upon request.15.[ADDRESS_687965] of all measurements as specified in the Statistical 
 be included in submissions to governmREDACTED  be included in submissions to governmCOPY 
This document 15.11
document 15.11
The 
document The cannot IEC/IRB upon request.
cannot IEC/IRB upon request.
15.11cannot 15.11be insurance policies held by [CONTACT_529488]/IRB upon request. be IEC/IRB upon request.used  or disability
used  or disability
inform the treating phused inform the treating ph
insurance policies held by [CONTACT_529489], in respect of the risks involved in this studyto the subjects, in respect of the risks involved in this study
 or disability to  or disabilitysupport Insurance and Liability
support Insurance and Liability
support The Sponsor has taken out a
support The Sponsor has taken out a n insurance policy
support n insurance policy
the subjects, in respect of the risks involved in this study support the subjects, in respect of the risks involved in this studyany Insurance and Liability any Insurance and Liabilitymarketing a discussion of the results and a list of all measurements as specified in the Statistical 
marketing a discussion of the results and a list of all measurements as specified in the Statistical 
 be included in submissions to governm
marketing  be included in submissions to governm
authorities worldwide, or used for whatever reason considered appropriate by
[CONTACT_529490], or used for whatever reason considered appropriate by
[CONTACT_529491] I
authorization  report in accordance with the relevant I
The report will include a thorough description of the clinical laboratory
authorization The report will include a thorough description of the clinical laboratory
a discussion of the results and a list of all measurements as specified in the Statistical authorization a discussion of the results and a list of all measurements as specified in the Statistical application on, arrangements will be 
application on, arrangements will be 
 drugs and other material in accordance with 
application  drugs and other material in accordance with and The IEC/IRB should also be informed and provided with 
and The IEC/IRB should also be informed and provided with 
Investigatorand Investigator
on, arrangements will be and on, arrangements will be any suspension and the reason(s) for the termination or suspension, in accordance with 
any suspension and the reason(s) for the termination or suspension, in accordance with 
The IEC/IRB should also be informed and provided with any The IEC/IRB should also be informed and provided with extensions or its representatives will 
extensions or its representatives will 
y(ies) of the termination or extensions y(ies) of the termination or 
suspension and the reason(s) for the termination or suspension, in accordance with extensions suspension and the reason(s) for the termination or suspension, in accordance with or variations y time for reasons including, 
variations y time for reasons including, thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687966] 2015 / Page 69of [ADDRESS_687967]. These documents 
should be retained for a longer period, however , if required b y the applicable regulatory 
requirement(s) or b y an agreement with the sponsor (ICH -GCP Guideline -Section 4.9.5).
The Investigator will contact [CONTACT_529492]. The 
Investigator will also notify  the Sponsor should he/she relocate or move the study related files 
to a location other than that specified in the Sponsor’s study master file.
15.12 Allocation of Responsibilities
The Investigator is responsible for the implementation of the protocol but can delegate tasks 
to the research team. The Investigator remains responsible for coordinating and informing 
his/her staff about the protocol and an y possible changes made to it. The Investigator should 
maintain a site signature [CONTACT_529502] y qualified persons to whom he/she has delegated 
significant stud y-related duties (“Delegation of Authority ” document with name, function, 
signature, initials, and dates of participation in the study  conduct and ty pe of tasks delegated). 
The list should be kept up to date.
15.13 Curriculum Vitae (CV)The Investigator sshould supply  their updated CV ( English translation) , dated and signed, 
together with a list of their collaborators responsible for the practical conduct of the study.
These collaborators should also provid e a rec ent English version of their CV , dated and 
signed.
Where applicable, a signed and dated FDA Form 1572 ( in Canada, a Qualified Investigator
Undertaking Form must also be provided) is required from each Investigator showing a 
current affiliation with the research center. All sub- Investigator s listed on the FDA 
Form [ADDRESS_687968] inform the Sponsor if information related to financial 
disclosure changes during the course of the study  and/or after study completion/end of study .REDACTED signature, initials, and dates of participation in the study
REDACTED signature, initials, and dates of participation in the studyCOPY y possible changes made to it. 
COPY y possible changes made to it. 
y qualified 
COPY y qualified persons to whom he/she has delegated 
COPY persons to whom he/she has delegated 
related duties (“Delegation of AuthorityCOPY related duties (“Delegation of Authority
signature, initials, and dates of participation in the studyCOPY signature, initials, and dates of participation in the study
This document A 
document A f
document financial 
document inancial financial f
document financial f
Investigator
document Investigatorcannot 15.[ADDRESS_687969] also be provided
current affiliation with to current affiliation withsupport signed and dated FDA Form 1572 (
support signed and dated FDA Form 1572 (
must also be providedsupport must also be providedany These collaborators should also provid
any These collaborators should also provid marketing  their updated CV (
marketing  their updated CV (
together with a list of their collaborators responsible for the practical conduct of the studymarketing together with a list of their collaborators responsible for the practical conduct of the study
These collaborators should also provid marketing These collaborators should also providauthorization related duties (“Delegation of Authority
authorization related duties (“Delegation of Authority ” document with name, function, 
authorization ” document with name, function, 
signature, initials, and dates of participation in the study
authorization signature, initials, and dates of participation in the study  conduct and ty
authorization  conduct and ty signature, initials, and dates of participation in the study  conduct and ty signature, initials, and dates of participation in the study
authorization signature, initials, and dates of participation in the study  conduct and ty signature, initials, and dates of participation in the studyapplication is responsible for the implementation of the protocol but can de
application is responsible for the implementation of the protocol but can de
remains responsible for coordinating and informing 
application remains responsible for coordinating and informing 
y possible changes made to it. 
application y possible changes made to it. 
persons to whom he/she has delegated application persons to whom he/she has delegated 
” document with name, function, application ” document with name, function, and is responsible for the implementation of the protocol but can de and is responsible for the implementation of the protocol but can deany extensions will contact [CONTACT_529493]/she relocate or move the study
extensions he Sponsor should he/she relocate or move the study  related files 
extensions  related files he Sponsor should he/she relocate or move the study  related files he Sponsor should he/she relocate or move the study
extensions he Sponsor should he/she relocate or move the study  related files he Sponsor should he/she relocate or move the studyor will contact [CONTACT_529494]. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687970] 2015 / Page 70of 72
15.15 Good Clinical Practice
Non-compliance with the protocol, I CH/GCP or local regulatory requirements by  [CONTACT_3786], Institution, institution staff or designees of the Sponsor will lead to prompt 
action by  [CONTACT_98226]. Continued non- compliance may result in the 
termination of the participants’ involvement in the study.
15.[ADDRESS_687971] to the provisions of the publication article of the agreement with the Investigator or 
his/her legal representative, the Sponsor will be responsible for the publication of the results 
of this study . The site shall not publish or present any research findings resulting from the 
Study or any  scientific work with respect to Sponsor’s drug or its development, without the 
Sponsor’s prior written approval of the content of the presentation, manuscript or other materials prepared for publication. The Sponsor will respond to requests for presentation or publication in a timely  manner and will not unreasonably withhold authorization.
16 REFERENCES
Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology  and concepts for organization of seizures and epi[INVESTIGATOR_31629]: report of th e ILAE 
Commission on Classification and Terminology, 2005 -2009. Epi[INVESTIGATOR_8330]. 2010;51:676-85.
Commission on Classification and Terminology of the International League Against Epi[INVESTIGATOR_002] . Proposal for revised clinical and electroencephalographic classification of epi[INVESTIGATOR_122240]. Epi[INVESTIGATOR_8330]. 1981;22:489-501.
Commission on Classification and T erminology  of the International League Against 
Epi[INVESTIGATOR_002] . Proposal for revised classification of epi[INVESTIGATOR_122241] s yndromes. Epi[INVESTIGATOR_8330].
1989;30:389-99.CPMP/EWP/566/ 98 rev 1 Note for guidance on clinical investigation of medicinal products 
in the treatment of epi[INVESTIGATOR_67552] (EMA) 16Nov 2000.
CPMP/I CH/2711/99 Note for guidance on clinical investigation of medicinal products in the 
paediatric population (EMA) 27 Jul 2000.
Cramer JA, Perrine K, Devinsky  O, Bryant -Comstock L , Meador K, Hermann B. 
Development and cross-cultural translations of a 31- item quality  of life in epi[INVESTIGATOR_122242] . 
Epi[INVESTIGATOR_8330]. 1998;39:81-8.Cramer JA, Van Hammée G. Maintenance of improvement in health- related quality  of life 
during long- term treatment with levetiracetam. Epi[INVESTIGATOR_451113]. 2003; 4:118 -23.
Engel J Jr. Report of the ILAE classification core group. Epi[INVESTIGATOR_8330]. 2006;47:1558-68.REDACTED Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised 
REDACTED Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised 
 and concepts for organization of seizures and epi[INVESTIGATOR_31629]: report of th
REDACTED  and concepts for organization of seizures and epi[INVESTIGATOR_31629]: report of th
Commission on Classification and Terminology REDACTED Commission on Classification and TerminologyCOPY The Sponsor will respond to requests for presentation or 
COPY The Sponsor will respond to requests for presentation or 
 manner and will not unreasonably withhold authorization.
COPY  manner and will not unreasonably withhold authorization.
This document Cramer JA, Perrine K, Devinsky
document Cramer JA, Perrine K, Devinsky
Development and cross
document Development and cross
Epi[INVESTIGATOR_529428]/2711/99 Note for guidance on clinical investigation of medicinal products in the 
cannot CH/2711/99 Note for guidance on clinical investigation of medicinal products in the 
ediatric population
cannot ediatric population
Cramer JA, Perrine K, Devinskycannot Cramer JA, Perrine K, Devinskybe in the treatment of epi[INVESTIGATOR_529429]/2711/99 Note for guidance on clinical investigation of medicinal products in the be CH/2711/99 Note for guidance on clinical investigation of medicinal products in the used CPMP/EWP/566/
used CPMP/EWP/566/ 98 rev 1
used 98 rev 1
in the treatment of epi[INVESTIGATOR_529430] 98 rev 1to 98 rev 1support lassification and 
support lassification and 
. Proposal for revised classification of epi[INVESTIGATOR_122241] s
support . Proposal for revised classification of epi[INVESTIGATOR_529431] . Proposal for revised clinical and electroencephalographic classification o
any . Proposal for revised clinical and electroencephalographic classification o
any 1981;22:489any 1981;22:489 -501.any -501.
lassification and any lassification and marketing  and concepts for organization of seizures and epi[INVESTIGATOR_31629]: report of th
marketing  and concepts for organization of seizures and epi[INVESTIGATOR_31629]: report of th
Commission on Classification and Terminology
marketing Commission on Classification and Terminology
Commission on Classification and Terminology
marketing Commission on Classification and Terminology
. Proposal for revised clinical and electroencephalographic classification o marketing . Proposal for revised clinical and electroencephalographic classification o
-501.marketing -501.authorization Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised 
authorization Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised 
 and concepts for organization of seizures and epi[INVESTIGATOR_31629]: report of th authorization  and concepts for organization of seizures and epi[INVESTIGATOR_31629]: report of thapplication with respect to Sponsor’s drug or its development, without the 
application with respect to Sponsor’s drug or its development, without the 
Sponsor’s prior written approval of the content of the presentation, manuscript or other 
application Sponsor’s prior written approval of the content of the presentation, manuscript or other 
The Sponsor will respond to requests for presentation or 
application The Sponsor will respond to requests for presentation or 
 manner and will not unreasonably withhold authorization.application  manner and will not unreasonably withhold authorization.and his/her legal representative, the Sponsor will be responsible for the publication of the results 
and his/her legal representative, the Sponsor will be responsible for the publication of the results 
 research findings resulting from the and  research findings resulting from the 
with respect to Sponsor’s drug or its development, without the and with respect to Sponsor’s drug or its development, without the any agreement with the 
any agreement with the In
any In
his/her legal representative, the Sponsor will be responsible for the publication of the results any his/her legal representative, the Sponsor will be responsible for the publication of the results extensions Inextensions Investigatorextensions vestigatoror  result in the 
or  result in the variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687972] 2015 / Page 71of 72
Engel J Jr, Pedley  TA, editors. Epi[INVESTIGATOR_002] : a comprehensive textbook. Philadelphia: Lippi[INVESTIGATOR_10354]-
Raven; 1998.
EuroQol Group. EQ -5D. A measure of health- related quality of life developed by  [CONTACT_122329]. User guide. 8th issue. April 2000.Hauser WA, Annegers JF, Kurland LT. Incidence of epi[INVESTIGATOR_529432], Minnesota: 1935-1948. Epi[INVESTIGATOR_8330]. 1993;34:453-68.Herrmann C. International experiences with the Hospi[INVESTIGATOR_74017]- a 
review of validation data and clinical results. J Psychosom Res. 1997;4 2:17-41.
Kwan P, Brodie MJ. Effectiveness of first antiepi[INVESTIGATOR_32551]. Epi[INVESTIGATOR_8330]. 2001;42:1255-60.Loiseau J, L oiseau P, Guvot M, Duche B, Dartigues JF, Aublet B. Survey  of seizure disorders 
in the French southwest. I. Incidence of epi[INVESTIGATOR_23935] s yndromes. Epi [INVESTIGATOR_8330]. 1990;31:391 -6.
Lüders HO, Acharya J, Alexopoulos A, Baumgartner C, Bautista J, Burgess R, et al. Are 
epi[INVESTIGATOR_122246]? Epi[INVESTIGATOR_122247]. 2006;8:81 -5.
Nasreddine W, Bey doun A, Atweh S, Abou -Khalil B. Emerging drugs for partial onset 
seizures. Expert Opin Emerg Drugs. 2010;15:415 -31.
Sander JW, Shorvon S D. Epi[INVESTIGATOR_122248]. J Neurol Neurosurg Ps ychiatry . 
1996;61:433-43.
REDACTED 2010;15:415
REDACTED 2010;15:415 -31
REDACTED -31
REDACTED  of the epi[INVESTIGATOR_31629]. J Neurol Neurosurg Ps
REDACTED  of the epi[INVESTIGATOR_31629]. J Neurol Neurosurg PsCOPY Khalil B. Emerging drugs for partial onset COPY Khalil B. Emerging drugs for partial onset 
-31COPY -31
This document cannot be used to support any marketing authorization Khalil B. Emerging drugs for partial onset 
authorization Khalil B. Emerging drugs for partial onset 
-31
authorization -31
authorization .
authorization .
 of the epi[INVESTIGATOR_31629]. J Neurol Neurosurg Ps
authorization  of the epi[INVESTIGATOR_31629]. J Neurol Neurosurg Psapplication a J, Alexopoulos A, Baumgartner C, Bautista J, Burgess R, et al. Are 
application a J, Alexopoulos A, Baumgartner C, Bautista J, Burgess R, et al. Are 
yndromes and seizure types outdated? Epi[INVESTIGATOR_529433]? Epi[INVESTIGATOR_122250] B. Emerging drugs for partial onset application Khalil B. Emerging drugs for partial onset and Survey
and Survey
lepsiaand lepsia .and .1990;31:391and 1990;31:391any Effectiveness of first antiepi[INVESTIGATOR_32551]. Epi[INVESTIGATOR_8330]. 2001;42:[ADDRESS_687973] antiepi[INVESTIGATOR_32551]. Epi[INVESTIGATOR_8330]. 2001;42:[ADDRESS_687974] antiepi[INVESTIGATOR_32551]. Epi[INVESTIGATOR_8330]. 2001;42:[ADDRESS_687975] antiepi[INVESTIGATOR_32551]. Epi[INVESTIGATOR_8330]. 2001;42:1255or variations thereof. 
A Brivaracetam / N01199 CONFIDENTIAL
Protoco l:  RPCE05C2110 / Integrated Amendment 7 Final / [ADDRESS_687976] 2015 / Page 72of [ADDRESS_687977] this 
clinical study  as outlined in this protocol and according to Good Clinical Practice.
REDACTED COPY 
This document cannot be used to support 
support 
any 
any 
marketing 
marketing authorization application and any extensions or variations 
variations 
variations thereof. 